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Abstract
The outcome of radical treatment for prostate cancer is appreciably influenced by the 
presence of hypoxia. Oxygenation status may therefore be another underlying 
biological parameter, beyond the classic prognostic factors (age, clinical stage, 
Gleason score and prostate specific antigen), that predicts for treatment failure in this 
malignancy. Angiogenesis plays a pivotal role in the growth, invasion, metastasis and 
survival of prostate tumours. Measurements of angiogenesis have been linked with 
clinical and pathological stage, histological grade and the potential for metastasis 
formation. They also provide prognostic information and have been correlated with 
disease-specific survival and progression after treatment.
Magnetic resonance imaging techniques are capable of detecting the molecular, 
biochemical, physiological and metabolic changes that occur due to pathological 
processes within tissues. Experiments presented in this thesis have sought to evaluate 
the ability of Dynamic Contrast Enhanced MRI (DCE-MRI), Dynamic Susceptibility 
Contrast MRI (DSC-MRI), Intrinsic Susceptibility Weighted MRI (also known as Blood 
Oxygen Level Dependent (BOLD) MRI) and Diffusion Weighted Imaging (DWI) to 
characterise the oxygenation and vascular status of prostate tumours in animal models 
and in patients with prostate cancer.
This research has demonstrated the feasibility of hypoxia imaging in prostate cancer. 
Although MRI can not precisely map tissue p02, the combination of BOLD-MRI and 
dynamic susceptibility contrast MRI provides a valuable surrogate and predicts the 
pattern of hypoxia, as determined by pimonidazole immunohistochemistry, with 
reasonable accuracy. The research has also shown that prostate cancer responds to 
carbogen gas breathing and that androgen deprivation causes profound vascular 
collapse within one month of starting therapy. These findings should help in the rational 
design of future studies that aim to target tumour vasculature and combat tumour 
hypoxia in prostate cancer.
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Chapter 1 
Introduction 
Prostate Cancer and its Biology
1.1 Prostate Cancer -  An Overview
1.1.1 Epidemiology
Carcinoma of the prostate is the commonest form of human cancer. Worldwide, more 
than 650,000 men are diagnosed every year, accounting for a tenth of all male 
malignancies. In the UK, it is the most common cancer in men, with a lifetime risk of 
being diagnosed with the disease of 1 in 13. Annually it is the cause of approximately 
10,000 deaths [1-4]. Substantial increases in incidence have been reported in recent 
years [5], which have been closely linked to the emergent use of trans-urethral 
resection for urinary outflow symptoms during the 1980s and the subsequent 
introduction of PSA testing in the 1990s [6-8]. Prostate cancer risk is closely associated 
with age, 60% of cases occurring in men over the age of 70 years. In 2002 there were 
31,923 new cases of prostate cancer diagnosed in the UK [2] and this figure will 
undoubtedly rise as the population at risk grows with the lengthening of life expectancy.
Despite this seemingly high burden of disease, only a third of all men diagnosed with 
prostate cancer actually die of their malignancy. The overall five-year survival rate for 
men diagnosed in England in 2000 -  2001 was 71%. For men that present with 
localised disease, 6 -  46% of patients will develop generalised disease without 
treatment, depending on age, stage, grade, PSA and ethnicity [9-18]. Untreated men 
diagnosed with early localised disease (TO -  T2), have only a 17% risk of developing 
metastases over the subsequent 20 years [16]. This risk increases substantially with T3 
disease (34% at 10 years) and high grade cancer (74% at 10 years). These figures 
translate into a disease specific survival at 5 and 10 years of 70 -  98% and 50 -  92% 
respectively, if localised prostate cancer of any grade or stage is left untreated.
1.1.2 Predicting Outcome
The fact that so many men diagnosed with prostate cancer would have a normal life 
expectancy without treatment has lead to considerable efforts to predict which patients
16
actually require therapy for localised disease. In the field of prostate cancer 
epidemiology, the definition of outcome can be a difficult concept. Most men are in their 
60s and 70s at the time of diagnosis. In a disease with a natural history measured in 
decades, the general health of a study population will have a proportionally large 
influence on outcome compared to the small differences observed between treatment 
groups. For many men with localised disease, life expectancy will be unaffected by the 
success of their primary anti-cancer treatment. Therefore in order to measure 
treatment efficacy, surrogate measures are required. The relationship between the 
surrogate marker and the incidence of ‘clinical events’ determines whether that 
particular measure has prognostic value.
The most commonly used biomarker in prostate cancer is PSA and the associated 
outcome measure is biochemical (PSA) relapse-free-survival (RFS). Like all other 
‘relapse-free’ or ‘progression-free’ estimates, PSA RFS is not a true measure of 
survival in that the end-point is not death. As a result it is subject to biases from the 
definition of relapse used and its method and frequency of measurement. In 1996 a 
consensus conference was convened to try to standardise the use of PSA as a 
biomarker for reporting outcomes in irradiated patients [19]. This ASTRO failure 
definition (three consecutive rises in PSA) provided a manner in which studies could be 
compared. However a number of features of the definition resulted in a discrepancy 
with the observed clinical outcome. Most notably these included a profound sensitivity 
to the length of follow up, a censoring artefact resulting from the fact that the date of 
relapse was backdated to a time midway between the PSA nadir and the third 
consecutive PSA rise and false positive results caused by benign fluctuations in PSA. 
A study by Thames et al. examined 102 different definitions of biochemical failure in 
4839 men with localised prostate cancer to determine which predicted clinical failure 
most accurately [20]. Four definitions were found to be superior to the ASTRO 
definition. One of these has now been adopted as the new consensus definition and is 
now referred to as the RTOG-ASTRO Phoenix definition [21]. It is defined as a rise in 
PSA of 2ng/ml above the nadir level with the date of relapse being the date of the PSA 
test that satisfies this criterion. It must be noted that this is a consensus of expert 
opinion based on the best available data in 2006, as patterns of treatment change 
other definitions may become more appropriate measures of outcome.
Modification of the standard PSA test may provide more accurate prognostic 
information. The rate at which serum PSA levels change (PSA velocity) may be an 
important indicator of the presence of life-threatening disease. In a recently published 
study PSA velocity was determined in 980 men who were participants in the Baltimore
17
Longitudinal Study of Aging [22]. PSA velocity, measured 10-15 years before 
diagnosis, was associated with cancer-specific survival of 92% among men with PSA 
velocity of 0.35 ng/mL per year or less and 54% among men with PSA velocity above 
0.35 ng/mL per year (P < 0.001). Furthermore, men with PSA velocity above 0.35 
ng/mL per year had a higher relative risk of prostate cancer death than men with PSA 
velocity of 0.35 ng/mL per year or less (RR = 4.7, 95% Cl = 1.3 to 16.5; P = 0.02).
The risk of relapse and death from localised prostate cancer depends on both clinical 
and biological factors. In localised disease the most powerful predictive factors for 
biochemical relapse are the pre-treatment serum PSA level, Gleason grade and TNM 
stage. Combination of these measures can be used to stratify patients. The ‘Partin 
tables’ were originally developed by urologists Alan Partin and Patrick Walsh based on 
accumulated data from 4,133 patients who had been surgically treated for prostate 
cancer [23]. They correlated PSA level, Gleason score, and estimated clinical stage 
with the definitive pathological stage. A probability was calculated for each of the 
following four: organ confined disease, extraprostatic extension, seminal vesicle 
invasion, and lymph node invasion. The primary value of the tables is for counselling 
patients regarding the probability of their tumour being a specific pathologic stage, 
rather than use as a strict decision-making tool. The nomograms help patients and their 
doctors make informed decisions based on the probability of a pathologic stage, the 
individual patient's risk tolerance, and the values they place on the various potential 
outcomes.
However, the Partin tables are calculated using clinical stage as assessed by digital 
rectal examination. Using modem imaging, highly accurate T  staging is now possible, 
with sensitivity and specificity of advanced MRI techniques frequently in excess of 90% 
[24-27]. As a result it is hard to justify a treatment decision based on a strategy that 
ignores some of the available information. Other normograms have been developed for 
the same purpose. A formula based only on PSA and grade, proposed by Roach et al, 
appears to be reasonably accurate at estimating the incidence of extracapsular 
extension in patients with low or intermediate risk disease [28]. The risk of biochemical 
failure following radiotherapy also correlated with the risk of extracapsular extension.
Numerous genetic and biological features have been shown to correlate with outcome 
following treatment for localised prostate cancer (table 1.1). Currently none of these 
are used to direct the treatment decision. This is largely due to the fact that in general 
these predictive markers are not modality specific. They indicate that a relatively poor 
outcome is likely whichever treatment is chosen. With further validation, some of these 
indices may be useful, alone or in combination, to determine whether radical treatment
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Table 1.1 Factors associated with poor outcome in localised prostate cancer -  other than Stage, 
Gleason grade and PSA.
Category Risk Factor Risk
Demographic Factors Age Age > 65 increases likelihood of systemic relapse following local therapy
Race Risk of relapse higher in African Americans compared to white Americans
Histological Subtype Periurethral Duct Carcinoma Often anaplastic with frequent mitoses
Transitional Cell Carcinoma Approximately double rate of positive lymph-nodes
Prostatic Duct Adenocarcinoma 35% 5-year survival (58% following radical RT)
Sarcomatoid Carcinoma Median survival < 2 years
Genetic Factors Abnormal p53 protein expression increased incidence of distant metastases, decreased RFS and decreased overall survival.
Low p27 protein expression Increased recurrence after radical prostatectomy
p21 over-expression Reduced 5-year survival
DNA content x 5 -  9 increased risk of relapse if tumour is not diploid
Morpholocical Factors Multifocal disease Approximately double recurrence rate
Tumour Volume Large volume predicts for LN and distant metastases
Microscopic Factors Nuclear Morphometry Low nuclear area and ellipsoid shape predict for poor prognosis
Microvessel Density (MVD) High MVD may predict for reduced disease specific survival
Cell Proliferation Ki-67 labelling index High index associated with a reduced 5-year PFS following surgery
S-phase fraction (SPF) High SPF associated with increased local progression and reduced time to metastases
Biological Factors Hypoxia Low prostate : muscle p02 ratio predicts for biochemical relapse
E-Cadherin Low levels correlate with recurrence after radical treatment
Insulin-Like Growth Factor High expression of binding protein predicts recurrence after prostatectomy
Androgen Receptor Expression higher AR expression results in poor overall survival in hormone-refractory prostate cancer
Surgery Positive Surgical Margin x 4 risk of biochemical relapse
Radiotherapy Radiation Dose Doses < 70 Gy associated with increased probability of biochemical recurrence
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is appropriate at all. However, certain biological properties of tumours have specific 
relevance to radiotherapy in that they are known to alter radiation sensitivity. These 
include angiogenesis, hypoxia and proliferation. Identification of the level and 
distribution of these factors may guide treatment selection and facilitate specific 
targeting of radioresistant tumours.
1.1.3 Imaging Biomarkers
The interest in imaging biomarkers in oncology derives from the extensive use of 
imaging technologies in diagnosis and patient care. The fact that many of the cutting- 
edge imaging technologies work in vivo makes them especially suitable for observing 
the response in live patients. The generic term biomarkers applies to all detection 
methods used in the life sciences and may be defined as any detectable biologic 
parameter, whether biochemical, genetic, histologic, anatomic, physical, functional, or 
metabolic. By logical extension, imaging biomarkers are defined as any anatomic, 
physiologic, biochemical, or molecular parameter detectable with one or more imaging 
methods used to help establish the presence and/or severity of disease.
Recent advances in imaging offer exciting opportunities to develop and validate 
oncological biomarkers as valuable adjuncts to diagnosis, tests of treatment efficacy, 
and/or treatment monitoring. State-of-the-art structural, functional, and molecular 
imaging methods allow the tumours to be visualized noninvasively in vivo at 
submillimeter and subsecond spatial and temporal scales. However, the development 
and validation of imaging biomarkers present some special challenges, including the 
following: equipment evaluation, procedure standardization, data regarding
reproducibility and replication, inter-observer variability, the production and 
measurement of reference standards, sensitivity to interventions or disease 
progression, inter-subject variance, choice of image reconstruction, automated versus 
observer-dependent image analysis and whether a reliable association can be 
demonstrated between the imaging biomarker and a clinical endpoint.
Every day, radiologists assess findings in imaging studies that gauge the effectiveness 
of medical treatments. These imaging biomarkers range from simple measurement of 
tumour mass to cutting-edge MR, PET or CT imaging sequences developed to enable 
evaluation of tumour biology. The clinical benefit of these techniques is obvious, 
however a broader and potentially more important use of these techniques is the 
systematic evaluation of the therapies themselves, where the imaging biomarkers 
become surrogate end points for clinical trials.
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Key to the enormous potential of imaging biomarkers is the reality that many medical 
therapies alter the anatomic, physiologic, biochemical, or molecular parameters readily 
visualized with imaging techniques. Particularly with established modalities such as 
conventional radiography, CT or MR imaging, a large pool of existing imaging 
technologies may be brought to bear in a cost-effective manner to help assess the 
presence and severity of many diseases. Even imaging modalities that are not yet 
clinically approved and not generally applicable in patients may be used effectively in 
preclinical decision making, as is the case with a number of molecular imaging 
methods.
1.2 Prostate Cancer Angiogenesis
1.2.1 Overview
Angiogenesis involves a cascade of events in which mature, resting host endothelial 
cells are stimulated to proliferate, degrade their basement membranes and to form new 
blood vessels. The angiogenic process is a complex multistep sequence involving many 
growth factors (cytokines) and interactions between varieties of cell types. 
Angiogenesis is crucial for normal development and persists into adult life. 
Physiological processes such as wound healing and the regeneration of the 
endometrium during the normal menstrual cycle are dependent on new vessel growth. 
Pathological processes such as diabetic retinopathy and cancer are equally reliant on 
angiogenesis. The development of a new blood supply is an essential requirement for a 
tumour to grow larger than about 1mm3 in size [29].
Angiogenesis plays a pivotal role in the growth, invasion, metastasis and survival of 
prostate cancer. Proliferation and apoptosis are intimately linked with prostate cancer 
angiogenesis [30]. Expression of angiogenic cytokines in prostate cancer can be 
induced as a response to hypoxic stress, by hormonal stimulation, but can also result 
from activation of oncogenes. Angiogenesis in prostate cancer is highly dependent on 
vascular endothelial growth factor (VEGF) [31]. It has been shown that VEGF is 
produced in abundance by the prostatic secretory epithelium of normal, hyperplastic, 
and tumour containing glands [32] (figure 1.1). With respect to the vasculature, it is 
clear that VEGF is required for vascular homeostasis in benign prostatic hyperplasia 
(BPH) and maintains a high fraction of immature vessels (those without investing 
pericytes or smooth muscle cells) in prostate cancers.
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Tumour cells promote angiogenesis by the upregulation of pro-angiogenic factors such 
as VEGF and its receptors as well as the downregulation of antiangiogenic factors such 
as thrombospondin-1 [33-37].
Figure 1.1 VEGF Immunostaining of malignant prostate tissue
The upregulation of pro-angiogenic genes including VEGF, Angiopoietin-2, Nitric oxide 
synthase (NOS), Platelet derived growth factor (PDGF) and Basic and Acidic 
fibroblastic growth factor (bFGF and a FGF) is a feature of the tumour 
microenvironment [35, 38-44]. VEGF increases vessel permeability and induces 
endothelial cell migration and proliferation in conjunction with Ang-2 [45-48]. 
Endothelial spouts are then formed that develop into blind ending tubes, which 
anastomose together to form vascular loops [49],
Tumour vessels may lack protective mechanisms such as mural cells and a basement 
membrane. Even if mural cells are present, they may not be functionally normal: 
Morikawa et at observed abnormalities in pericyte shape and abnormal separations 
between alpha smooth muscle actin and CD31-positive cells on tumour vessels, 
indicating that pericytes were only loosely associated with endothelium [50] (figure 
1.2). Tumour vessels may not always have an intact endothelial cell lining. 'Mosaic' 
vessels have been observed that have focal regions where tumour cells appeared to 
be in contact with the vessel lumen [51, 52], These features are likely to contribute to 
the increased vascular permeability of tumour vessels compared to those found in 
normal tissues.
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Figure 1.2 Anti-smooth muscle actin stain of malignant prostate tissue
Pericytes
Increased microvessel density (MVD) counts are seen in BPH [53] and in high grade 
prostatic intraepithelial neoplasia [54]. Higher MVD counts are also associated with 
prostate cancer with Gleason scores greater than seven. Immuno-histochemical 
studies have found that MVD in prostate cancer and BPH are higher than in the 
peripheral zone [55] but there is an overlap in MVD counts between tumours and BPH.
MVD is a potential prognostic factor that has been correlated with clinical and 
pathological stage, metastasis and histological grade in prostate cancer. MVD has also 
been correlated with disease-specific survival and progression after treatment [56-58]. 
MVD has not however been shown to correlate consistently with outcome after radical 
prostatectomy [59].
There are a number of features of tumour vascularity that are characteristic of 
malignancy which are amenable to study by imaging techniques. These include: (1) 
Spatial heterogeneity and chaotic structure. (2) Poorly formed, fragile vessels with high 
permeability to macromolecules. (3) Arteriovenous shunting, high vascular tortuosity 
and vasodilatation. (4) Intermittent or unstable flow due to transient rises in already 
raised interstitial pressure. These and other microenvironment characteristics can be 
reflected by currently available, clinical imaging techniques such as dynamic contrast 
enhanced MRI, perfusion CT, diffusion MRI, proton MR spectroscopy and ultrasound.
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1.2.2 The laboratory measurement of angiogenesis
1.2.2.1 The Immunohistochemicai Quantification of Angiogenesis
Microvessel Density: Microvessel density (MVD) is widely used as a surrogate 
measure of angiogenesis in pathological specimens and tumour models. It simply 
involves counting the number of blood vessels within a particular tissue region. 
Immunohistochemicai staining techniques are used to identify the microscopic vessels 
with several different vessel wall antigens being used as markers. Commonly used 
antibodies for assessing MVD in prostate cancer are anti-factor VIII related antigen 
(FVIIIAG or von Willebrand’s factor), anti-CD34 and anti-CD31. These antibodies have 
different sensitivities and immunostaining characteristics. Anti-CD31 is known to stain 
plasma cells, macrophages and in some instances, carcinoma cells. Anti-CD34 also 
stains immature haematopoetic cells.
A study has evaluated these three endothelial markers of microvessels in benign and 
malignant prostatic tissue [60]. Fifteen benign hyperplastic prostate and 54 prostate 
cancer specimens were immunohistochemically stained for CD31, CD34 and vWF. The 
MVD obtained by each marker was quantified by a vessel count in standardized grids 
within the area of maximum angiogenesis. The data on MVD was interrelated and 
compared to tumor staging, grading and clinical follow-up. A significant correlation of 
the CD31/CD34/vWF-MVD data was observed in BPH tissue, but not in cancer. In 
prostate carcinoma, the most sensitive marker for newly derived blood vessels was 
CD34. While CD34-MVD demonstrated a significant association with tumour grading 
and PSA follow-up, CD31- or vWF-MVD did not. The group concluded that CD34 is the 
best marker for the immunohistochemicai visualization of microvessels in benign and 
malignant human prostate tissue specimens.
Despite the fact that MVD counting is seemingly a simple technique, the area of tumour 
that is counted differs between researchers. Many count in areas seen to have high 
vascularity at low magnification, the so-called ‘hotspot’ method. Alternatively, some 
count in randomly selected areas or in specifically defined areas, such as the tumour 
edge. Methods of MVD measurement are varied and as yet no standardisation has 
been achieved. At a consensus meeting Vermeulen et al. have attempted to redress 
the problem by suggesting a standardised technique [61]. This involved counting 
vessels in the presumed highest angiogenic area. However, it is apparent that this has 
not been taken up as a standard method and will not work in some tumour types. 
Chalkley Point Counting: This technique employs a 25-point eyepiece graticule, 
which is applied over a vascular ‘hotspot’ at x250 magnification [62]. The graticule is
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oriented so that maximum numbers of points are superimposed over areas of 
immunohistochemically-highlighted microvessels. The Chalkey count is the number of 
grid points that hit stained microvessels. It is therefore a relative area estimate rather 
than a true vessel count. One advantage of using this system is the reduction in bias 
produced by eliminating the uncertainly caused by distinguishing whether two adjacent 
stained areas represents one or two separate blood vessels.
Automated Analysis: Computerised analysis methods for immunohistochemicai 
analysis are now increasingly used and are often reported in medical literature [63-67]. 
In general, these techniques employ standard immunohistochemicai staining as 
described above. The histological slide is digitised and computer software differentiates 
the brown immunohistochemicai stain from the background stain (usually blue 
haematoxylin). Results are displayed as the proportional area of brown stain as a 
percentage of the total area of the slide or region of interest. This gives a mean total 
vascular area rather than a true vessel count. Correlations between the two measures 
have been documented in prostate cancer (appendix A).
1.2.2.2 Table 2: Examples of non-immunohistochemical
angiogenesis models and assays
Model /  Assay Technique Measurement
The dorsal 
skinfbld window 
chamber model 
(rodents)
The cornea 
pocket assay
The Matrigel 
plug assay
Sponge assays
The chick 
chorioallantoic 
membrane 
(CAM) assay
A flap of skin is dissected away from opposing 
surfaces of a dorsal skin flap leaving a fascial 
plane with associated vasculature. Tumour 
cells or small tumour pieces can be implanted 
into the window chamber 
A cell line is evaluated by inserting the 
suspension into a micro pocket that has been 
surgically produced in the rabbit cornea 
Observations of the implants are performed 
with a slit lamp stereomicroscope.
Matrigel is a matrix of a mouse basement 
membrane neoplasm known as Engelbreth- 
Holm-Swarm murine sarcoma
Subcutaneous implantation of various artificial 
sponges in animals can be used to study 
angiogenesis in vivo
The early chick embryo lacks a mature 
immune system. Tissue grafts are placed on 
the CAM through a window made in the 
eggshell
Allows for the direct examination of in 
vivo tumour angiogenesis and 
microcirculation
Angiogenic activity is evaluated on 
the basis of the number and growth 
rate of newly formed capillaries.
Matrigel containing test 
angiogenesis-inducing compounds or 
tumor cells can be injected 
subcutaneously in mice 
Compounds to be evaluated are 
either injected directly into the 
sponges or incorporated into ELVAX 
or hydron pellets, which are placed in 
the center of the sponge 
Compounds are either prepared in 
slow release polymer pellets, 
absorbed by gelatin sponges or air- 
dried on plastic discs and then 
implanted onto the CAM.
25
1.3 The Endocrine Regulation of Prostate Cancer
Androgens seem to regulate VEGF expression in prostate cancer cells and benign 
prostatic tissues [68]. VEGF expression in androgen-dependent cell lines is down 
regulated upon androgen withdrawal. Prostate tumours from these cell lines undergo 
vascular regression prior to tumour cell death [69]. Studies have demonstrated a link 
between androgen action and angiogenesis in androgen-responsive LNCaP [68], PC- 
82 and A2 [70] human prostate cancer xenografts. Androgen deprivation causes a 
reduction in tumour VEGF levels resulting in inhibition of angiogenesis and the collapse 
of tumour vasculature mediated by vascular endothelial cell apoptosis [69]. This results 
in tumour vessels adopting more normal vascular characteristics, including reduced 
diameter, tortuosity, vascular permeability and leukocyte adhesion.
Animal experiments have convincingly demonstrated that blood flow to the prostate 
gland is drastically reduced within a very short period of time following surgical 
castration in animal models [71, 72]. As measured in rat ventral prostate tissue, blood 
flow rates were reduced by 50% within 24 hours of castration. Neither a sham surgical 
castration procedure, nor immediate testosterone replacement following orchidectomy 
affected flow in this way. Prostatic capillaries degenerate during the early period after 
castration, whereas the larger vessels that survive become highly constricted [73]. This 
effect may be mediated by nitric oxide synthase (NOS) and cyclic GMP (cGMP). Acute 
prostatic vasoconstriction is likely to contribute significantly to a decrease in prostate 
blood flow following castration.
Clinical studies have provided evidence for a relationship between androgenic steroid 
stimulation and vascular activity in human prostate tissue using the 5-a reductase 
inhibitor Finasteride, which is widely used to treat the symptoms of benign prostatic 
hypertrophy. This suggests that hormonal therapy has the potential to alter the vascular 
system of the human prostate. Also, Immunohistochemicai examination of prostate 
tissues obtained from patients treated with androgen-withdrawal for prostate cancer 
have noted a significant reduction of tissue microvascularity compared to hormone- 
naTve patients [74].
These results imply that blood flow regulation is a major mechanism through which 
androgen ablation affects the prostate gland. It explains the rapid changes in prostate 
volume and may be the primary factor influencing cell death. However, this dramatic 
reduction in blood flow potentially initiates tissue hypoxia, a consequence that has 
profound implications with regard to radioresistance.
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Androgen deprivation has been the most common form of therapy for advanced 
prostate cancer since the 1940s following the demonstration, by Charles Huggins, that 
surgical castration could cause disease regression [75]. The advent of 
pharmacological methods for androgen ablation has led to the inclusion of hormonal 
therapies into radical treatment strategies for localised prostate cancer with the aim of 
increasing cure rates. There is still some uncertainty as to the optimal combination and 
schedule for endocrine therapies within the context of treatment for early prostate 
cancer, however a number of recent clinical studies have provided an evidence base 
for their use.
Neo-adjuvant hormonal therapy prior to radical prostatectomy does not improve overall 
survival, however it does reduce the rate of positive surgical margins and can 
significantly improve other pathological variables such as lymph node involvement and 
pathological staging [76-85]. Similarly, androgen deprivation following radical 
prostatectomy does not improve overall survival [86-88] although one study suggested 
an improvement in disease-specific survival at both five and ten years [87].
In combination with radiotherapy, androgen deprivation can be administered 
beforehand (neo-adjuvant) during (concomitant) or afterwards (adjuvant). Four 
randomised studies using neo-adjuvant and concomitant androgen deprivation have 
been published [89-92]. No overall survival benefits were observed in any of the 
reports, although sub-group analysis of one study suggested a possible advantage for 
the patients with Gleason grade 2-6 tumours [92]. The results from these four studies 
have been pooled in a meta-analysis [93]. The combined data confirms the lack of an 
overall survival benefit or any advantage in terms of disease specific survival. However, 
the meta-analysis did demonstrate a significant improvement in terms of both 
biochemical and clinical disease free survival (odds ratios of 1.93 and 1.86 
respectively; p < 0.00001) in favour of neo-adjuvant androgen deprivation.
Four other trials have demonstrated the effectiveness of androgen deprivation in the 
adjuvant setting [86, 94-96]. The study by Bolla et al. was the only one of the four to 
demonstrate an overall survival advantage in its own right (78% versus 62% survival at 
5 years in favour of three years of adjuvant goserelin, p = 0.0002). However meta­
analysis of the 2844 patients included in these four studies demonstrates that overall 
survival, at both 5 years and 10 years, was significantly improved in the groups that 
received adjuvant hormones (odds ratio 1.29, p = 0.007 for 5 years and odds ratio 
1.44, p = 0.003 for 10 years). A similar advantage was seen in terms of disease
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specific survival (odds ratio 2 .10, p < 0 .00001) and disease free survival (odds ratio 
0.91, p < 0.0001) at five years.
Several other reports have assessed the use of neo-adjuvant, concomitant and 
adjuvant androgen deprivation together in combination with radiotherapy. The 
Radiation Therapy Oncology Group (RTOG) protocol 92-02 compared two months of 
neo-adjuvant and two months of concomitant hormonal therapy with or without the 
addition of two years of adjuvant androgen deprivation [97]. The patients that received 
the additional adjuvant therapy benefited from superior efficacy outcomes in terms of 
disease free survival, cause specific survival, biochemical failure, distant metastases 
and local progression. There was no benefit with respect to overall survival other than 
for a subgroup of patients with Gleason scores of eight to ten. Laverdiere et al. 
reported a two-part study in which patients were initially randomised between external 
beam radiotherapy alone, three months of androgen ablation prior to radiation therapy 
and a third arm which received hormonal treatment for three months before 
radiotherapy continued until six months after radical treatment [91]. Initial analysis after 
two years of follow-up demonstrated that both arms that received androgen deprivation 
were superior to the group that were treated with radiotherapy alone. These two arms 
comprised the second part of the study, which contrary to RTOG 92-02, showed that 
there was no significant benefit from the addition of an adjuvant component to the pre- 
radiotherapy androgen deprivation.
The issue regarding the use of hormonal therapy in combination with permanent (low 
dose-rate) prostate brachytherapy is also the source of some uncertainty. Two large, 
non-randomised studies have reported conflicting results. A retrospective study of 938 
consecutive patients from West Virginia, USA, demonstrated that after brachytherapy, 
androgen deprivation had no impact on overall or cause-specific survival for any risk 
group, although there was a suggestion of a beneficial effect on PSA progression free 
survival for high-risk patients [98]. In contrast, a much larger retrospective series from 
Arizona, USA, evaluated 2,378 consecutive patients, 464 of which had received pre­
implant androgen deprivation for prostate downsizing [99]. The hormone treated group 
showed a 24% overall survival detriment at 10 years (44% versus 20%, p = 0.02), 
which was independent of stage, grade, PSA level and age.
Mechanistically, the sequencing of hormonal therapy and radiotherapy is of great 
importance. Androgen deprivation prior to or during radiation therapy has the potential 
to cause vascular, physiological, biochemical and genetic changes within a prostate 
tumour that may influence its radiobiology in terms of intrinsic radiosensitivity, initial
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clonogen number, potential clonogen doubling time, cell-loss factor and repopulation 
rate. In this scenario, hormonal therapy can be considered to be acting as a radio­
modulator. By contrast, in the adjuvant setting androgen deprivation has no influence 
on tumour radiosensitivity and its actions can be regarded as additive rather than 
synergistic.
There is little doubt that much of the clinical benefit attributed to androgen deprivation 
results from its cytotoxicity and resulting reduction in tumour clonogen number. 
However, if this cytoreductive effect comes at the expense of an increased radio­
resistance amongst the remaining tumour clonogens, then part or all of the beneficial 
effects of hormonal therapy may be lost, or even reversed, if the interaction between 
androgen deprivation and radiation is allowed to occur prior to or during radiotherapy.
It is relevant that only studies that have used androgen deprivation in the adjuvant 
setting have shown a survival benefit for combined modality treatment. Whereas the 
only study to demonstrate a detrimental effect caused by androgen deprivation, 
examined the use of neo-adjuvant hormones. No published study has ever compared 
neo-adjuvant with adjuvant androgen deprivation in the setting of radical radiotherapy. 
As a result there is no clinical data that informs on the synergistic (or possibly 
antagonistic) interaction between these two therapy modalities. A randomised trial, in 
which both arms receive the same duration of hormonal therapy and same 
radiotherapy method, with the randomisation determining only whether the androgen 
deprivation starts before or after radiotherapy, would effectively control for all factors 
other than the interaction between hormones and radiotherapy. This strategy could 
provide an insight into the role that androgen deprivation plays in the radiobiology of 
prostate cancer and whether the biological changes induced by hormonal treatment 
impacts on its clinical radiosensitivity. However, in the absence of clinical data, one 
must turn to other evidence in order to draw a conclusion regarding the consequence 
of combining androgen deprivation and radiotherapy.
A study using the androgen dependent Shionogi in vivo spontaneous murine mammary 
tumour system, found that neoadjuvant androgen deprivation, in the form of 
orchidectomy 12 days prior to irradiation, profoundly and significantly reduced the 50% 
tumour control dose (TCD50) when compared to adjuvant androgen deprivation (a 
reduction from 85.7 Gy to 43.3 Gy) [100]. If radiation therapy was deferred after the 
neoadjuvant androgen deprivation until an androgen independent state had been 
achieved and the tumour had regrown to its original volume, then the advantage of 
prior neoadjuvant androgen deprivation was lost (the TCD50 value rose to 73.3Gy). This
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study provided one of the first pieces of evidence for a synergistic effect between 
androgen ablation and irradiation and confirmed the findings of a prior study using the 
Dunning 3227 rat prostate cancer cell line in nude mice that was reported in abstract 
form only [101]. However, these results could be explained by additive cell killing, with 
fewer clonogens left for survival measurements. The TCD50 assay cannot distinguish 
between an additive effect on cell killing and an interaction resulting in supra-additive 
cell death. It must also be noted that the Shionogi model has some important 
distinctions from human prostate cancer. The tumour is exquisitely sensitive to 
androgens, with volume reductions in excess of 80% seen in the majority of tumours 
after neoadjuvant androgen deprivation, which contrary to the situation in human 
prostate cancer, leaves little for the radiotherapy to eradicate. The Shionogi tumours 
rapidly become androgen insensitive, with tumour regrowth to original volumes within 
25 -  35 days of orchidectomy. Furthermore, the animal tumours are homogeneous 
rather than a mixture of benign, hyperplastic and malignant tissue as is the case in the 
human prostate.
In the normal prostate, androgen deprivation causes apoptotic cell death, reducing 
epithelial cell numbers by up to 80% [102]. However, in both animal tumour models and 
human prostate cancer, the dominant effect of androgen deprivation is cell cycle arrest 
rather than cell death [103, 104]. A study using double thymidine analogue labelling 
and flow cytometry of Dunning prostate R3327-G tumour-bearing rats, demonstrated a 
profound shift from predominantly proliferating tumour cells (65% proliferating cells) to 
mostly quiescent tumour cells (>90% quiescent cells) 3 days after castration [105]. The 
potential doubling time (Tpot) increased from 6 to 42 days. The apoptosis rate was 
measured at approximately 1%, equivalent to the proliferation rate, resulting in no net 
gain or loss of cell numbers following androgen deprivation. Similar studies using the 
Ki-67 labeling index have also shown that the predominant effect of androgen ablation 
in human prostate cancer is to reduce proliferation rather than to cause cell death [104, 
106].
Quiescence and lengthening of Tpot have long been associated with radio-resistance 
[107]. Therefore, for neo-adjuvant or concomitant androgen deprivation to result in an 
improvement in radiation response, these changes must be countered by other effects 
such as a reduction in the clonogen repopulation rate, increased radiation induced 
apoptosis or enhanced intrinsic tumour radiosensitivity. Evidence from Joon et al. 
suggests that the apoptotic index following radiation may be increased by pre- 
treatment with androgen ablation [108]. This group also used the Dunning R3327-G 
tumour model and measured the peak apoptotic index following radiotherapy in
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androgen-deprived rats versus controls. They showed that apoptosis, measured six 
hours after irradiation, increased almost five-fold, suggesting a supra-additive 
interaction between androgen ablation and radiation due to modulation of apoptosis. 
Garzotto et al. have reported conflicting results using the LNCaP cell line [109]. This 
group demonstrated a five-fold reduction in postmitotic apoptosis following the 
deprivation of androgenic stimuli, which they attribute to cell cycle delay.
A study using androgen-sensitive LNCaP cells in culture, irradiated with 2 or 8 Gy, 
three days after androgen deprivation, demonstrated that despite an increase in 
apoptosis as measured by the TUNEL assay, clonogenic survival experiments showed 
no advantage over the androgen deprivation or radiotherapy alone control groups in 
terms of radiosensitivity [110]. These results suggest that there is no interaction 
between androgen deprivation and radiotherapy, when cell death is measured globally 
via clonogenic assay. The fact that there may have been a small degree of supra- 
additivity in terms of apoptosis, implies that the level of apoptosis is only a minor 
component of overall cell death, alternatively that the increases in apoptosis occurred 
in a sub-population of cells that would have been killed by the radiotherapy in any case 
or that the increase in apoptosis induced in one sub-population of tumour cells is 
countered by the induction of radioresistance in another sub-population.
Given that androgen deprivation cannot eradicate prostate cancer, with ubiquitous 
findings of residual cancer in prostatectomy specimens resected after primary 
treatment with hormones, a hypoxic environment is likely to reduce the tumour control 
probability for the remaining clonogens. No study has specifically addressed this issue. 
A report by Parker et al. used the Eppendorf polarographic electrode system to 
measure the intraprostatic p02 of 55 men with clinically localized prostate cancer 
before high-dose conformal radiotherapy [111]. They demonstrated a wide variation of 
tumour oxygen levels ranging between 0.2 and 57.3 mmHg. No difference was 
observed on the basis of whether the patient had been previously treated with 
androgen deprivation. However, only nine patients had received neo-adjuvant 
hormones, making the study underpowered to answer this question given the variability 
of p02 readings. A paired study, with measurements before and after androgen 
withdrawal, would be a more robust method of analysis and would control for inter­
subject variation.
MRI techniques have the ability to take measurements from the entire prostate gland 
and characterise the nature of the component tissues. Multiple examinations are 
possible for every patient and the non-invasive nature of the procedure allows
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investigation of the true physiological environment. Padhani was the first to publish 
results of paired Tr weighted DCE MRI measurements of vascular permeability before 
and after three months of androgen withdrawal [112]. Reductions in tumour 
permeability were observed (p <0.001) and these reductions coincided with a decrease 
in serum PSA levels in 91% of patients. Further development and validation of 
functional MRI technology now allows the use of a combination of Trweighted DCE 
MRI, T2*-weighted DSC MRI, diffusion weighted imaging and BOLD MRI to obtain 
information pertaining to vascular flow, volume, permeability, cellularity and tissue 
hypoxia.
1.4 Tumour Hypoxia
1.4.1 Overview
Oxygen was first identified as a factor that could influence cancer biology when its 
effect on radiation response was discovered in 1909 [113]. The radiation response of 
skin was shown to reduce when blood flow was interrupted by direct compression. 
Mottram in 1935 supported this hypothesis with the finding that variation in tumour 
radiosensitivity depends on the size of tumour islands within a mass, which in turn is 
governed by the proportion of cells at a significant distance from a blood vessel [114]. 
This was the first time diffusion dependent hypoxia was suggested as a concept. 
Mottram observed that this phenomenon also exists in testicular irradiation, where 
spermatids distant from blood vessels continue to produce spermatozoa, even when 
the dose given is large enough to cause sterility. In 1942, two further papers described 
experiments showing that anoxic mice survived higher doses of whole body radiation 
[115, 116]. Manipulating tissue oxygenation to overcome the hypoxia problem was 
shown to be feasible in a report by Hollcraft [117]. The regression of lymphosarcoma 
xenografts produced by a fixed dose of radiation was greatest when breathing oxygen 
and 5% carbon dioxide, intermediate when breathing air and least when breathing 92% 
Nitrogen and 8% oxygen at the time of irradiation.
The relationship of radiosensitivity to varying oxygenation was first shown in mammals 
by Gray et al in 1953 in an Ehrlich mouse ascites model [118]. A series of experiments 
showed the dependence of radiosensitivity on oxygen, consistent with studies on non­
mammalian cells. Cell survival was reduced by a factor of 2.5 to 3 when irradiated in 
oxic conditions (100% 0 2 Vs 100% nitrogen). This enhancement did not occur when 
densely ionising radiation was used. They also showed that the response to 
radiotherapy could be increased when oxygen was given to mice under 3 atmospheres 
compared to 1 atmosphere pressure.
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Thomlinson and Gray provided the first evidence of the detrimental effects of hypoxia in 
human tumours [119]. A series of human lung cancers were characterised by a 
particular appearance, in which cords of tumour cells of varying sizes were surrounded 
by stroma containing vascular supply. The larger tumour cords had a necrotic centre 
surrounded by a rim of intact cells. All tumour cords with radii greater than 200pm 
exhibited necrosis but no necrosis was seen in tumour cords with a radius less than 
160pm. The surrounding sheath of intact tumour cells never exceeded 180pm, 
irrespective of the size of the necrotic centre. Thomlinson and Gray postulated the 
variability of measured values obtained around the mean was due to both tumour cords 
not running exactly perpendicular to the plane of the section, and to partial blood vessel 
compression reducing oxygen concentration at the periphery of the cords. These 
distances are equivalent to the calculated distance that oxygen would be expected to 
diffuse through the tumour and imply a rim of viable cells exist in a chronically hypoxic 
state around the edge of the necrotic regions.
Further evidence that a sub-population of viable hypoxic cells exists in tumours came 
from cell survival assays of solid lymphosarcoma xenografts in mice [120]. Survival 
curves derived from endpoint dilution assays exhibited a steep slope at low doses and 
a shallower slope at higher doses. When the experiment was repeated under anoxic 
conditions, cell survival was increased and the slope matched the steeper gradient 
across the whole dose. The proportion of hypoxic cells was estimated to be about 1% 
from the ratio of the cell survival in each experiment. More recently, the range of 
hypoxic cells human tumours has been estimated to be much higher [121].
Hypoxia is an important factor in radiotherapy treatment failure and has been 
associated in clinical studies with poor local tumour control and relapse in carcinomas 
of the head and neck, prostate, bladder and cervix and also in soft tissue sarcomas 
[122-127].
1.4.2 The biology of tumour hypoxia
There are two distinct mechanisms that can generate regions of hypoxia within 
tumours. Chronic diffusion limited hypoxia, as already described, occurs in tumour cells 
that are situated at a distance from the nearest blood vessel. Depending on whether 
the nearest vessel is a venule, capillary or arteriole clinically relevant hypoxia will begin 
to arise at a distance of 70 -  100pm. The partial pressure of oxygen will decline further 
as the distance from a vessel increases up to approximately 160 - 180pm, where
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anoxia will lead to necrotic cell death. Diffusion limited hypoxia is relatively stable and 
will not vary minute-by-minute or hour-by-hour. However, over the life of an individual 
tumour, the balance between tumour growth and angiogenesis will affect the vascular 
distribution, thereby influencing the pattern of diffusion-limited hypoxia over time. It is 
the cells bordering the necrotic region, which are viable and clonogenic, yet exist in a 
hypoxic environment, that are likely to exhibit a resistant phenotype.
Evidence has emerged that another, distinct, type of hypoxia may contribute to the 
overall pattern of tumour oxygenation at any given point in time. Acute, transient, 
perfusion limited hypoxia results from temporary, reversible cessation of blood flow by 
closure or blockage of blood vessels within tumours. The first direct evidence for this 
came from experiments using the fluorescent perfusion marker Hoechst 33342 [128]. 
This group, based at the Gray Cancer Institute, categorised tumour cells into 10 groups 
depending on their proximity to a functional blood supply. This was done using a 
fluorescence activated cell sorter based on the cell’ s Hoechst ‘concentration’ (i.e. ratio 
of fluorescence intensity and peripheral light scatter). The study demonstrated that 
even cells close to a blood supply might become transiently hypoxic at any particular 
time and that larger tumours were more prone to perfusion-limited hypoxia. These 
findings were confirmed using laser Doppler studies that allowed direct measurement 
of red cell flow in both murine and human tumours [129]. Results demonstrated that in 
human tumour microregions, 26% showed a change in erythrocyte flux by a factor of 2 
or more over a 60 minute measurement period. More than 50% of changes were 
completed within 20 minutes. Within the 1 hour monitoring period at least 30% of the 
changes were reversed. These findings demonstrate that microregional changes in 
erythrocyte flux, resulting in transient, perfusion-driven changes in oxygenation, are a 
feature of human malignancies as well as experimental transplanted tumours.
1.4.3 The molecular basis of tumour hypoxia
The key regulator of cellular oxygen homeostasis is the dimeric hypoxia-inducible 
transcription factor HIF. The stability HIF-1 is oxygen dependent. Under conditions of 
normal oxygenation it is rapidly degraded by the ubiquitin proteosome pathway. One of 
the steps in the degradation process involves the hydroxylation of a HIF-1 a proline 
residue by prolyl hydrolase. This enzyme has an absolute requirement for the presence 
of oxygen and ferrous (Fe2+) iron as cofactors for activity. In the absence of oxygen, 
HIF-1 a is stabilised, which allows its translocation to the nucleus where it binds with the 
HIF-1 p sub-unit. The resultant HIF heterodimer then activates the transcription of a 
number of genes that participate in the normal adaptive response of the cell to hypoxia.
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These genes include VEGF (angiogenesis), erythropoetin (red blood cell production), 
glycolytic enzymes (glucose metabolism and energy) and carbonic anhydrase (pH 
balance).
Like many other cellular processes, HIF is regulated by p53. This tumour suppressor 
gene promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF- 
1a subunit. Loss of p53 in tumour cells enhances HIF-1 a levels and augments HIF-1 - 
dependent transcriptional activation of the vascular endothelial growth factor (VEGF) 
gene in response to hypoxia [130]. Hypoxia induces p53 and therefore causes 
apoptosis in cells that possess wild-type p53. However, oncogenically transformed 
cells that contain mutated p53 are unable to undergo apoptosis in response to hypoxia 
and are therefore conferred a survival advantage. By selecting for mutant p53, hypoxia 
not only leads to deregulation of HIF-1 a and stimulation of angiogenesis but also to 
genetic instability and enhanced tumour progression.
Immunohistochemicai studies using monoclonal antibodies to HIF-1 a have 
demonstrated high levels of immunoreactivity in human tumour specimens compared 
with very low levels in normal tissues [131]. HIF-1a expression correlates with VEGF 
expression, microvessel density and tumour grade [132-136].This is manifest in the 
clinical observation that hypoxia and HIF-1 a expression selects for an aggressive 
phenotype and poor prognosis in many tumour sites [125, 134,137-140].
1.4.4 Hypoxia in prostate cancer
Hypoxic regions exist in human prostate carcinoma [111, 141]. Both Movsas et al. in 
1999 and Parker et al. in 2004 used the Eppendorf microelectrode to characterize the 
range and heterogeneity of oxygen partial pressures in the prostates of men with 
prostate or bladder cancer. Movsas’ group took 2145 individual p02 measurements 
from 12 patients. They showed that the oxygen measurements from the pathologically 
involved portion of the prostate were significantly lower than those from normal muscle. 
Similarly, higher p02 readings were obtained from the pathologically normal prostates 
than from the prostates of patients with prostate carcinoma. Increasing levels of 
hypoxia were observed with increasing clinical stage. Significant predictors of 
oxygenation included the type of tissue and clinical stage. As a confounding factor in 
this study, the type of anaesthesia used was also predictive of prostate oxygenation. In 
a subsequent report, the same investigators found that p02 also correlates with age 
[142].
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Parker investigated the prostates of 55 men prior to radical radiotherapy for prostate 
cancer. p02 values ranged from 0.2 to 57.3 mmHg, with a median of 4.5 mmHg. The 
percentage of the 40-50 individual p02 measurements in each patient that were less 
than 5 mmHg ranged between 0 and 100%, with a median of 60%. This confirmed that 
biologically significant hypoxia exists in the majority of patients with clinically localized 
prostate cancer. No correlation was observed between p02 and Gleason score, 
prostate-specific antigen level or haemoglobin concentration. Contrary to Movsas’ 
report, no association was found between the level of oxygenation and T-stage or age 
and there was no significant difference in p02 between prostate cancer and benign 
prostate tissue.
The outcome of radical radiotherapy for prostate cancer is appreciably influenced by 
the presence of hypoxia. Movsas’ group from the Fox Chase Cancer Center, USA, 
prospectively studied 57 patients with localized disease [126]. A prostate : muscle p02 
ratio of less than 0.05 resulted in significantly worse biochemical relapse-free survival 
at 2 years (31% versus 92%, p <0.0001). Although this study was reported after a 
median follow-up of only 19 months, the substantial difference in relapse between the 
two groups is notable. Oxygenation status may therefore be another underlying 
biological parameter beyond the classic prognostic factors (age, clinical stage, Gleason 
score and prostate specific antigen) that predicts for treatment failure in prostate 
cancer. A modeling study based on these clinical data has predicted an oxygen 
enhancement ratio for prostate cancer of 1.4 (95% confidence interval of 1.2 -  1.8), 
which is consistent with the in vitro OER measurements of human tumour cell lines 
under chronic hypoxia conditions [143]. As in many other malignancies, these 
evaluations suggest that hypoxia is likely to be a valid therapeutic target in prostate 
cancer.
1.4.5 The detection and measurement of tumour hypoxia
There are a wide range of different methods to measure tissue oxygenation that have 
been evaluated [144, 145]. An ideal technique would be non-invasive, technically 
simple, reproducible, able to evaluate the whole tumour mass and give a real-time 
measurement of tissue p02 for a tumour in any body location. No such instrument 
exists. Each method of measurement has its own limitations and the chosen technique 
needs to be considered in the context of the clinical or laboratory situation in which it is 
to be used.
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Broadly, measurements of tumour oxygenation can be divided into invasive and non- 
invasive techniques. Invasive methods involve inserting an electrode into the tumour or 
sampling the mass with a biopsy or total excision. Non-invasive approaches utilize 
radiological imaging (table 1.3):
Table 1.3 Examples of methods for measuring tumour hypoxia
In vitro In-vivo Invasive Non-lnvasive
Laboratory Laboratory Clinical Methods Clinical Methods
Methods Methods
Comet Assay Needle pC>2 probes Extrinsic Immuno- SPECT
Eppendorf histochemistry PET
Oxylite Pimonidazole Nitroimidazoles
Intrinsic Immuno- 
histochemistry 
HIF 1a 
CA9 
GLUT1
18F-miso
Cu-ATSM
EF-5
18f - f a z a
MRI
BOLD
DCE
MRS
Diffusion
Extrinsic Immunohistochemicai Markers of Hypoxia -  The Nitroimidazoles 
The nitroimidazoles are a group of nitro-aromatic molecules originally used as anti­
protozoal agents. Their investigation grew out of the findings that nitroaromatic 
compounds were hypoxic cell radiosensitisers. Varghese et al. performed experiments 
using 14C-labelled misonidazole on Chinese hamster ovary cells in vitro and KHT 
murine fibrosarcoma tumour cells in vivo [146]. The radioactivity associated with the 
acid-insoluble precipitate from cells incubated in nitrogen in vivo was 400% higher than 
that of cells incubated in air. When aqueous extracts of a KHT tumour grown on a C3H 
mouse after intraperitoneal injection with misonidazole were analysed, the reduction 
product was found in higher concentration in the tumour compared with normal tissue. 
These experiments proved that misonidazole formed reduction products under hypoxic 
conditions and that they were retained within hypoxic cells. It was also the first 
identification of hypoxia using an 2 nitroimidazole within an in vivo tumour.
The metabolism of 2-nitroimidazoles occurs in a series of one-electron reductions 
(figure 1.3). A nitro-radical anion, produced by the first one-electron reduction step, 
avidly reacts with oxygen and is oxidised back to the parent molecule so that in well-
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oxygenated conditions there is effectively no substrate for the second step. In low 
oxygen concentrations, one-electron product is further reduced to the nitroso (2 e-), 
hydroxylamine (4 e-), and amine (6 e-) derivatives. Eventually, the imidazole ring 
fragments. The reactive portions of the molecule bind to a range of macromolecular 
components such as thiol groups. All atoms of the ring and side-chain of the 2- 
nitroimidazole are retained. The side-chain also binds to cellular macromolecules 
because of fragmentation of the amine. Although variability in the rate of binding of 
nitroimidazoles by different cell lines was seen by Chapman in his work on TF MISO, 
an analogue of misonidasole [147], the local cellular oxygen concentration is the most 
important determinant of binding rate [148].
In totally anoxic conditions, binding is proportional to the square-root of the 
concentration of misonidazole [149]. Small quantities of oxygen convert this to first- 
order kinetics by reducing the concentration of a reactive free radical and so reducing 
its ability to react with itself by second order kinetics [150]. The oxygen-dependence of
2-nitroimidazoles binding in cells is similar to their dependence of radiosensitivity. 
Hodgkiss et al. incubated Chinese Hamster cells in vitro with NITP, a theophylline 
bound 2-nitroimidazole, at a range of oxygen concentrations [151]. Using a fluorescent 
antibody and flow cytometrical quantitation, the hypoxic;oxic differential was 1,400 
ppm, similar to the value of 3800ppm for half the radiosensitising effect described by 
Begg [152],
A histological assessment of hypoxia in tumours provides information on relationships 
between hypoxia and other microregional factors. It also allows exploration of the 
association between hypoxia and factors such as necrosis, vascularity, proliferation, 
differentiation, apoptosis, and oxygen regulated protein expression. Raleigh et al raised 
polyclonal antibodies in rabbits to the haemocyanin adduct of CCI-103F (a 
hexafluorinated 2-nitroimidazole). Florescence studies showed that the marker bound 
within spheroids and tumour sections in patterns similar to those seen in the 
autoradiographic studies [153]. Subsequent testing in spontaneous canine tumours 
clearly showed binding occurred 10-12 cell diameters away from tumour blood vessels,
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Figure 1.3 The bioreductive metabolism of Pimonidazole
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consistent with the where ‘chronically’ hypoxic cells would reside. The hypoxic fraction 
ranged from 4 to 13% according to an analysis of multiple tumour sections. Staining 
was seen adjacent to necrosis, although not exclusively and some binding occurred in 
cells close to blood vessels. Most staining was restricted to tumour cells although some 
staining of smooth muscle cells surrounding arterioles in some sections of normal 
tissue and tumour tissue was observed [154]. Further work from the same group 
confirmed immunohistochemistry was a feasible and straightforward method of 
assessing hypoxia in tumours including the development of an enzyme linked 
immunosorbent assay for the binding of CCI-103F [155].
In addition, the first investigation of the spatial relationship between hypoxia and 
proliferation was demonstrated in canine tumours using this method [156]. In this study, 
serial sections were stained for pre-administered CCI-103F to reveal hypoxic regions 
and proliferating cell nuclear antigen (PCNA) to localise proliferation. Characteristically, 
diffusion limited hypoxic staining away from vessels was evident, whereas proliferating 
cells were predominantly near blood vessels. The two cell populations showed a 
degree of geographical overlap. Whilst immunoglobulins could be raised to the 
fluorinated component of CCI-103F, it had not been clinically tested.
As a result attention turned to pimonidazole, the 2-nitroimidazole with an 
immunologically detectable piperidine side-chain. There was a wealth of 
pharmacokinetic and pharmacodynamic data supporting its safe use in humans from 
the radiosensitiser trials of the 1980s. It also had good chemical stability, water 
solubility and wide tissue distribution. Initial studies using pimonidazole showed the 
lifetime of hypoxic cells in canine tumours was of the order of days [157] and that the 
high binding of 2-nitroimidazoles in the liver did reflect normal tissue hypoxia and not 
native nitroreductases [158]. Pimonidazole has now been used in many experimental 
studies and clinical trials worldwide. At the pimonidazole dose of 0.5 g/m2 used in 
hypoxia marking, pimonidazole causes neither central nervous system toxicity nor 
sensation (e.g., flushing). Central nervous system toxicity was of particular interest 
because this was the dose limiting at the higher, multiple doses used in radiosensitizer 
trials.
Protein adducts of reductively activated pimonidazole are effective immunogens for the 
production of both polyclonal and monoclonal antibodies. The antibodies have been 
used for immunoperoxidase analysis of formalin fixed, paraffin embedded sections and 
for immunofluorescence analysis of frozen fixed sections. Another attractive feature of
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pimonidazole is the fact that pimonidazole adducts in vivo are long-lived. This provides 
flexibility in the timing of biopsy taking which is an advantage in a clinical setting.
Pimonidazole binding assays provide hypoxia measurements with a high spatial 
resolution. Another strength of the technique is that dead cells do not generate a signal 
because they do not metabolize nitroimidazoles. Oxygen microelectrode 
measurements have been compared with the nitroimidazole binding assays in patients 
with squamous cell carcinomas [159]. Despite a trend that tumors with high p02 values 
measured with microelectrodes expressed less nitroimidazole binding, there was a lot 
of scatter in the data and no significant correlation was found between the two assays. 
Necrosis is suggested as being the major confounding factor. The direction of the bias 
is opposite for the two methods: microelectrode readings characterize necrosis as 
anoxic, whereas absence of nitroimidazole binding in necrotic areas would identify 
them as oxic. Evaluation of pimonidazole binding can be corrected for necrosis but the 
quantitative impact of necrosis on the result of microelectrode measurements is 
impossible to correct for in human tumors.
Hypoxic fraction estimated by pimonidazole binding agreed well with the hypoxic 
fraction measured using the comet assay in a number of animal and human tumors 
indicating that pimonidazole labeling can give a reliable estimate of radiobiologically 
relevant hypoxia [160]. The spatial relationship between tumor vasculature and 
pimonidazole binding was studied with a multiple staining and functional microscopic 
imaging technique in a human glioma xenograft model. With the perfusion marker 
Hoechst 33342 perfused and non-perfused vessels could be discriminated. The density 
of the perfused vessels was inversely related to the pimonidazole hypoxic fraction. At 
critical distances from perfused vessels, hypoxia occurred and the largest proportion of 
hypoxia was found at distances beyond 100 mm [161]. These data suggest that 
predominantly diffusion-limited hypoxia was detected.
Recently, it was demonstrated that there is a significant association between 
pimonidazole binding and loco-regional and disease-free survival in head and neck 
carcinomas. Of even greater interest is the observation that this association 
disappeared in a group of patients treated with ARCON, strongly suggesting that the 
nitroimidazole binding assay can provide a selection tool for hypoxia modifying 
treatments on an individual patient basis [162].
Pimonidazole is not the only nitroimidazole that can be detected by means of 
immunohistochemistry (table 1.4). CCI-103F was the first and NITP was the second
41
hypoxia marker used in this way. A disadvantage of these substances was the poor 
water solubility. In mice, a vehicle of DMSO and peanut oil was necessary for 
intraperitoneal administration, and these markers were never approved for clinical use. 
This led to the development of antibodies against more suitable hypoxia markers such 
as EF5 and pimonidazole. Unfortunately, attempts to raise antibodies against reduction 
products of misonidazole, the most widely used imaging agent, resulted in antibodies 
with relatively weak specificity that were unsuitable for general use.
Table 1.4 Nitroimidazoles as hypoxia markers
Marker name Chemical name Dose (species) Minimum time to 
tumor excision
Approved 
for clinical 
use
Pimonidazole
NITP (A2- 
nitroimidazole)
CCI-103F
EF5
(1-(2-nitro-1-
imidazolyl)-
3-A/-piperidino-
2-propanol)
7-(4’-(2-
nitroimidazol-
1-yl)-butyl)-
theophylline
(1-(2-hydroxy-3-
hexafluoroisopro
poxy-
propyl)-2-
nitroimidazole)
[2-(2-nitro-1 H- 
imidazol- 
1-yl )-/V-
(2,2,3,3,3-penta-
fluoropropyl)
acetamide]
60-80 mg/kg (mice) 
0.5 g.m'2 (humans) 
0.285 g.m'2 (dogs)
30-60 min (mice) 
>2 h (patients)
156 mg kg' (mice) 1-2 h (mice)
60-80 mg.kg' (mice) 
200 pM (rat)
40 mg.kg'1 (dog)
100 pM (rat)
9-21 mg/kg (human)
2 h (mice) 
24 h (dogs)
3 h (mice)
24h (patients)
Yes
(Europe, 
Canada 
and USA)
No
No
Yes (USA)
1.4.6 Carbogen Gas Breathing
1.4.6.1 Overview
Carbogen is a normobaric gas mixture of carbon dioxide and oxygen, which is usually 
administered at one of two concentrations (95% 0 2 with 5% C02 or 98% 0 2 with 2% 
C02). Carbogen has been demonstrated to improve the oxygenation of both 
experimental and human tumours. However, there is evidence to suggest that, at least 
in some tumours, enhanced blood flow may also contribute to its action. This gas 
mixture increases intravascular oxygen availability resulting in greater oxygen uptake
42
by tumours. Carbogen also transiently opens non-functional blood vessels, likely to be 
a result of the C02 component of the gas mixture. This further increases oxygen 
delivery to regions of perfusion-limited hypoxia and also causes an increased leakage 
of molecules from the plasma to the extracellular space. Extracellular tumour pH has 
been shown to decline in response to carbogen gas breathing, in particular if the 
tumours are large and hypoxic [163].
The rationale for the use of a high oxygen-content gas to improve tumour oxygenation 
is that the resulting increase in arterial p02 will enhance the diffusion of oxygen into the 
tissue. The addition of 2 or 5% C02 was originally proposed to counteract any 
vasoconstriction induced by pure oxygen breathing. A study in a murine tumour model 
was performed to determine how the C02 content of the inspired gas influences 
radiosensitivity [164]. Gas mixtures containing 0, 1, 2.5 and 10% C02, balanced with 
oxygen, were compared with 5% C 02 + 95% 0 2. Measurements of tumour oxygenation 
and perfusion were also made during the breathing of each gas. The results showed 
that the level of radiosensitization achieved is dependent on both the C 02 content of 
the inspired gas and the duration of gas breathing. No radiosensitization was evident 
following inhalation of 90% 0 2 + 10% C 02. All other gases elicited radiosensitization. 
However, that achieved with 100% 0 2 disappeared at the extended pre-irradiation 
breathing time of 45 min. Changes in oxygenation, as measured by p02 electrodes, did 
indicate improved oxygenation status following the inhalation of the gases. However, 
the time course and extent of the changes did not mirror accurately the changes in 
radiosensitization. All the gases with a C 02 content of 2.5% or greater induced a 10- 
20% reduction in microregional blood flow.
This study implies that the decreased radiosensitization seen at extended breathing 
times of 100% oxygen is unrelated to blood flow changes. The fact that 
radiosensitization is seen with extended breathing times of gases containing 2.5 & 5% 
C02, despite blood flow decreases, is indicative of other overriding physiological 
changes, perhaps related to oxygen utilization. The studies overall indicate that, at 
least in the tumour investigated, radiosensitization is maintained if the C02 content of 
the inspired gas is reduced from 5% to 2.5 or even 1%.
In humans, tolerance to carbogen can be a problem with patients feeling flushed and 
breathless during inhalation. These symptoms are considerably reduced if 2% C02 is 
used instead of 5% C02. A study comparing tumour oxygenation during inhalation of 
hyperoxic gas containing either 2% or 5% C02 has been performed [165]. Tumour p02 
was measured in 16 patients using the Eppendorf p02 histograph. After breathing gas
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containing either 5% or 2% C 02 an increase in median p02 was measured in every 
tumour, the frequency of low p02 values (less than or equal to10 mmHg) fell from 47% 
to 29% in the 5% group and from 55% to 17% in the 2% group. This confirms that 
breathing 2% C 02 and 98% 0 2 is well tolerated and effective in increasing tumour 
oxygenation.
1.4.6.2 Accelerated radiotherapy with Carbogen and
Nicotinamide (ARCON)
Nicotinamide (niacinamide) is one of the two principal forms of the B-complex vitamin 
niacin. Nicotinamide, via its major metabolite NAD++ (nicotinamide adenine 
dinucleotide), is involved in a wide range of biological processes, including the 
production of energy, the synthesis of fatty acids, cholesterol and steroids, signal 
transduction and the maintenance of the integrity of the genome. It also causes 
vasodilation of cutaneous blood vessels.
Niacin deficiency has been found to inhibit DNA repair in cell culture models. NAD++ is 
the substrate for Poly(ADP-ribose)polymerase (PARP), an enzyme involved in DNA 
repair. Extensive damage to DNA results in the depletion of NAD++, which can trigger 
cellular apoptosis. In addition, nicotinamide, via NAD++, modulates the expression of 
the p53 tumour suppressor protein in human breast, skin and lung cells. These 
mechanisms may account, in part, for some of the the possible anti-cancer activity of 
nicotinamide.
In terms of hypoxia modification, nicotinamide appears to reduce impaired tumour 
blood flow and thus affects the proportion of acutely hypoxic cells. A major component 
of its activity is the improvement of tumour oxygenation resulting from a reduction in 
microregional ischaemia. Nicotinamide is known to reduce arterial blood pressure in 
rodents, suggesting a vascular component in its mechanism of action. A direct effect on 
supplying blood vessels probably contributes to the oxygenating action of nicotinamide 
in tumours. Athough the precise mechanism remains obscure, studies on murine 
tumours suggest that nicotinamide, at least at high doses, reduces the occurrence of 
transient decreases in microregional perfusion [166].
Both carbogen and nicotinamide have radiosensitizing properties. When used together 
in animal models they produce enhancement ratios of 1.9 with conventionally 
fractionated radiotherapy and 2.8 with accelerated radiation schedules [167, 168]. Over 
the past 15 years a number of early phase human studies have been conducted using 
ARCON in a variety of tumour sites [169-173]. All of these studies encountered 
significant nausea and vomiting due to the nicotinamide resulting in reduced patient
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compliance. The common conclusion is that a dose of 80mg/kg or higher is not feasible 
and future studies should proceed with a starting dose of 60mg/kg. As none of these 
studies were randomised, it was not possible to formally evaluate efficacy. However 
two studies had sufficient patient numbers and length of follow up to draw tentative 
conclusions in comparison with historical controls. A study in glioblastoma multiforme, 
ARCON seemed to have no apparent benefit and concluded with the suggestion that a 
phase III trial was not justified [174]. In contrast, a larger study of 215 patients with 
locally advanced head and neck cancer indicated very favourable rates of locoregional 
tumour control and overall survival [175]. The actuarial 3-year local control rates were 
80% for larynx, 69% for hypopharynx, 88% for oropharynx, and 37% for oral cavity 
tumors. Regional control rates were 100% for NO, 93% for N1, and 74% for N2 
disease.
Following promising early toxicity data, the ARCON schedule has also been tested in 
bladder cancer [176]. A multi-centre phase III trial (BCON) comparing 55Gy in 20 
fractions of external beam with or without carbogen and nicotinamide has recently 
completed accrual. Results are expected by 2009.
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Chapter 2 
Introduction - MRI for the biological 
assessment of prostate cancer
2.1 Overview
Magnetic resonance imaging can produce images with high definition and image 
quality and provides the gold standard for morphological and anatomical assessment of 
prostate cancer. The technique utilizes the characteristic properties of protons, which 
vary depending on their chemical and physical environment. This environment differs 
between the various body tissues and in a number of pathological processes, such as 
malignancy. ‘Weighting’ the sequence that generates the image can produce various 
types of contrast. This is done by observing different aspects of the physical process 
that occur when the water protons interact with the applied magnetic field.
Given the fact that the MRI image is generated by changes that occur at the atomic 
level, it is not therefore surprising that this method may be useful in detecting the 
molecular, biochemical, physiological and metabolic changes that occur due to 
pathological processes within tissues. The key is to find sequences that will maximize 
the contrast caused by variations in a particular biological parameter, for example 
between areas of hypoxia and well oxygenated regions of tissue. Alternatively an 
exogenous contrast agent can be given and viewed over time to give measurements of 
perfusion and permeability of tissues, which can serve as markers for biological 
processes such as vascularization.
There are four functional magnetic resonance based imaging techniques: Dynamic 
Contrast Enhanced MRI (DCE-MRI), Intrinsic Susceptibility Weighted MRI -  also 
known as Blood Oxygen Level Dependent (BOLD) MRI, Diffusion Weighted Imaging 
(DWI) and Magnetic Resonance Spectroscopy (MRS).
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2.2 Dynamic Contrast Enhanced Magnetic Resonance 
Imaging (DCE-MRI)
2.2.1 Background
Review of the older MRI literature shows that ^-weighted contrast enhanced images 
can depict prostatic zonal anatomy (not visible on unenhanced TVweighted images) 
but in general, TVweighted spin-echo images are better in this regard. The normal 
central gland enhances more than the peripheral prostate; both enhancing 
homogeneously. In the presence of BPH, enhancement of the central gland becomes 
heterogeneous [1]. Prostate cancer also enhances following contrast medium 
administration. Much of the early literature indicated no additional role of contrast 
enhancement compared to conventional T2-weighted imaging for the assessment of 
prostate cancer [1, 2]. However in 1995, Brown et al. showed improved depiction of 
the intraprostatic location of tumours when images are obtained early after contrast 
administration [3], and Huch Boni et al. reported that contrast enhancement improved 
the detection of minimal seminal vesicle invasion by tumour [4]. Parallel developments 
in rapid MRI data acquisition methods lead to further clinical studies, which used a 
rapid series of images acquired continuously after bolus administration of contrast 
medium over a short period of time (1-7 minutes). This MRI technique, now called 
dynamic contrast enhanced MRI (DCE-MRI) has over time become established for 
improving lesion detection and staging and for the detection of suspected tumour 
recurrence. DCE-MRI is only one of many MRI methods that can directly evaluate the 
functional angiogenic status of tissues.
2.2.2 Dynamic contrast-enhanced MRI (DCE-MRI) technique
When a paramagnetic, low-molecular weight contrast agent is injected intravenously, it 
enters the tumour blood vessels and subsequently passes into the extra-vascular 
extra-cellular space. A high first pass extraction occurs in most normal tissues (with the 
exception of the brain, testes and retina) as well as in hyperplastic prostatic tissues and 
prostate cancer. In tumours, typically 12-45% of the contrast media leaks into the EES 
during the first pass [5]. Once out of the blood vessels the contrast agent is free to 
diffuse within the interstitial space until whole body distribution and renal excretion 
lowers the vascular concentration below that in the interstitial space at which stage, 
contrast medium passes back into the vascular space (figure 2.1).
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Figure 2.1 Body compartments accessed by low molecular weight 
contrast media injected intravenously
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Three major factors determine the behaviour of low molecular weight contrast media in 
the prostate gland during the first few minutes after injection: blood perfusion (contrast 
agent delivery), transport of contrast agent across vessel walls and diffusion of contrast 
medium in the interstitial space. If the delivery of the contrast medium to a tissue is 
insufficient to maintain a higher vascular concentration compared to that in the EES 
(flow-limited situations or where vascular permeability is greater than inflow), then 
blood perfusion will be the dominant factor determining contrast agent kinetics; this 
situation is commonly found in tumours. If tissue perfusion is sufficient and transport 
out of the vasculature does not deplete intravascular contrast medium concentration 
(non-flow limited situations -  e.g. in areas of fibrosis or glandular atrophy after 
hormonal and/or radiation treatment) then transport across the vessel wall (i.e. 
permeability surface area product) is the major factor that determines contrast medium 
kinetics. As low molecular weight contrast media do not cross cell membranes, their 
volume of distribution is effectively the interstitial space or EES (this excludes the 
glandular lumina). It is these differences in contrast agent behaviour between normal 
and hyperplastic prostatic tissues and tumour that are exploited by DCE-MRI to provide 
lesion / tissue specific information.
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MR sequences can be designed to be sensitive to the vascular phase of contrast 
medium delivery (so-called T2* or dynamic susceptibility contrast (DSC)), which reflect 
tissue perfusion and blood volume. Sequences can also be designed to be sensitive to 
the presence of contrast medium in the EES thus reflecting on microvessel perfusion, 
permeability and extracellular leakage space (so-called Ti or relaxivity based methods). 
These methods are compared in table 2.1 and illustrated in figure 2.2
Table 2.1 Comparison between Ti and T2* weighted dynamic imaging
T2*W imaging 
(susceptibility methods)
TiW imaging 
(relaxivity methods)
Tissue signal intensity change Darkening Enhancement
Duration of effect and optimal 
data acquisition
Seconds / subsecond Minutes / 2-25 seconds
Magnitude of effect Small larger
Optimal contrast medium dose > 0.2 mmol/kg b.w. 0.1-0.2 mmol/kg b.w.
Quantification method used Relative more than absolute Relative and absolute
Physiological property measured Perfusion/blood volume Transendothelial permeability, 
capillary surface area, lesion 
leakage space
Kinetic parameters derived Blood volume and flow, transit 
time
Transfer and rate constants, 
leakage space
Pathological correlates Tumour grade and microvessel 
vessel density
Microvessel density
Vascular endothelial growth 
factor (VEGF)
Principle uses for prostate 
evaluations
Mapping of hypoxia in tumours 
when used with BOLD-MRI
Lesion localisation and 
characterisation
Monitoring the effectiveness of 
therapy response
Detecting relapsed disease
2.2.3 T2* weighted DSC-MRI
2.2.3.1 Data acquisition
Perfusion-weighted images can be obtained with "bolus-tracking techniques" that are 
sensitive to susceptibility effects caused by the passage of contrast material in a 
capillary bed. Bolus injection of contrast medium is essential to the success of this 
technique. The degree of signal intensity loss observed on susceptibility-weighted 
images is dependent on sequence types and parameters used, the vascular
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concentration of the contrast agent and microvessel size and density [6, 7] (figure 2.2). 
The signal to noise ratio (SNR) of images can be improved by using higher doses of 
contrast medium (i.e., > 0.2-mmol/kg body weight) [6]. MRI systems capable of rapid 
image acquisition are required to adequately characterize these effects. High 
specification, echo-planar capable machines allow rapid multi-slice data acquisition. 
Although such studies are possible on conventional MRI systems using standard 
gradient-echo sequences, data acquisition is limited to a fewer slices. When examining 
the prostate, even small amounts of rectal air and rectal movement can cause 
additional, intrinsic susceptibility artefacts that may adversely affects the quality of 
DSC-MRI examinations.
Figure 2.2 Comparison of the Ti-weighted DCE-MRI and T2-weighted 
DSC-MRI data collections
k ' —_ k Z k
Time (secs) vs T,W-DCE-MRI 
Time (secs) vs Tj'W-DSC-MRI
Injection
Contrast medium injection took place after the 4th data point for the Tr weighted DCE-MRI 
study (time resolution 12 seconds) and after 10 data points for the DSC-MRI (time resolution 2 
seconds). The zero point on the time scale represents the point of injection of contrast medium 
for both studies, which were performed consecutively. The data are for the region indicated by 
the arrow on the morphological T2-weighted image. First pass susceptibility effects cause 
marked darkening of the prostate gland (Bottom row of images). Note how the signal intensity 
remains below the baseline due to rapid loss of compartmentalization of the Gd-DTPA. On the 
contrary, marked and sustained early enhancement of the prostate is seen on TVweighted 
DCE-MRI (top row). The onset and short duration of early T2*-weighted DSC-MRI effects 
corresponds precisely to the upslope on the Tr weighted enhancement curves for the same 
region of interest confirming that the upslope has a significant vascular contribution.
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2.2.3.2 Data quantification
A linear relationship between blood concentration of the contrast agent and change in 
transverse relaxation time is usually assumed. Analysis also assumes that the contrast 
agent remains in the vascular space throughout the examination period, acting as a 
blood pool agent. If this were the case, tracer kinetic principles can be used to provide 
estimates of relative blood volume (rBV), relative blood flow (rBF) and mean transit 
time (MTT) derived from the first-pass of contrast agent through the microcirculation. 
These variables are related by the central volume theorem equation (BF = BV/MTT) 
[8]. In the prostate, loss of compartmentalisation of the contrast medium always occurs 
because of high capillary permeability. This loss of compartmentalization of the 
injection bolus and the J : enhancing effects of diluted contrast agent in the EES 
counters T2* signal intensity-lowering effects, resulting in falsely lowered blood volume 
computations. Therefore, the conventional approach of deriving kinetic parameters 
obtained from the integral of the time-susceptibility curve should not be undertaken. 
Solutions for obtaining more reliable perfusion data under these circumstances include 
(1), optimisation of pulse sequence parameters to minimise T, signal enhancing 
effects, (2) pre-dosing with a small amount of contrast medium to allow J : shortening 
effects to occur before the arrival of the main bolus of contrast medium and thus 
minimise competing T, and T2* effects, and (3) fitting of a gamma-variate function 
(figure 2.3).
Figure 2.3 Model fitting of DSC-MRI data and parametric map formation
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Same patient as illustrated in figure 2. T2* signal intensity data from figure 2 is converted into 
R2* (=1/T2*) shown as the white line for the pixel at the centre of the cross-hairs on the 
parametric map (left) and then fitted with a gamma variate function (green then red line). 
Parametric map (left) representing relative blood flow (rBF; colour scale 0-20 arbitrary units) is 
derived on a pixel-by-pixel basis using this procedure.
59
2.2.3.3 Clinical experience of DSC-MRI
A limited number of studies have reported mainly in abstract form on the feasibility of 
using DSC-MRI to examine the prostate gland [9-11] (figure 2.4). Observations have 
shown that it is possible to demonstrate first pass, signal intensity lowering effects and 
that limited tissue characterisation is possible. That is, significant differences have 
been noted between peripheral gland and tumour with respect to signal intensity 
change [9]. However, no systematic differences between BPH and tumour 
enhancement values have been observed. Furthermore no published studies have as 
yet correlated DSC-MRI with patient prostate cancer serum PSA levels, tumour stage, 
Gleason score, or with MVD or VEGF immunostaining. Recent work has evaluated the 
potential of DSC-MRI for the assessment of prostate gland and prostate cancer 
hypoxia [11]. In this study 20 patients were imaged with Blood Oxygen Level 
Dependent (BOLD)-MRI and DSC-MRI prior to radical prostatectomy and regional 
hypoxia assessments were undertaken using pimonidazole immunostaining. The data 
showed that low relative blood volumes (rBV), when used alone, had a low sensitivity 
(24%) for the presence of regional hypoxia but sensitivity was high (91%) as was the 
positive predictive value (86%).
Figure 2.4 Correlation of DCE-MRI and DSC-MRI with whole mount 
histology and diffusion weighted images
T .Transfer constant» relative Blood Volume Leakage space
i  ; I
The T2-weighted image shows small focal areas of low signal intensity in the peripheral zone 
(arrows) corresponding to tumour foci on histology (circled regions). The tumour nodule on the 
left of the gland has a high transfer constant (colour scale 0-1 min'1) and relative blood volume 
(colour scale 0-300 arbitrary units). Tumour lesions are not visible on the leakage space map 
(colour scale 0-100%). Note how the central gland has high transfer constant values also.
T2-weighted
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2.2.4 Ti weighted (relaxivity based) dynamic MRI
2.2.4.1 Data acquisition
To monitor the tissue enhancing effects of contrast agents using Ti-weighted 
sequences requires that confounding T2 and T2* signal intensity lowering effects must 
be minimised. Trweighted gradient-echo, saturation recovery/inversion recovery 
snapshot sequences are often used for prostate imaging. The choice of sequence and 
parameters used is dependent on intrinsic advantages and disadvantages of the 
sequences taking into account T  ^ sensitivity, anatomical coverage, acquisition times, 
susceptibility to artefacts arising from sources of magnetic field inhomogeneities (e.g., 
from rectal gas, surgical clips etc) and the need for quantification. It is recognized that 
high-resolution and short imaging-time are competing examination strategies on 
current equipment. Higher temporal resolution imaging still necessitates reduced 
spatial resolution, decreased anatomic coverage or a combination thereof. Higher 
temporal resolution techniques are essential for DSC-MRI and appear to improve 
tissue characterisation on Trweighted DCE-MRI; one study has suggested that 
characterisation of prostatic tissues is optimal using image acquisition times of 2 
seconds [12].
In order to model tissue contrast behaviour the contrast agent concentration at each 
time point during the imaging procedure needs to be known. If the T1 relaxation rates 
can be accurately estimated, then tissue concentration of the contrast agent can be 
calculated [13, 14]. Some workers assume that the change in signal intensity (delta SI) 
or relative signal intensity (as a percentage change) is directly proportional to tissue 
contrast concentration using their sequence. However, when contrast agent 
concentrations become large (e.g., within vessels) then this becomes a poor 
approximation, because signal intensity varies nonlinearly with contrast agent 
concentration.
Common causes for failed examinations include poor contrast medium bolus 
administration (particularly if manual injection techniques are used) and the presence 
of hip prostheses, surgical clips and rectal gas, each causing susceptibility artefacts 
and technical failures (poor signal to noise ratio of images or unexpected machine gain 
changes during the data acquisition). Patient or internal organ movements (rectal 
movement or bladder filling affecting prostatic position) are also not uncommon and 
can lead to technical failures. For example, Padhani et al. have reported that 16% of 55 
patients had anterior prostatic displacements of > 5 mm due to rectal motion during
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DCE-MRI examinations lasting 7 minutes and noted an inverse correlation between the 
degree of rectal distension of the frequency of rectal movements [15].
2.2.4.2 Quantification, uncertainties and limitations
Signal intensity enhancement on Ti-weighted DCE-MRI images can be assessed in
several ways (qualitatively and quantitatively using kinetic model free variables or by 
the derivation of physiological indices using pharmacokinetic models). Qualitative 
assessments, based on the shape of the signal intensity-time curve, are useful 
clinically for tissue characterisation and for assessing response to treatment. Model 
free indices (often called semi-quantitative) describe tissue enhancement using a 
number of descriptors. These include onset of enhancement (time from injection or first 
appearance in a pelvic artery to the first increase in tissue signal intensity), initial and 
mean gradient of the upsweep of enhancement curves, maximum signal intensity, 
washout gradient and the integral areas under enhanced curves over fixed periods of 
time. Such model free parameters have the advantage of being relatively 
straightforward to calculate but have limitations including the fact that they may not 
accurately reflect contrast medium concentration in the tissue of interest and can be 
influenced by scanner settings (including gain and scaling factors).
Quantitative kinetic parameters are derived from concentration-time curves that are 
mathematically fitted using one of a number of recognised pharmacokinetic models [16] 
(figure 2.5). Examples of modelling parameters include the volume transfer constant of 
the contrast agent (K*308 - formally called permeability-surface area product per unit 
volume of tissue), leakage space as a percentage of unit volume of tissue (ve) and the 
rate constant (kep also called K2i ). These standard parameters are related 
mathematically (keP = Ktrans / ve) [17].
Experience shows that observed data obtained may not fit the model chosen: each 
model makes a number of assumptions that may not be valid for every tissue or tumour 
type. For example, the application of the Tofts’ model includes a standard description 
of the time varying blood concentration of contrast agent, also called the input function, 
that the supply of contrast medium is not perfusion limited and that tissue blood volume 
contributes negligible signal compared with that arising from contrast medium in the 
interstitial space [17]. Buckley has suggested that the application of commonly 
accepted models and their respective model-based assumptions to DCE-MRI data 
leads to systematic overestimation of K*3"8 [18]. Other potential sources of error arise 
from assumptions made for the determination of contrast medium concentration in vivo.
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Figure 2.5 Converting signal intensity into contrast concentration & 
model fitting
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Contrast medium injection took place after the 4th data point. Time signal intensity data is first 
converted into contrast agent concentration and then the model fitting procedure (continuous 
green line) is done using the Tofts’ model. Parametric maps representing transfer constant 
(K*308; colour scale 0-1 min'1), leakage space (ve; colour scale 0-100%), rate constant (keP; 
colour scale 0-4 min'1) are shown. The non-model dependent parameter (initial area under the 
Gd-DTPA concentration curve for 60 seconds (lAUGCeo); colour scale 0-40 mmol.sec) is shown 
for comparison.
For example, MRI contrast medium is detected only indirectly by its effect on 
extracellular tissue water. In tissues, extracellular water exchanges with the bulk of the 
water, which is intracellular. Accepting that there are outstanding issues with regard to 
model-based assumptions and the measurement of tissue contrast agent 
concentration, quantitative kinetic parameters such as K113"® and ve do allow 
comparisons to be made between patients, in the same patient at multiple time points 
and between patients at different imaging centres. Furthermore physiological indices 
can provide valuable insights on the causes of changing enhancement patterns seen 
after therapeutic interventions.
2.2.4.3 Validation of Ti weighted dynamic MRI in prostate 
cancer
It is possible to show characteristic differences in the enhancement patterns of 
peripheral prostate gland compared to the central gland and/or tumours. Studies show 
that prostate cancer enhances to a greater extent than the peripheral gland and that
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there is an overlap with the enhancement of the central gland. The enhancement 
patterns observed are likely to be related to underlying variations in tissue perfusion, 
MVD and tissue VEGF expression. Immuno-histochemical studies have found that 
MVD in prostate cancer and BPH are higher than in the peripheral zone. These studies 
also show that there is an overlap in MVD counts between tumours and BPH [19, 20]. 
Although many clinical studies have correlated tissue MRI enhancement with immuno­
histochemical MVD measurements (see Padhani 2002 for a review [21]), no systematic 
correlative studies have been performed in prostate cancer. There are also no clinical 
studies correlating tissue MRI enhancement with immuno-histochemical VEGF staining 
in prostate cancer.
Although initial observations by Jager et al., suggested that poorly differentiated 
prostate cancer showed earlier onset and faster rate of enhancement compared to 
other histological grades [12], this has not been bome out by subsequent reports [22, 
23]. Engelbrecht and colleagues demonstrated a weakly positive correlation between 
several DCE-MRI parameters and Gleason scores, with correlation coefficients ranging 
from -0.34 to +0.21 for peripheral zone carcinomas, with the strongest associations 
being for onset time and time to peak enhancement (correlation coefficients of 0.21 and
0.22 respectively) [22]. For central zone cancers, correlation coefficients ranged 
between -0.22 and +0.29, peak enhancement being the best correlate of Gleason 
score with a Pearson coefficient of 0.29. Other similar studies have shown no 
significant association between tumour grade and DCE-MRI kinetic parameters. 
Padhani et al. commented that the lack of correlation might be explained by histological 
sampling errors inherent in TRUS needle biopsy techniques. Engelbrecht et al. 
however used whole mount prostatectomy sectioning but had relatively few patients 
with well or poorly differentiated cancers which contributed to the lack of good 
correlation [22, 23].
2.2.4.4 Clinical experiences with Tf-weighted dynamic MRI
Primary diagnosis of prostate cancer
Following the widespread availability of PSA testing many men are referred for 
ultrasound guided biopsy with a high clinical index of suspicion that malignancy will be 
detected. The pre-biopsy probability of histological confirmation of cancer is up to 70% 
if the PSA £ 10ng/ml. However, a proportion of these men will have a negative biopsy, 
posing the clinical problem of whether this is a true-negative or false-negative result 
and the patient will usually be subjected to repeated biopsies. Some of these men will 
then be referred to MRI for diagnosis and localisation.
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The investigation by DCE-MRI of men for primary detection has been limited although 
there are two published reports evaluating this modality in previously undiagnosed 
patients. Hara et al. evaluated 90 men using low temporal resolution DCE-MRI [24]. 
Impressively, their reported cancer detection rate was 92.9% with a specificity of 
96.2%. Furthermore, the solitary false-positive case was found to have cancer following 
additional biopsies. The second, much smaller, study evaluated 14 patients with 
endorectal MRI prior to TRUS-guided biopsies [25]. Multiple MRI parameters were 
correlated with histology. K1'"’8, onset time, mean gradient and maximum enhancement 
of the gadolinium concentration-time curve showed a significant difference between 
tumour and normal tissue. The overall sensitivity and specificity were 59% and 74% 
respectively. Whilst these early reports show some promise, the case for DCE-MRI in 
this setting is not proven. More definitive, larger studies that take inter- and intra- 
observer variation into account are needed to define the role of functional MRI 
techniques. A more realistic approach, given current evidence, would be to use a 
multifunctional imaging approach combining DCE-MRI, 1H-MRS and DW-MRI to 
determine areas of the prostate associated with a high probability of cancer, thereby 
allowing targeted re-biopsy of a particular prostate region in addition to standard sector 
sampling. However, as a caveat to this strategy, it should be noted once a prostate 
gland has been needled, reactive enhancement in areas devoid of cancer, which is 
often diffuse, can obscure any tumour for a prolonged period of time.
Localisation and staging of prostate cancer
Despite the fact that there is debate regarding the optimal technique for Tr weighted 
dynamic data acquisition, numerous studies have found dynamic sequences superior 
to conventional T2-weighted sequences in terms of accuracy, sensitivity and specificity 
using histopathological confirmation as the gold standard (table 2.2). Jager et al in 
1997 reported on 57 patients that were imaged conventionally and with dynamic 
sequences [12]. Dynamic imaging improved sensitivity from 57.5% to 73.5% and 
accuracy from 72% to 77.5%, whilst not affecting specificity (80.5% versus 81% 
respectively). Namimoto supported this finding reporting a diagnostic accuracy of 75% 
for T2-weighted images, and 79% for dynamic images [26]. The accuracy of the 
combination of dynamic MR images with postcontrast Ti-weighted images was 82%. It 
was concluded that dynamic MR imaging was useful in the differentiation of low 
intensity lesions in the peripheral zone. Recently, a prospective study using whole- 
mount histopathology from radical prostatectomy specimens for correlation examined 
34 prostates using T2-weighted MRI, DCE-MRI and 1H-MRS [27]. Localization accuracy 
and ROI-based receiver operating characteristic (ROC) curves were calculated. Areas
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under the ROC curve for T2-weighted MR, DCE-MRI, and 1H-MRS were 0.68, 0.91, 
and 0.80, respectively. Furthermore, reader accuracy in tumour localization with 
dynamic MRI was significantly better than that with quantitative spectroscopic imaging 
(P < 0.01) in both the peripheral and central gland.
Although one would expect more accurate tumour localization to lead to better staging 
performance, there is only limited direct clinical evidence to confirm this. It would 
appear that DCE-MRI can help in patients with equivocal capsular penetration, seminal 
vesicle or neurovascular bundle involvement. A study designed to compare the staging 
accuracy of experienced versus less experienced readers, once again using whole- 
mount histopathology from radical prostatectomy specimens for comparison, showed 
that DCE-MRI improved the performance of less experience readers [28]. Staging 
performance for the less experienced readers with DCE-MRI resulted in significant 
improvement of the area under the receiver operating characteristics curve compared 
with T2-weighted MR imaging alone (0.66 and 0.82, respectively; P = 0.01). More 
experienced readers gained little from the addition of dynamic sequences.
Table 2.2 Studies comparing dynamic sequences with conventional T2-
weighted sequences for prostate tumour localisation
Study Year Numberof
Patients
Tumour/
segment
number
Sensitivity
(%)
T2 dyn
Specificity
(%>
T2 dyn
Accuracy
(%)
T2 dyn
Histo-
pathological
correlation
Jager 1997 57 102 57.5 73.5 80.5 81 72 77.5 Prostatectomy
Namimoto 1998 42 44 95 86 57 74 75 79 TRUS+Biopsy
Ogura 2001 38 85 - 59 - 88 - 72 prostatectomy
Muramoto 2002 34 34 - 100 - 85 - 92 Both
Ito 2003 31 122 - 87 - 74 - 82 TRUS+Biopsy
Kiessling 2004 27 27 - 70* - 88* - - prostatectomy
Schlemmer 2004 28 28 79* 68* - - - - prostatectomy
Hara 2005 82 'XAAA*sJ"■■■■■ - 92.9 - 96.2 - 80.5 TRUS+Biopsy
Kim 2005 53 53 65 96 60 82 62 88 prostatectomy
Kozlowski 2006 14 14 - 59 - 74 - - Both
Futterer 2006 34 476 67§ 69-
95§
74§ 80-
96§
71§ SI-
915
prostatectomy
*for Slope52
f for peripheral zone lesions only
*14 cores per patient, each core divided into 3; 82x14x3=3444 
§2 readers evaluated each image. Best results presented
66
2.3 Blood Oxygen Level Dependent Magnetic 
Resonance Imaging (BOLD-MRI)
2.3.1 Background
It has previously been extremely difficult to characterise the oxygen status of an 
individual prostate tumour prior to treatment. Immunostaining for hypoxia can only be 
performed once the tumour has been removed from the body. 19F nuclear magnetic 
resonance oximetry of perfluorocarbons (PFCs) has not been the subject of human 
trials and is limited by the limited distribution of PFC emulsions. Direct tumour 
measurement with electrodes (Eppendorf) is imprecise because of the inability of the 
operator to determine tumour regions within the prostate using the trans-rectal 
ultrasond probe. A non-invasive technique that accurately and repetitively measures 
tumour oxygenation may find broad applications in clinical and basic cancer research.
BOLD-MRI capitalizes on the differing magnetic properties of oxygenated and 
deoxygenated blood. Oxyhaemoglobin contains iron in the Fe3+ (diamagnetic) state, 
deoxyhaemoglobin contains iron in the Fe2+ (paramagnetic) state. Deoxyhemoglobin 
serves as an intravascular contrast agent because it brings about an increase in the 
transverse relaxation rates of blood and surrounding tissues. Microscopic field 
gradients in the vicinity of red blood cells and vessels are modulated by changes in the 
paramagnetic deoxyhaemoglobin concentration, which leads to signal attenuation in 
susceptibility weighted MRI sequences (T2*). In other words, the blood oxygen level 
itself is acting as a contrast agent. As the oxygenation of hemoglobin is closely related 
to the p02 of blood (described by the oxygen-haemoglobin dissociation curve), which is 
assumed to be in equilibrium with tissue p02, BOLD MRI is expected to provide a 
sensitive index of the oxygenation status of tissue immediately adjacent to perfused 
microvessels. Tissues with increased deoxyhaemoglobin concentration are seen as 
higher signal on the resulting BOLD MRI image.
The BOLD MRI effect can be quantified by plotting the natural log of signal intensity 
against the echo time to derive tissue relaxivity (the power of the exponent is 1/T2* or 
R2*, the rate of relaxation). This is performed for each imaging voxel and parametric 
R2* maps are produced (figure 2.6).
This phenomenon was first demonstrated in the brain by Ogawa and colleagues [29]. 
Its success in detecting the changes in oxygenation caused by neuronal activity has led
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to a number of clinical applications for its use in the field of neurology, including the 
assessment of haemodynamic changes, multiple sclerosis, stroke, degenerative brain 
disease, spinal injury and uses in psychology.
Figure 2.6 Calculation of R2*
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Its use in oncology is less prevalent and largely experimental at present. In 1994 the 
first report was published showing that T2* weighted MRI images may be useful in the 
detection of tumour hypoxia in an animal model [30]. Rats bearing an adenocarcinoma 
xenograft were imaged breathing air and 100% 0 2, with portions of the tumour 
exhibiting an increase in signal intensity of up to 50% following hyperoxia. Following 
this there has been demonstration of the enhancement effect of increased oxygenation 
on the BOLD image in a number of other experimental tumour models [31] and 
evidence that T2* weighted images can differentiate tumours from normal tissue [32].
2.3.2 Validation
Validation of the technique has been achieved by correlation with direct microelectrode 
measurements [33, 34], intravital microscopy [35] and immunohistochemistry [36], In 
rodent tumors, changes in the BOLD signal in response to vasomodulation, particularly 
by exposure to inhaled carbogen, mirror changes in tissue p02 [33, 34, 37-39],
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Carbogen inhalation affects BOLD MRI imaging for GH3 prolactinomas and RIF-1 
fibrosarcomas in different ways [31] most likely reflecting the underlying vascular 
status, including vascular volume, vessel size, and perfusion. Large decreases in 
signal are observed in GH3 tumors, suggesting oxygenation of deoxyhemoglobin in 
response to carbogen. RIF-1 tumors however, show less response, suggesting poorer 
oxygenation. For RIF-1 tumors, many areas may not be perfused, whereas GH3 
tumors are fairly well perfused.
A recent report has also provided the first evidence that BOLD contrast can offer a 
prognostic indication of acute radiotherapeutic response in rodent tumours [40]. In this 
experiment GH3 prolactinona and RIF-1 fibrosarcoma xenografts were irradiated with a 
single fraction. The disparity between intrinsic R2* and the change in R2* (AR2*) is 
reflected in a differential response to radiation therapy. RIF-1 tumors, which exhibit a 
relatively slow baseline R2* and negligible AR2* with carbogen, show no 
radiosensitization by carbogen. Whereas GH3 tumors, which show a relatively fast 
basal R2* and significant carbogen-induced AR2*, exhibited significant 
radiosensitisation. These results suggest that BOLD MRI can be used to identify 
patients who may benefit from vasomodulation during radiotherapy.
More recently, a number of research groups have sought to validate this application in 
human tumours. In human prostate cancer, areas highlighted by the T2* sequences are 
correlated with regions that stain with pimonidazole, an immunohistochemical marker 
for tumour hypoxia [41]. A further study has demonstrated BOLD imaging responses in 
a number of tumour types [42] and this technique is also a valuable tool in 
differentiating areas of prostate cancer from regions of benign prostatic hypertrophy in 
humans, as demonstrated by a study validated by histopathological comparison 
between prostatectomy specimens and corresponding BOLD images [43].
A preliminary report has suggested that R2* correlates with pimonidazole staining In the 
prostate gland. It appears to be most sensitive for identifying hypoxic regions within 
tumors but not within benign prostate hyperplasia [11]. A study reported by Hoskin et 
al. showed that the sensitivity of R2* in depicting tumour hypoxia was high (88%), 
improving with the addition of low blood volume information (95%) without changing 
specificity (36% and 29% respectively) [44]. Fast R2* increased the positive predictive 
value for hypoxia by 6% (70% to 76%); conversely, slow R2* decreased the likelihood 
of hypoxia being present by 24% (70% to 46%; and by 41% when combined with rBV 
information). This early study indicates that R2* maps from BOLD-MRI have high 
sensitivity but low specificity for defining intraprostatic tumour hypoxia. The high
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negative predictive value (70%) when combined with blood volume information 
indicates that BOLD-MRI may be a suitable technique for mapping prostatic tumour 
oxygenation.
2.3.3 Limitations
The BOLD MRI signal can reflect the hypoxic status of tumors but does not directly 
measure p02 values. The R2* quantity depends upon the total number of 
deoxyhaemoglobin molecules within each imaging voxel. The proportion of blood that 
is deoxygenated (i.e. the deoxyhaemoglobin : oxyhaemoglobin ratio) is not reflected. 
Therefore, if two similar regions with equivalent p02 are compared, the region that 
simply contains more blood volume will exhibit a higher R2* value because it contains 
more deoxyhaemoglobin molecules. In other words, BOLD-MRI is blood volume and 
therefore blood flow dependent (blood flow = blood volume / transit time). Obtaining 
perfusion measurements from the same region of interest can compensate for this. 
This can be achieved by combining BOLD-MRI with dynamic susceptibility contrast 
MRI, dynamic CT, diffusion weighted MRI or even Doppler ultrasound.
The R2* rate is related to the presence of deoxyhaemoglobin molecules within the red 
blood cell, however the parameter of interest is p02. The relationship between the 
proportion of haemoglobin that is oxygenated and the intravascular p02 is described by 
the sigmoidal oxygen-haemoglobin dissociation curve (figure 2.7). At p02 levels below 
about 40mmHg, the relationship is virtually linear. This indicates that for quantifying 
clinically relevant tumour hypoxia (<10mmHg), R2* is likely to be proportional to 
intravascular p02. For well-oxygenated regions, with p02 values that approach that of 
arterial blood, the relative increase in haemoglobin saturation for any given rise in p02, 
is much less. Therefore, BOLD-MRI should be more capable of discriminating between 
changes in low p02 levels than changes in high p02 levels. Image contrast on BOLD 
MRI can also be affected by carbon dioxide tension, hematocrit, pH, temperature and 
the presence of 2,3-diphosphoglycerate because of their effect on the oxygen- 
haemoglobin dissociation curve.
By virtue of the fact that the BOLD signal is created by blood cells, this technique can 
only reflect intravascular p02. There is no MRI ‘probe’ of the extravascular space. 
Tumour cells exist in the extravascular compartment, it is therefore the tissue p02 that 
influences tumour biology. Consequently, BOLD-MRI assumes that intravascular p02 is
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a reflection of the surrounding tissue p02. Oxygen diffuses from the vascular stroma 
into tumour, where it is consumed by the tumour cells. As a result there is a p02
Figure 2.7 The oxygen-haemoglobin dissociation curve
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gradient surrounding each tumour capillary up to a diffusion distance of about 180pm 
where cells are unable to survive and become necrotic. Therefore the intravascular p02 
does not give a true representation of the extracellular environment surrounding each 
tumour cell. Despite this, given the high vascular permeability within tumours, it is 
highly unlikely that a hypoxic tumour would contain blood vessels with a high 
intravascular p02 or a well oxygenated tumour would contain a high volume of 
deoxygenated blood.
R2* maps minimize, but do not completely eliminate, inflow effects that can contribute 
to contrast on single-echo gradient-echo images, while retaining sensitivity to 
oxygenation changes that may be caused by alterations in blood flow. Other limitations 
with particular relevance to imaging of the prostate gland include susceptibility artefacts 
generated by large quantities of rectal gas and movement of the gland caused by rectal 
filling during the image acquisition time. These may be partially reduced by asking 
patients to empty their bowels before the scan.
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2.4 Magnetic Resonance Spectroscopy (MRS)
2.4.1 Background
Magnetic resonance spectroscopy is a routine laboratory technique that has been in 
use by experimental scientists since the 1950s to obtain physical, chemical, electronic 
and structural information about a molecule. Over the past fifteen years software has 
been developed that allows medical MR scanners to be used in the same way, with the 
added advantage of combining the spectroscopic data with an anatomical image.
It was noticed that nuclei with an odd number of protons, like 1H and 31P, could absorb 
RF energy when placed in a magnetic field of a specific strength. When this absorption 
occurs, the nucleus is described as on resonance. Different atoms within a molecule 
resonate at different frequencies at a given field strength. The observation of the 
resonance frequencies of a molecule allows a user to discover structural information 
about the molecule. Importantly, this resonance frequency is influenced by the 
chemical environment surrounding the ‘resonating’ nucleus, which can partially shield 
the nucleus from the external magnetic field. This shift in resonance frequency, known 
as the chemical shift, allows MRI to differentiate between chemical species within 
tissues. The information obtained is presented as a biochemical spectrum rather than 
an image, providing a variety of quantitative data depending on the nucleus involved 
and the chemical environment that surrounds it. Disease processes, such as cancer, 
have altered chemical environments compared to the surrounding normal tissue and 
therefore produce a different spectrum of nuclear magnetic resonance, (figure 2.8)
Most clinical MRS in oncology is concerned with signals from 1H o r 31P atoms that 
occur naturally in body tissues. 19F signals from anticancer drugs can be used to 
analyse pharmacokinetics and pharmacodynamics. Synthetic 13C-labelled molecules 
are also used to assess the biochemical and physiological parameters of tumours and 
their response to treatment.
Spectroscopy is being used with increasing frequency in oncology especially in cases 
of brain and prostate cancer. One of the biggest challenges in prostate radiotherapy is 
determining the pattern of malignant change within a gland that is also 
heterogeneously filled with areas of benign hypertrophy. Dose escalation to the whole 
gland is limited by urethral and rectal toxicity. Spectroscopy is being evaluated as a 
method by which the malignant regions of the organ can be selectively identified [45],
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thereby allowing dose escalation to limited portions of the gland and sparing excessive 
dose to the normal tissues.
Figure 2.8a Magnetic resonance spectroscopy of the prostate gland
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Recent studies in pre-prostatectomy patients have indicated that the metabolic 
information provided by MRS combined with the anatomical information provided by 
MRI can significantly improve the assessment of cancer location and extent within the 
prostate, extracapsular spread, and cancer aggressiveness. Additionally, pre- and 
post-therapy studies have demonstrated the potential of MRI/MRS to provide a direct 
measure of the presence and spatial extent of prostate cancer after therapy, a measure 
of the time course of response, and information concerning the mechanism of 
therapeutic response. In addition to detecting metabolic biomarkers of disease 
behaviour and therapeutic response, MRI/MRSI guidance can improve tissue selection 
for pathological analysis. High-resolution MRS studies have already identified unique 
spectral patterns for healthy glandular and stromal tissues and prostate cancer.
In one study, prostate tissue samples (n = 199) obtained from 82 prostate cancer 
patients after prostatectomy were compared with metabolite profiles from high- 
resolution proton magnetic resonance spectroscopy [46]. The findings suggested that 
tissue metabolite profiles differentiated malignant from benign samples obtained from 
the same patient (p < 0.005) and correlated with PSA levels (p < 0.006). Furthermore, 
metabolite profiles obtained from histologically benign tissue samples of Gleason score 
6 and 7 prostates delineated a subset of less aggressive tumours (p < 0.008) and 
predicted tumour perineural invasion within the subset (p < 0.03).
In another report, spectral profiles from 123 patients who underwent endorectal MR 
imaging and MR spectroscopic imaging were compared with the corresponding 
pathology [47]. Voxels in the peripheral zone were considered suspicious for cancer if 
Choline and Creatine : Citrate ratio was at least two standard deviations above the 
normal level. The overall sensitivity of MR spectroscopic imaging was 56% for tumour 
detection, increasing from 44% in lesions with Gleason score of 3 + 3 to 89% in lesions 
with Gleason score greater than or equal to 4 + 4.
In addition MRS is being evaluated as a diagnostic and monitoring tool in cancers of 
the breast, where it has been used to identify axillary lymph node metastases [48] as 
well as to predict the aggressiveness of the primary tumour [49] and its responsiveness 
to chemotherapy [50] and in leukaemia, in which examination of the bone marrow [51] 
or phospholipid content of the peripheral blood [52] may give an indication of 
phenotype. In head and neck cancers where it has been shown that it can detect the 
presence of cervical lymph node metastases [53] and can be predictive of radiotherapy 
response [54], can differentiate between various histological types of salivary gland 
neoplasm [55] and can distinguish benign from malignant thyroid nodules [56]. MRS
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has also been successfully tried in cancers of the colon, cervix, pancreas, oesophagus 
and soft tissue sarcomas. There have also been preliminary reports of using 
spectroscopy of body fluids such as bile or semen to detect the presence of malignant 
cells as a diagnostic test for hepato-biliary or prostate cancer respectively [57, 58].
MR spectroscopy has the ability to detect biochemical and molecular targets that have 
prognostic significance. It does this without the need for any tissue to be removed from 
the body and provides an assessment of the whole tumour in its intact living state with 
no artefacts generated by cutting and fixing the tissue. As most cancer patients will 
undergo imaging as part of their diagnostic and planning work-up these prognostic 
analyses can be incorporated within existing procedures, thereby negating the need for 
additional predictive tests.
MRS is not without its problems. A common difficulty is magnetic field distortion, chiefly 
resulting in inadequate water suppression and distorted spectral line-shapes. In some 
cases, metabolite signals are hidden under much stronger lipid or water resonances. 
Often several metabolites are present at relatively high concentrations in a particular 
tissue, however the MR sensitivity for their detection is poor due to their signal energy 
being spread over a large number of closely spaced resonances or from signal 
cancellation of overlapping resonances. For example, glutamate is present at a similar 
concentration as N-acetyl aspartate, though in practice its signal is barely detectable. 
Another area for future improvement in MRS is undoubtedly in the area of improved 
spectral analysis, which will need to overcome the presence of low signal to noise 
ratios and unknown lipid, water or macromolecular baseline signals. With the 
realisation that MRS is a potentially powerful clinical tool that may solve some difficult 
clinical dilemmas, development is progressing rapidly. Also, due to the fact that it is 
entirely non-invasive and adds little to the imaging time and department throughput, 
MRS is quickly gaining popularity.
2.4.2 Magnetic resonance spectroscopy of fluorinated 
nitroimidazoles for the dectection of tumour hypoxia
MRS provides details of tissue chemistry from several administered nuclei including 1H, 
31P, 13C, 23Na. The para-magnetic nucleus, 19F can be relatively easily conjugated other 
molecules to allow particular aspects of the tissue of interest to be evaluated. 
Fluorinated 2- nitroimidazoles have been produced to allow hypoxic cells to be 
identified by this method. Raleigh et al. synthesised a hexafluorinated 2-nitroimidazole 
(CCI-103F) [59]. In Balb/C mice it was preferentially bound within tumour with a
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plasma-to-tumour ratio of 0.8. Li et al used this technique in SCCVII tumours finding 
that the signal obtained positively correlated with tumour size consistent with the fact 
that larger SCCVII tumours have larger hypoxic fractions [60]. Further analysis of the 
fraction of surviving tumour cells after a single fraction of 10Gy irradiation revealed that 
tumours that retained larger amounts of CCI-103F had higher surviving fractions. 
Further studies established the proof of principle that fluorinated probes were suitable 
MRS directed markers of hypoxia [61].The same analogue was evaluated with another 
fluorinated 2-nitroimidazole (Ro 07-0741) by Maxwell et al [62]. Ro 07-0741 is a mono- 
fluorinated probe and was found to be less lipophilic than its hexafluorinated 
counterpart. Signal was readily detectable by MRS in EMT6 tumour, liver, and brain 
soon after i.v. injection in BALB/c mice. Tumour levels remained constant up to 10 
hours after injection whilst there was a reduction in signal intensity from brain and liver. 
The work was repeated in KHT and RIF-1 tumours in C3H/He mice. RIF-1 tumours 
have a lower hypoxic fraction than KHT tumours and the comparative signal obtained 
reflected this difference. However, the problem of the lipophilic nature of these 
compounds remains to be solved: a hydrophilic compound would not only be less 
neurotoxic, but also be less susceptible to metabolism by non-nitroreductive pathways. 
This was the rational for the design of SR4554, that consists of a hydrophilic side 
chain, three fluorine atoms to enhance magnetic detection and the 2-nitroimidazole ring 
to bioreduce only within hypoxic cells [63]. In vivo and clinical studies are in progress.
2.5 Diffusion Weighted Imaging (DWI)
Diffusion imaging is essentially a method of measuring the Brownian motion of 
molecules, which in biological tissue means the diffusion of water molecules. In living 
tissues water does not diffuse equally in all directions, preferring to follow the direction 
of ordered tissue planes, fibres and other structural elements within the organ, with its 
flow restricted by natural barriers such as cell membranes, macromolecules and 
variations in interstitial pressure. As a result the diffusion image can be seen as a 
measure of three-dimensional spatial order within an organ. Cancer, by its very nature, 
tends to produce disorder, destroying natural tissue layers, distorting fibres and altering 
the usual motion of water molecules.
All forms of anti-cancer therapy tend to cause cellular breakdown, necrosis and a 
reduction of tumour interstitial fluid pressure. This leads to an increase in the 
movement of water between the various fluid compartments and a subsequent 
increase in the ‘apparent diffusion coefficient’ (ADC) measured by MRI. Therefore an
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increase in ADC value can be interpreted as a response to treatment. In this way 
diffusion imaging offers a new way of assessing and studying cancer in-vivo.
Diffusion data is obtained by applying extra opposing gradient pulses of differing 
duration and amplitude to T2-weighted MR sequences. If there is no net movement of 
water molecules during this period of time, there will be exact cancelling out of the 
applied balanced gradients and therefore no change in signal intensity. If there is water 
movement there will be imbalance which results in a signal change in the images 
obtained. The degree of diffusion weighting is indicated by the b-value (measured in 
s/mm2). The larger the b-value, the greater the decrease in measured signal intensity. 
The gradient of the ln[signal intensity] time plot for a number of b-values gives the 
apparent diffusion coefficient (ADC).
The only established clinical use of diffusion-weighted imaging at present is the 
detection of ischaemic stroke in the acute phase [64]. Little is known about its potential 
in oncology although a number of pre-clinical and early phase clinical studies have 
begun to investigate its usefulness. It has been shown in a number of tumour types that 
diffusion imaging can help differentiate between benign and malignant tumours [65, 66] 
and has possible implications for radiotherapy treatment planning [67]. As with 
spectroscopy, diffusion imaging may be able to differentiate between recurrent 
malignant glioma and radiation induced necrosis [68]. As a prognostic indicator, 
diffusion weighted imaging has also shown promise. In a pre-clinical study using rat 
mammary tumours, a low pre-chemotherapy ADC value has been shown to correlate 
with response [69]. Similarly, in a study of 14 patients with colorectal cancer, the ADC 
maps were predictive of response to neo-adjuvant chemo-radiotherapy [70].
In prostate cancer, diffusion imaging has shown early promise in the improvement of 
tumour detection, with sensitivity and specificity values for the discrimination of tumour 
from benign hypertrophy and normal peripheral zone frequently exceeding 80% [71-75] 
(figure 2.9). However its potential is more far-reaching. The overall apparent diffusion 
coefficient (ADC) encompasses both the diffusion of water molecules within tissue as 
well as contributions from the flow of water molecules within vessels [76]. It is possible 
to distinguish between these two components of measured water diffusion by altering 
the degree of diffusion weighting. With the use of lower b-values (<100 s/mm2) water 
movement caused by flow within vessels will be the predominant factor determining 
ADC. For higher b-values, the movement of water molecules in the extravascular 
space is preferentially measured, reflecting the cellularity of the extracellular matrix. As 
a result, diffusion weighted MRI can be used to measure perfusion or cellular density.
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Larger clinical trials are required to evaluate whether this technique can offer predictive 
information in cancer medicine and the extent to which it can help guide treatment 
planning.
Figure 2.9 Diffusion MRI of the prostate gland
Two patients are shown with tumour indicated by an arrow. T2-weighted images (left column) 
are compared with diffusion weighted ADC maps (right column). In the top row the patient has 
tumour in the right posterior peripheral zone and in the bottom row the patient has a small focus 
of tumour in the left posterior peripheral zone. Regions with low ADC value correspond to areas 
of low signal intensity on the T2-weighted images.
2.6 Functional imaging for radiotherapy planning
Modern computer software and improvements in linear accelerator design now allow 
the radiation oncologist to design irregularly shaped fields that conform accurately to 
the desired target volume and also permit modulation of the radiation beam intensity 
within that volume. The use of ‘intensity modulated radiation therapy’ (IMRT) has 
proliferated in recent years with the expectation that the very precise dose distributions 
that are now possible will minimize normal tissue side-effects and allow escalation of 
radiation dose to the tumour. In the ‘pre-conformal’ era the weighting and energy of 
each radiation beam was decided depending on the patient’s contour, the depth of the
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tumour from each entry portal and the relative position of any structures that need to be 
avoided. This ‘forward-planning’ approach was also used in the early, non-conformal 
CT-based planning systems, the only difference being that a computer program 
calculated the absorbed dose-distribution more accurately based on the pixel intensity 
of the cross sectional imaging used, allowing greater refinement of each beam 
parameter.
It is now possible to approach the planning process in reverse. The starting point being 
the specification of the required dose in the target volume and dose limits within other 
specified volumes that contain normal tissues. An iterative computer algorithm then 
calculates the optimum beam intensities that will generate the desired homogenous 
dose-distribution within the target volume without exceeding the specified normal-tissue 
dose limits. This is termed ‘inverse treatment planning’ and is currently used to produce 
the most highly conformal radiotherapy plans in use today.
However, it is possible to go a step further. Throughout the history of radiotherapy the 
goal has been to produce a homogenous dose distribution across the target volume. 
Tumours, on the other hand, are not homogenous blocks of tissue. Within each tumour 
volume there are areas that are proliferating and areas that are quiescent, hypoxic 
regions and well oxygenated regions and portions with altered vascularity, varying 
metabolism and genetically determined differences in radiation resistance lying 
adjacent to each other. The use of functional imaging techniques to identify these 
biological variations within the tumour results in functional ‘maps’ which can be 
superimposed onto the standard anatomical cross-sectional imaging, highlighting sub­
volumes within the target that may require a higher radiation dose. These sub-volumes 
could represent areas of increased proliferation or relative radioresistance, such as 
hypoxia. It is also possible to use functional imaging to differentiate areas of tumour 
from areas of benign change, within an organ that has traditionally been treated in its 
entirety, with a view to only irradiating the malignant areas, for example with prostate 
cancer.
In order to target these biological sub-volumes with a higher absorbed dose than the 
surrounding tissue requires the intentional creation of dose-inhomogeneity. This 
technique of dose ‘painting’ (in 2D) or dose ‘sculpting’ (in 3D) as originally described by 
Ling and colleagues [77], involves the same inverse planning technique as previously 
described, with the addition of a ‘biological target volume’ within the planning target 
volume which can be assigned a separate, higher, dose level, essentially resulting in a
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hot-spot of absorbed dose over this new, functionally guided, biological target. (Figure 
2.10)
Figure 2.10 Radiotherapy planning with DCE-MRI
A simulated high dose-rate brachytherapy plan (right image) conforming to the ‘biological target’ 
as determined by a K*ans map of the prostate (left image). The dynamic MRI image has shown 
an area of high K ^"5 values (arrow) in the posterior aspect of the prostate gland. The red line on 
the radiotherapy plan indicates the 8.5 Gray (per fraction) isodose, this is the dose prescribed to 
the whole gland. The yellow line shows the 15 Gray isodose (a boost of 175%), directed at the 
biological target.
There are a number of theoretical and practical advantages with this approach. Firstly, 
despite sophisticated planning techniques, conventional dose escalation will ultimately 
result in dose limits defined by normal tissue toxicity. For example, in the case of 
prostate cancer (where there is a proven case for dose escalation [78]), IMRT can 
safely deliver 80-82Gy to the whole prostate with acceptable normal tissue toxicity 
[79]. However, despite the fact that highly conformal dose distributions can be 
theoretically produced to deliver doses approaching 100Gy in some patients, with a 
rectal dose volume histogram (DVH) that is within tolerance, this treatment is 
unacceptable. This is because of unavoidable urethral toxicity, a structure that, 
because of its position running through the centre of the target volume, can never be 
avoided even with the most advanced planning algorithms. Dose sculpting, on the 
other hand, provides a mechanism by which the portions of the prostate that require 
the highest radiation dose because of their intrinsic biology, can be dose escalated 
separately from the remainder of the gland, thereby increasing the probability of 
achieving the required dose level without exceeding any normal tissue dose limit.
Secondly, the functional information gained in the planning stages of the radiotherapy 
process may lead to the optimal choice of treatment modality, or combination of 
treatment modalities. If the tumour is found to be very hypoxic, radiotherapy could be
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combined with hypoxic sensitizers or the breathing of high oxygen containing gas 
mixtures. Highly proliferating cancers may be more appropriately treated with combined 
chemo-radiotherapy or in conjunction with other biological agents. Tumours with 
extensive evidence of neo-vascularization or expression of vascular growth factors may 
benefit from treatment with anti-angiogenic or anti-vascular drugs. In the future there 
may be ways to target specific steps in tumour metabolism or offer gene therapy for 
specific defects defined by molecular imaging in conjunction with localized therapy. 
Finally, the prognostic information obtained from the functional approach will allow 
better risk stratification and therefore a greater ability to discriminate between those 
patients that require an aggressive approach and those who are likely to be cured by 
less intensive efforts.
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Chapter 3 
The reproducibility of and correlation
between quantitative and semi-quantitative 
dynamic, blood oxygen level dependent and 
diffusion MRI parameters in the malignant
human prostate
3.1 Aim
To determine the reproducibility of Tr weighted dynamic contrast enhanced MRI, T2*- 
weighted dynamic susceptibility contrast MRI, BOLD MRI and diffusion-weighted 
imaging for the prostate as a whole, prostate tumour, normal prostatic peripheral zone 
and benign prostatic central zone, in patients with prostate cancer, before and after 
three months of androgen deprivation. Also, to correlate the various MRI parameters 
obtained.
3.2 Introduction
All quantitative biological measurements exhibit variability. This is caused by natural 
variation in the quantity being measured, variation in the measurement process and 
errors introduced during analysis. For any measurement to be useful in the 
determination of whether a change has occurred, for example as a result of treatment, 
knowledge of its reproducibility is required. An estimate of measurement error enables 
interpretation of whether a change in an observation has occurred as a result of 
parameter variability or whether the difference is real. This estimate of error can be 
calculated for the study group as a whole or on an individual patient-by-patient basis.
With regard to dynamic and intrinsic susceptibility-weighted magnetic resonance 
imaging studies of the prostate, variability can occur at several stages of the 
examination. Patient movement can be minimised with careful explanation of the 
procedure and ensuring comfort and relaxation during the examination. Internal 
prostate movement is largely unavoidable but can be slightly reduced by asking the 
patient to empty their rectum before the scan. A study using cine-MRI has 
demonstrated significant prostatic movement in 58% of patients during a seven minute 
acquisition, with correlation between the incidence of prostate movement and the 
degree of rectal distension [1]. Measurement factors such as MRI scanner type and
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settings, data acquisition technique and number of imaging sites may introduce 
variability between departments and between studies. For comparative studies, the 
ability to image the same plane through the prostate on successive examinations will 
influence reproducibility. This in turn is influenced by the extent to which any 
intervention between examinations alters the morphological appearance, size and 
shape of the prostate gland. Analysis methods, including the mathematical model used, 
parameter derived, assumptions made, input function measurement and inter- and intra 
-observer variability in ROI placement will also affect the overall reproducibility of the 
measurement.
The International Standards Organisation (ISO: 5725, 1994 [2]) definitions of 
repeatability and reproducibility are as follows:
1. Repeatability refers to test conditions that are as constant as possible, where 
the same operator using the same equipment within a "short time interval" 
obtains independent test results with the same method on identical items in 
the same laboratory.
2. Reproducibility refers to test conditions under which results are obtained with 
the same method on identical test items, but in different laboratories with 
different operators using different equipment.
Repeatability refers to the ability of a measurement system to provide consistent 
readings on a given object with control over external sources of error. Repeatability 
therefore informs on equipment variation. An MRI test-retest examination, without 
moving the patient over a short period of time, is considered a repeatability study.
Reproducibility on the other hand is the ability for multiple experiments, performed in 
different departments at different times, to achieve consistent results on identical 
objects. Thus, reproducibility measures the typical error between observers when each 
observes the same quantity. Reproducibility informs on appraiser / experimental 
variation. An MRI measurement repeated on a patient several days apart is considered 
to be a reproducibility study. Even if the equipment and analysis technique used for the 
two measurements is identical, the experimental conditions are different because of the 
timing element.
In general, high precision is obtained when both repeatability and reproducibility errors 
are small.
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There are a limited number of published reports documenting the reproducibility of 
dynamic and susceptibility-weighted MR imaging in normal human tissues and 
tumours.
A study of 19 patients assessed the reproducibility of the T1-weighted DCE MRI 
parameters Ktrans, ve and maximum contrast medium accumulation (MCMA) in pelvic 
muscle, bone marrow and fat [3]. Results showed high variability in bone marrow and 
fat, making these tissues unsuitable for obtaining reliable kinetic parameter estimates. 
This study also demonstrated low, statistically non-significant, variance ratios for pelvic 
muscle, suggesting that the within-subject variance was large compared to the 
between-subject variance. In a similar study of 21 patients with a variety of tumour 
types, the reproducibility of semi-quantitative (gradient, enhancement and AUC) and 
quantitative (K6®"*, veand keP) parameters was compared [4]. ve, enhancement and AUC 
were shown to be highly reproducible DCE-MRI parameters. K^ 3"55, kep and gradient had 
greater variability, with larger changes in individuals required to be statistically 
significant, but were nevertheless sufficiently reproducible to detect changes greater 
than 14-17%.
Reproducibility of T, and T2* -weighted parameters, including R2*. in a variety of pelvic 
tumours (predominantly ovarian or uterine in origin) has been reported by Lankester et 
al [5]. These are the only published data regarding the reproducibility of T2* or R2*- 
weighted parameters in extra-cranial human tumours. Of the quantitative Ti-weighted 
measurements, K^"5 was again shown to be the least reproducible with a wCV of 
20.3%. ve and kep had wCV values of 8.3% and 17.4% respectively. The T2* 
reproducibility statistics for rBV and rBF gave wCV values of 19.7% and 16.8% 
respectively, although on an individual patient basis a change of ±54.5% for rBV and 
±46.4% for rBF would be required to be considered a significant change at the 95% 
confidence level. For R2*, wCV was 17.5% with a 48.6% change required for 
significance.
These studies all conclude that a measure of reproducibility is essential for valid 
assessment of treatment effect and should be incorporated into any clinical research 
protocol that utilises dynamic or susceptibility weighted MRI parameters for response 
assessment. A benchmark of reproducibility values has been provided that can now be 
used as a comparison with future studies.
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3.3 General Description of Statistical Measures of 
Reproducibility
Spontaneous variability of parameter estimates:
Within-subject coefficient of variation (wCV):
This is the within-subject standard deviation divided by the mean, multiplied by 100 to 
give a percentage.
Variance ratio (F):
Is the ratio of the between-patient variance and within-patient variance. A parameter 
with a larger variance in the patient population, but a small variance within individual 
patients (wCV) would have a higher variance ratio
Measurement error:
Interclass correlation coefficient (ICC):
A measure of the precision of parameter estimates. It is the average correlation 
coefficient across all possible orderings of the data when there is no obvious choice of 
X and Y axis for each of the pairs of measurements.
Repeatability statistic:
The threshold value (as a percentage change) below which the absolute difference 
between two measurements on the same patient (n=1) is expected to lie for 95% of the 
pairs of observations. From this, one can calculate the number of patients in the group 
that achieved a parameter change that would be considered significant, at the 95% 
confidence level, as a real change rather than simply being due to measurement 
variability.
3.4 Patients and Methods
3.4.1 General
The reproducibility analysis was carried out as part of the androgen deprivation study, 
using the same 20 patients (chapter 6).
As depicted in figure 6.1, page 189 each patient was examined with five multi­
parameter MRI scans. The first two scans and the last two scans were used for the 
assessment of reproducibility. Scans one and two were performed a few days apart
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prior to the commencement of androgen deprivation in order to determine the 
reproducibility of each of the MRI parameters in the baseline physiological state without 
endocrine manipulation. Scans four and five were performed a few days apart three 
months after the commencement of androgen deprivation in order to determine the 
reproducibility of each of the MRI parameters in the androgen deprived state. The 
mean number of days between scans one and two was 2.75 days (range 1 - 8  days) 
and the mean number of days between scans four and five was 2.55 days (range 1 -  
14 days).
As the reproducibility study was incorporated within the androgen deprivation study, the 
MRI protocols and methods for image analysis are identical to those described in 
chapter 5 and as a result will not be repeated here. The same parameters were 
measured or calculated.
3.4.3 Statistical Methods for Reproducibility Calculations
The standard consensus approach to assessing reproducibility was used [6-8].
For each patient, the difference between the measurements of a parameter at each 
reproducibility scan, d, was calculated.
The distribution of d was tested for normality using the Shapiro-Wilk test.
In order to establish whether the size of d was dependent upon the parameter value, 
Kendall’s tau for correlation of the absolute value of d against the mean parameter 
value for the two scans was calculated [7]. If this test demonstrated that error was 
indeed proportional to the mean, at the 95% confidence level, then the data were 
transformed using natural logarithms (In). The Shapiro-Wilk and Kendall’s tau test were 
then repeated.
The following statistical measures of reproducibility were then obtained from a one way 
analysis of variance (ANOVA) on the original or transformed data:
The mean squared difference (dsd) was calculated:
3.4.2 MRI Protocol
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The within-patient standard deviation (wSD) was calculated:
dsdwSD =
V2
The within patient coefficient of variance was calculated:
wSD
a) For original data: wCV = --
mean
b) For In transformed data wCV = Exp(wSD)-1
The repeatability parameter, r, was calculated as follows:
a) For original data:
b) For In transformed data
r% =
\mean y
xlOO
_ lOOx Exp^nmean±r) 
mean
The variance ratio (F)
The ratio of the between patient variance and within patient variance can be 
mathematically described by:
F =
2 / 
Xn  ! n
Z / / d
where n=numerator and d=denominator
The Interclass correlation coefficient (ICC) was calculated as follows:
IQQ _ mSSB -  SST 
(m -1  )SST
where m is the number of observations per subject, SSB is the sum of squared 
between subjects and SST is the total sum of squares (as per one way ANOVA 
above).
In order to determine whether there were any significant correlation between any of the 
baseline kinetic parameter values, Spearman’s p (rho) was calculated.
Statistical analysis was performed using the StatsDirect statistical software package 
(StatsDirect, Cheshire, UK) and Microsoft® Excel 2000 (Microsoft Corporation, 
Washington State, USA).
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3.5 Results
3.5.1 General
Patient characteristics and scheduling details were the same as for the androgen 
deprivation study (tables 6.1 and 6.2, p187&193). The median time between the first 
two examinations and the last two examinations was 2 days and 1.5 days respectively.
Due to patient movement and other reasons that are described in section 6.4.1, p192 
it was not possible to generate all of various parametric maps from every scan. The 
numbers of data pairs used for each reproducibility calculation are given in tables 3.1 -  
3.5. The baseline means of the median kinetic parameter values for whole prostate are 
given in tables tables 3.1 -  3.5. In general these values are comparable with literature 
values for normal human tissues and human tumours [3-5, 9, 10].
3.5.2 Results of the reproducibility analysis
Reproducibility statistics are also shown in tables 3.1 -  3.5. No parameter, either for 
baseline pairs or pairs after three months of androgen deprivation, had a mean 
difference significantly different from zero. In other words, there was no systematic 
change in parameter value, in either direction, between the paired sets of scans either 
at baseline or at three months (appendix C). This confirms that the first scan of the 
pair has no influence on the second scan, which may have been the case if there had 
been significant contrast retention in the prostatic tissues from the first scan at the time 
of the second scan, which has been occasionally observed (figure 3.1).
The distribution of each parameter was not significantly different from normal, either at 
baseline or at three months. The Kendall’s tau test confirmed the proportionality of 
error and mean value for K*3"8, kep, AUCeo, rBV and rBF. As a result the data for these 
five parameters were logarithmically transformed (In). After transformation, Kendall’s 
tau was no longer significant, indicating no further dependence of error on the mean, 
thereby allowing calculation of valid reproducibility statistics. The difference between 
values for ve, R2*, ADC (b-values 0 -  1000 s/mm2), ADC (b-values 0 - 5 0  s/mm2) and 
ADC (b-values 150 -  1000 s/mm2) showed no dependence on the mean and therefore 
no transformation was required for these data.
When assessed by the within-patient coefficient of variance (wCV), the most 
consistently reproducible region of interest was whole prostate. The variance ratio also 
demonstrated the whole prostate ROI to be highly reproducible although not as reliably 
as with wCV. The least reproducible ROI was undoubtedly the normal peripheral zone,
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whichever reproducibility statistic was used. Tumour ROIs were generally slightly less 
reproducible than whole prostate ROIs but more reproducible than peripheral zone, 
other than for the diffusion-weighted ADC parameters, in which the tumour ROIs were 
consistently the least reproducible.
For whole prostate, tumour and central zone ROIs, there was a consistent deterioration 
in reproducibility following three months of androgen deprivation (when measured by 
wCV or variance ratio) other than for the R2* parameter (see below). The reproducibility 
of peripheral zone ROIs tended to improve following androgen withdrawal, other than 
for ADC measurements, although the initial reproducibility of this ROI was poor, as 
previously described.
Consistent with the findings of Lankester [5], Galbraith [4] and Padhani [3], ve was the 
most reproducible Ti-weighted DCE-MRI parameter. AUC6owas almost as reproducible 
as ve, with slightly more variability in terms of wCV and variance ratio for most ROIs. 
Kfranss a|S0 demonstrated good reproducibility, with wCV values for whole prostate and 
tumour being slightly superior to that previously described in the literature for pelvic 
tumours (13.9% for whole prostate and 20.1% for prostate tumour, compared with 
20.3% reported by Lankester and 24% reported by Galbraith). The T2*-weighted 
parameters demonstrated poor reproducibility, with variance ratios ranging between 2.5 
and 5.5 for baseline rBV measurements and between 2.2 and 3.9 for baseline rBF 
readings, indicating a large variation within patients compared to the variation between 
patients.
The effect of androgen deprivation on the reproducibility of K**™ was essentially 
neutral, with wCV and variance ratio worsening for whole prostate and central zone 
ROIs, and improving for tumour and peripheral zone ROIs. For the other Tr weighted 
parameters and the T2*-weighted measurements, the effect of androgen deprivation 
tended to worsen reproducibility.
R2* proved to be a notable exception, with a consistent and considerable improvement 
in reproducibility following androgen deprivation therapy. The baseline wCV values for 
whole prostate and tumour (21.7% and 23.3% respectively), with a requirement of a 
60.1% change for whole prostate ROIs and a 64.6% change for tumour ROIs required 
to indicate a significant change for an individual patient at the 95% confidence level, 
compared unfavourably with the results reported by Lankester (who showed a wCV of 
17.5% with a 48.6% change to demonstrate significance, in a variety of pelvic 
tumours). After androgen deprivation, R2* reproducibility improved with a wCV of 12.3%
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for whole prostate and 11.8% for tumour, with 34.1% and 32.8% changes required for 
significance, respectively. This resulted in R2* becoming one of the most reproducible 
MRI parameters of all, with only baseline ve having superior values.
As for other published studies [3, 11], R2* was calculated for normal pelvic muscle 
(obturator internus). This normal tissue demonstrated exceptional reproducibility, with a 
baseline wCV of 4% and 3 month wCV of only 1.2%. After androgen deprivation, a 
change of 3.3% would be sufficient to demonstrate a significant change in an individual 
patient, at the 95% confidence level.
3.5.3 Correlation between MRI parameters
The reproducibility statistics for the diffusion-weighted ADC measurements suffered 
from poor patient numbers, with only seven patients in each reproducibility cohort. 
Despite this, whole prostate ADC maps demonstrated reasonable reproducibility (wCV 
of 10.3 -  16.2% at baseline, 10.5 -  23.3% at 3 months). Given the patient numbers, it 
is not possible to comment on the effect of androgen withdrawal on the reproducibility 
of ADC values with any degree of certainty.
Correlation between the different parameters at baseline is shown in tables 3.6 to 3.9. 
For whole prostate ROIs, AUC6o was found to correlate very strongly with Ktrans (p = 
0.95, p < 0.0001) and strongly with ve (p = 0.74, p = 0.0003). Klrans also correlated 
strongly with ve (p = 0.79, p < 0.0001). Even stronger correlations were observed for 
tumour measurements: AUC60 versus K*3"8 (p = 0.98, p < 0.0001) and AUC60 versus keP 
(p = 0.83, p < 0.0001). Many other kinetic parameter values exhibited significant 
correlation with each other. Relative blood flow and relative blood volume exhibit 
extremely high correlation (p = 0.98 for both whole prostate and tumour, p < 0.0001) 
reflecting their close mathematical relationship and the narrow range of mean transit 
time (MTT) values observed (rBF = rBV/MTT).
R2* did not correlate with any other parameter for whole prostate, tumour or central 
gland although did exhibit a degree of correlation with K*3"8, kep and AUC6o for 
peripheral zone. ADC values generally did not exhibit significant correlation with other 
parameters reflecting the low numbers of patients that underwent diffusion weighted 
imaging.
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Table 3.1 Reproducibility and Repeatability Statistics -  Ti-weighted
DCE - MRI
istrans
Whole Prostate - K*'®"8 Baseline ! Whole Prostate - Ktrans 3 Months
Number of patients 19 Number of patients 20
Mean ROI size (pixels) 6725 Mean ROI size (pixels) 5222
Mean number of pixels 6060 Mean number of pixels 
Mean value (mins1)
3864
Mean value (mins'1) 0.206 0.146
Repeatability for n=1 (%) -30.3 to 43.4 Repeatability for n=1 (%) -33.4 to 50.2
Variance ratio (F) 12.5 Variance ratio (F) 10.0
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.84 ICC 0.81
wCV 13.9% wCV 15.8%
Tumour - K1™"8Baseline Tumour - K^"8 3 Months
Number of patients 19 Number of patients 19
Mean ROI size (pixels) 1046 Mean ROI size (pixels) 614
Mean number of pixels 987 Mean number of pixels 425
Mean value (mins-1) 0.273 Mean value (mins'1) 0.130
Repeatability for n=1 (%) -39.8 to 66.2 Repeatability for n=1 (%) -38.6 to 62.8
Variance ratio (F) 11.2 Variance ratio (F) 23.2
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.83 ICC 0.91
wCV 20.1% wCV 19.2%
Peripheral Zone - K1™18 Baseline Peripheral Zone - Ktrans3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 162 Mean ROI size (pixels) 116
Mean number of pixels 136 Mean number of pixels 86
Mean value (mins1) 0.126 Mean value (mins'1) 0.069
Repeatability for n=1 (%) -62.1 to 163.8 Repeatability for n=1 (%) -41.0 to 69.4
Variance ratio (F) 3.3 Variance ratio (F) 13.5
P-value for F 0.008 P-value for F < 0.0001
ICC 0.51 ICC 0.85
wCV 41.9% wCV 21.0%
Central Zone - KtransBaseline Central Zone - K*'®"8 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 174 Mean ROI size (pixels) 126
Mean number of pixels 172 Mean number of pixels 123
Mean value (mins'1) 0.253 Mean value (mins'1) 0.206
Repeatability for n=1 (%) -40.5 to 68.2 Repeatability for n=1 (%) -50.8 to 103.3
Variance ratio (F) 14.9 Variance ratio (F) 6.6
P-value for F < 0.0001 P-value for F 0.0001
ICC 0.87 ICC 0.73
wCV) 20.6% wCV 29.2%
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Ve
Whole Prostate - ve Baseline Whole Prostate - ve 3 Months
Number of patients 19 Number of patients 20
Mean ROI size (pixels) 6725 Mean ROI size (pixels) 5222
Mean number of pixels 6060 Mean number of pixels 3864
Mean value (%) 41.6 Mean value (%) 47.3
Repeatability for n=1 (%) -24.7 to 24.7 Repeatability for n=1 (%) -33.1 to 33.1
Variance ratio (F) 13.4 Variance ratio (F) 7.6
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.85 ICC 0.76
wCV 8.9% wCV 11.9%
Tumour-veBaseline Tumour - ve 3 Months
Number of patients 19 Number of patients 19
Mean ROI size (pixels) 1046 Mean ROI size (pixels) 614
Mean number of pixels 987 Mean number of pixels 425
Mean value (%) 41.2 Mean value (%) 45.3
Repeatability for n=1 (%) -34.6 to 34.6 Repeatability for n=1 (%) -48.6 to 48.6
Variance ratio (F) 11.0 Variance ratio (F) 5.9
P-value for F < 0.0001 P-value for F 0.0002
ICC 0.82 ICC 0.70
wCV 12.5% wCV 17.5%
Peripheral Zone - ve Baseline Peripheral Zone - ve 3 Months
Number of patients 18 iNumber of patients 18
Mean ROI size (pixels) 162 Mean ROI size (pixels) 116
Mean number of pixels 136 Mean number of pixels 86
Mean value (%) 29.2 Mean value (%) 35.2
Repeatability for n=1 (%) -41.1 to 41.1 Repeatability for n=1 (%) -76.7 to 76.7
Variance ratio (F) 11.7 Variance ratio (F) 4.5
P-value for F < 0.0001 P-value for F 0.001
ICC 0.83 ICC 0.62
wCV 14.8% wCV 27.7%
Central Zone -
■
ve Baseline Central Zone - ve 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 174 Mean ROI size (pixels) 126
Mean number of pixels 172 Mean number of pixels 123
Mean value (%) 32.6 Mean value (%) 42.2
Repeatability for n=1 (%) -36.1 to 36.1 Repeatability for n=1 (%) -35.1 to 35.1
Variance ratio (F) 19.3 Variance ratio (F) 10.7
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.90 ICC 0.82
wCV 13.0% wCV 12.7%
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ep
Whole Prostate - k«D Baseline Whole Prostate - keo 3 Months
Number of patients 19 Number of patients 20
Mean ROI size (pixels) 6725 Mean ROI size (pixels) 5222
Mean number of pixels 6060 Mean number of pixels 3864
Mean value (mins1) 0.513 Mean value (mins'1) 0.327
Repeatability for n=1 (%) -30.3 to 43.6 Repeatability for n=1 (%) -39.1 to 64.2
Variance ratio (F) 5.7 Variance ratio (F) 4.1
P-value for F 0.0002 P-value for F 0.0014
ICC 0.69 ICC 0.59
wCV 13.9% wCV 19.6%
Tumour -  keo Baseline Tumour -  k«D 3 Months
Number of patients 19 Number of patients 19
Mean ROI size (pixels) 1046 Mean ROI size (pixels) 614
Mean number of pixels 987 Mean number of pixels 425
Mean value (mins'1) 0.680 Mean value (mins'1) 0.311
Repeatability for n=1 (%) -44.8 to 81.3 Repeatability for n=1 (%) -60.6 to 153.7
Variance ratio (F) 4.9 Variance ratio (F) 2.6
P-value for F 0.0006 P-value for F 0.023
ICC 0.65 ICC 0.42
wCV 24.0% wCV 39.9%
Peripheral Zone - keo Baseline Peripheral Zone - keo 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 162 Mean ROI size (pixels) 116
Mean number of pixels 136 ^ean number of pixels 86
Mean value (mins'1) 0.461 Mean value (mins'1) 0.217
Repeatability for n=1 (%) -66.8 to 201.4 Repeatability for n=1 (%) -58.4 to 140.4
Variance ratio (F) 2.0 Variance ratio (F) 1.5
P-value for F 0.008 P-value for F < 0.0001
ICC 0.30 ICC 0.18
wCV 48.9% wCV 37.2%
Central Zone -  k«DBaseline Central Zone -  keD3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 174 Mean ROI size (pixels) 126
Mean number of pixels 172 Mean number of pixels 123
Mean value (mins'1) 0.808 Mean value (mins'1) 0.500
Repeatability for n=1 (%) -35.8 to 55.8 Repeatability for n=1 (%) -58.1 to 138.9
Variance ratio (F) 9.5 Variance ratio (F) 2.6
P-value for F < 0.0001 P-value for F 0.0001
ICC 0.80 ICC 0.43
wCV 17.4% wCV 37.0%
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AUCeo
Whole Prostate - AUC Baseline Whole Prostate -  AUC 3 Months
Number of patients 19 Number of patients 20
Mean ROI size (pixels) 6725 Mean ROI size (pixels) 5222
Mean number of pixels 6620 Mean number of pixels 5024
Mean value (mmol.s) 10.84 Mean value (mmol.s) 7.46
Repeatability for n=1 (%) -32.3 to 47.7 Repeatability for n=1 (%) -41.0 to 69.4
Variance ratio (F) 10.9 Variance ratio (F) 8.6
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.82 ICC 0.78
wCV 15.1% wCV 21.0%
Tumour -  AUC Baseline Tumour -  AUC 3 Months
Number of patients 19 Number of patients 19
Mean ROI size (pixels) 1046 Mean ROI size (pixels) 614
Mean number of pixels 1041 Mean number of pixels 590
Mean value (mmol.s) 14.23 Mean value (mmol.s) 7.28
Repeatability for n=1 (%) -36.3 to 57.1 Repeatability for n=1 (%) -49.4 to 97.7
Variance ratio (F) 23.0 Variance ratio (F) 15.7
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.91 ICC 0.87
wCV 17.7% wCV 27.9%
Peripheral Zone - AUC Baseline Peripheral Zone - AUC 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 162 Mean ROI size (pixels) 116
Mean number of pixels 153 Mean number of pixels 108
Mean value (mmol.s) 7.32 Mean value (mmol.s) 4.84
Repeatability for n=1 (%) -58.5 to 140.8 Repeatability for n=1 (%) -45.0 to 81.9
Variance ratio (F) 4.5 Variance ratio (F) 6.0
P-value for F 0.0014 P-value for F 0.0002
ICC 0.62 ICC 0.70
wCV 37.3% wCV 24.1%
Central Zone -  AUC Baseline Central Zone -  AUC 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 174 Mean ROI size (pixels) 126
Mean number of pixels 173 Mean number of pixels 126
Mean value (mmol.s) 13.02 Mean value (mmol.s) 12.01
Repeatability for n=1 (%) -32.8 to 48.9 Repeatability for n=1 (%) -44.5 to 80.2
Variance ratio (F) 16.2 Variance ratio (F) 8.4
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.88 ICC 0.78
wCV 15.5% wCV 23.7%
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Table 3.2 Reproducibility and Repeatability Statistics -  T2*-weighted
DSC -  MRI
rBV
Whole Prostate - rBV Baseline Whole Prostate - rBV 3 Months
Number of patients 19 Number of patients 20
Mean ROI size (pixels) 648 Mean ROI size (pixels) 448
Mean number of pixels 500 Mean number of pixels 289
Mean value (AU) 141.42 Mean value (AU) 47.94
Repeatability for n=1 (%) -68.6 to 218.3 Repeatability for n=1 (%) -84.0 to 525.2
Variance ratio (F) 3.5 Variance ratio (F) 1.6
P-value for F 0.005 P-value for F 0.15
ICC 0.53 ICC 0.21
wCV 51.9% wCV 93.8%
Tumour -  rBV Baseline I Tumour -  rBV 3 Months
Number of patients 18 [Number of patients 18
Mean ROI size (pixels) 126 Mean ROI size (pixels) 68
Mean number of pixels 97 Mean number of pixels 37
Mean value (AU) 251.77 Mean value (AU) 34.18
Repeatability for n=1 (%) -81.1 to 427.7 Repeatability for n=1 (%) -81.2 to 430.6
Variance ratio (F) 2.5 Variance ratio (F) 4.6
P-value for F 0.033 P-value for F 0.001
ICC 0.40 ICC 0.63
wvCV 82.3% wCV 82.7%
Peripheral Zone - rBV Baseline Peripheral Zone - rBV 3 Months
Number of patients 17 Number of patients 17
Mean ROI size (pixels) 45 Mean ROI size (pixels) 30
Mean number of pixels 32 Mean number of pixels 17
Mean value (AU) 86.97 Mean value (AU) 23.69
Repeatability for n=1 (%) -88.2 to 747.21 Repeatability for n=1 (%) -80.0 to 399.7
Variance ratio (F) 5.5 Variance ratio (F) 1.6
P-value for F 0.0006 P-value for F 0.17
ICC 0.67 ICC 0.21
wCV 116.3% wCV 78.7%
Central Zone -  rBV Baseline Central Zone -  rBV 3 Months
Number of patients 17 Number of patients 17
Mean ROI size (pixels) 43 Mean ROI size (pixels) 36Mean number of pixels 36 Mean number of pixels 27
Mean value (AU) 164.80 Mean value (AU) 72.60
Repeatability for n=1 (%) -81.5 to 440.7 Repeatability for n=1 (%) -93.3 to 1384.4
Variance ratio (F) 3.7 Variance ratio (F) 1.4
P-value for F 0.005 P-value for F 0.26
ICC 0.56 ICC 0.13
wCV 83.9% wCV 164.8%
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rBF
Whole Prostate - rBF Baseline Whole Prostate - rBF 3 Months
Number of patients 19 Number of patients 20
Mean ROI size (pixels) 648 Mean ROI size (pixels) 448
Mean number of pixels 500 Mean number of pixels 289
Mean value (AU) 2.37 Mean value (AU) 0.98
Repeatability for n=1 (%) -62.5 to 166.7 Repeatability for n=1 (%) -83.3 to 499.0
Variance ratio (F) 3.7 Variance ratio (F) 1.3
P-value for F 0.003 P-value for F 0.30
ICC 0.56 ICC 0.09
wCV 42.5% wCV 90.8%
Tumour -  rBF Baseline Tumour -  rBF 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 126 Mean ROI size (pixels) 68
Mean number of pixels 97 Mean number of pixels 37
Mean value (AU) 4.20 Mean value (AU) 0.78
Repeatability for n=1 (%) -77.9 to 351.5 Repeatability for n=1 (%) -78.8 to 371.9
Variance ratio (F) 2.2 Variance ratio (F) 4.2
P-value for F 0.05 P-value for F 0.002
ICC 0.35 ICC 0.60
wCV 72.3% wCV 75.1%
Peripheral Zone - rBF Baseline Peripheral Zone - rBF 3 Months
Number of patients 17 Number of patients 17
Mean ROI size (pixels) 45 Mean ROI size (pixels) 30
Mean number of pixels 32 Mean number of pixels 17
Mean value (AU) 1.54 Mean value (AU) 0.52
Repeatability for n=1 (%) -83.8 to 516.0 Repeatability for n=1 (%) -80.1 to 401.3
Variance ratio (F) 2.9 Variance ratio (F) 0.9
P-value for F 0.017 P-value for F 0.59
ICC 0.47 ICC -0.09
wCV 92.8% wCV 79.0%
Central Zone -  rBF Baseline Central Zone -  rBF 3 Months
Number of patients 17 Number of patients 17
Mean ROI size (pixels) 43 Mean ROI size (pixels) 36
Mean number of pixels 36 Mean number of pixels 27
Mean value (AU) 2.82 Mean value (AU) 1.22
Repeatability for n=1 (%) -75.9 to 314.5 Repeatability for n=1 (%) -90.9 to 1000.0
Variance ratio (F) 3.9 Variance ratio (F) 1.6
P-value for F 0.004 P-value for F 0.18
ICC 0.57 ICC 0.19
wCV 67.1% wCV 137.7%
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Table 3.3 Reproducibility and Repeatability Statistics -
BOLD MRI
r 2 *
Whole Prostate - R2* Baseline Whole Prostate - R2* 3 Months
Number of patients 20 Number of patients 20
Mean ROI size (pixels) 6804 Mean ROI size (pixels) 5534
Mean number of pixels 6804 Mean number of pixels 5534
Mean value (s'1) 17.24 Mean value (s'1) 20.73
Repeatability for n=1 (%) -60.1 to 60.1 Repeatability for n=1 (%) -34.1 to 34.1
Variance ratio (F) 2.5 Variance ratio (F) 5.1
P-value for F 0.025 P-value for F 0.0003
ICC 0.40 ICC 0.66
wCV 21.7% wCV 12.3%
Tumour-R2* Baseline Tumour-R2* 3 Months
Number of patients 19 iNumber of patients 19
Mean ROI size (pixels) 924 Mean ROI size (pixels) 668
Wean number of pixels 924 Mean number of pixels 668
Mean value (s'1) 16.59 Mean value (s'1) 23.41
Repeatability for n=1 (%) -64.6 to 64.6 Repeatability for n=1 (%) -32.8 to 32.8
Variance ratio (F) 2.3 Variance ratio (F) 3.6
P-value for F 0.039 P-value for F 0.004
ICC 0.37 ICC 0.55
wCV 23.3% wCV 11.8%
Peripheral Zone - R2* Baseline Peripheral Zone - R2* 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 155 Mean ROI size (pixels) 121
Mean number of pixels 155 Mean number of pixels 121
Mean value (s'1) 14.09 Mean value (s'1) 19.66
Repeatability for n=1 (%) -115.7 to 115.7 Repeatability for n=1 (%) -61.0 to 61.0
Variance ratio (F) 2.1 Variance ratio (F) 3.1
P-value for F 0.06 P-value for F 0.011
ICC 0.34 ICC 0.49
wvCV 41.8% wCV 22.0%
Central Zone - R2* Baseline Central Zone - R2* 3 Months
Number of patients 18 Number of patients 18
Mean ROI size (pixels) 190 Mean ROI size (pixels) 145
Mean number of pixels 190 Mean number of pixels 145
Mean value (s'1) 10.35 Mean value (s'1) 13.73
Repeatability for n=1 (%) -140.4 to 140.4 Repeatability for n=1 (%) -81.4 to 81.4
Variance ratio (F) 1.7 Variance ratio (F) 3.3
P-value for F 0.15 P-value for F 0.008
ICC 0.22 ICC 0.51
wCV 50.7% wCV 29.4%
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Table 3.4 Reproducibility and Repeatability Statistics -  BOLD MRI
R2* - Normal Tissue (Obturator Intemus Muscle)
Obturator Intemus Muscle - R2* Baseline Obturator Intemus Muscle - R2* 3 Months
Number of patients 20 Number of patients 20
Mean ROI size (pixels) 11632 Mean ROI size (pixels) 10956
Mean number of pixels 11632 Mean number of pixels 10956
Mean value (s'1) 25.02 Mean value (s'1) 25.01
Repeatability for n=1 (%) -11.2 to 11.2 Repeatability for n=1 (%) -3.3 to 3.3
Variance ratio (F) 8.07 Variance ratio (F) 71.7
P-value for F < 0.0001 P-value for F < 0.0001
ICC 0.77 ICC 0.97
wCV 4.0% wCV 1.2%
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Table 3.5 Reproducibility and Repeatability Statistics 
Diffusion Weighted Imaging
ADC (b-values 0 -  1000 s/mm2)
Whole Prostate -  ADC Baseline Whole Prostate -  ADC 3 Months
Number of patients 7 INumber of patients 7
Mean ROI size (pixels) 6804 Mean ROI size (pixels) 5534
Mean number of pixels 6804 Mean number of pixels 5534
Mean value (x10'3mm2s'1) 130.4 Mean value (x10‘3mmV1) 131.0
Repeatability for n=1 (%) -28.5 to 28.5 Repeatability for n=1 (%) -29.0 to 29.0
Variance ratio (F) 2.4 Variance ratio (F) 4.6
P-value for F 0.13 P-value for F 0.033
ICC 0.35 ICC 0.59
wCV 10.3% wCV 10.5%
Tumour-ADC Baseline | Tumour -  ADC 3 Months
Number of patients 7 iNumber of patients 7
Mean ROI size (pixels) 924 Mean ROI size (pixels) 668
Mean number of pixels 924 Mean number of pixels 668
Mean value (xlO^mmV1) 62.7 Mean value (xlO^mmV1) 53.8
Repeatability for n=1 (%) -131.3 to 131.3 Repeatability for n=1 (%) -190.4 to 190.4
Variance ratio (F) 1.8 Variance ratio (F) 0.4
P-value for F 0.23 P-value for F 0.88
ICC 0.20 ICC -0.52
wCV 47.4% wCV 68.7%
Peripheral Zone -  ADC Baseline Peripheral Zone -  ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 155 Mean ROI size (pixels) 121
Mean number of pixels 155 Mean number of pixels 121
Mean value (x10'3mmV1) 149.4 Mean value (x10'3mmV1) 119.2
Repeatability for n=1 (%) -38.3 to 38.3 Repeatability for n=1 (%) -88.8 to 88.8
Variance ratio (F) 6.0 Variance ratio (F) 2.9
P-value for F 0.016 P-value for F 0.09
ICC 0.67 ICC 0.43
wCV 13.8% wCV 32.1%
Central Zone -  ADC Baseline Central Zone -  ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 190 Mean ROI size (pixels) 145
Mean number of pixels 190 Mean number of pixels 145
Mean value (xlO^mmV1) 152.0 Mean value (x10"3mmV1) 142.1
Repeatability for n=1 (%) -17.9 to 17.9 Repeatability for n=1 (%) -29.6 to 29.6
Variance ratio (F) 13.3 Variance ratio (F) 1.8
P-value for F 0.0016 P-value for F 0.24
ICC 0.84 ICC 0.20
wCV 6.5% wCV 10.7%
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Early ADC (b-values 0 - 5 0  s/mm2)
Whole Prostate -  Early ADC Baseline Whole Prostate -  Early ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 6804 Mean ROI size (pixels) 5534
Mean number of pixels 6804 Mean number of pixels 5534
Mean value (x10'3mmV1) 414.9 Mean value (x10‘3mm2s'1) 381.4
Repeatability for n=1 (%) -44.8 to 44.8 Repeatability for n=1 (%) -64.5 to 64.5
Variance ratio (F) 0.8 Variance ratio (F) 0.7
P-value for F 0.62 P-value for F 0.67
ICC -0.21 ICC -0.26
wCV 16.2% wCV 23.3%
Tumour -  Early ADC Baseline I Tumour -  Early ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 924 Mean ROI size (pixels) 668
Mean number of pixels 924 Mean number of pixels 668
Mean value (x10'3mmV1) 385.5 Mean value (x10'3mmV1) 434.8
Repeatability for n=1 (%) -85.3 to 85.3 Repeatability for n=1 (%) -271.6 to 271.6
Variance ratio (F) 5.7 Variance ratio (F) 0.3
P-value for F 0.018 P-value for F 0.92
ICC 0.66 ICC -0.59
wCV 30.8% wCV 98.0%
Peripheral Zone -  Early ADC Baseline Peripheral Zone -  Early ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 155 Mean ROI size (pixels) 121
Mean number of pixels 155 Mean number of pixels 121
Mean value (x10'3mmV1) 405.8 Mean value (x10‘3mmV1) 357.2
Repeatability for n=1 (%) -77.9 to 77.9 Repeatability for n=1 (%) -157.0 to 157.0
Variance ratio (F) 3.0 Variance ratio (F) 1.2
P-value for F 0.09 P-value for F 0.38
ICC 0.44 ICC 0.02
wCV 28.1% |wCV 56.7%
Central Zone -  Early ADC Baseline Central Zone -  Early ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 190 Mean ROI size (pixels) 145
Mean number of pixels 190 Mean number of pixels 145
Mean value (x10'3mmV1) 366.1 Mean value (xlO^mmV1) 361.1
Repeatability for n=1 (%) -72.8 to 72.8 Repeatability for n=1 (%) -75.9 to 75.9
Variance ratio (F) 3.0 Variance ratio (F) 0.9
P-value for F 0.09 P-value for F 0.52
ICC 0.44 ICC -0.11
wCV 26.3% wCV 27.4%
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Late ADC (b-values 150 -  1000 s/mm2)
Whole Prostate -  Late ADC Baseline Whole Prostate -  Late ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 6804 Mean ROI size (pixels) 5534
Mean number of pixels 6804 Mean number of pixels 5534
Mean value (xlO^mmV1) 104.0 Mean value (x10'3mm2s‘1) 87.3
Repeatability for n=1 (%) -36.4 to 36.4 Repeatability for n=1 (%) -51.7 to 51.7
Variance ratio (F) 3.5 Variance ratio (F) 3.1
P-value for F 0.064 P-value for F 0.081
ICC 0.50 ICC 0.46
wCV 13.1% wCV 18.7%
Tumour -  Late ADC Baseline Tumour -  Late ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 924 Mean ROI size (pixels) 668
Mean number of pixels 924 Mean number of pixels 668
Mean value (xlO^mmV1) 42.3 Mean value (x10"3mm2s'1) 38.6
Repeatability for n=1 (%) -201.1 to 201.1 Repeatability for n=1 (%) -255.7 to 255.7
Variance ratio (F) 0.9 Variance ratio (F) 0.5
P-value for F 0.545 P-value for F 0.79
ICC -0.13 ICC -0.39
wCV 72.6% wCV 92.3%
Peripheral Zone -  Late ADC Baseline Peripheral Zone -  Late ADC 3 Months
Number of patients 7 INumber of patients 7
Mean ROI size (pixels) 155 Mean ROI size (pixels) 121
Mean number of pixels 155 Mean number of pixels 121
Mean value (xlO^mmV1) 126.8 Mean value (xlO^mmV1) 91.7
Repeatability for n=1 (%) -41.2 to 41.2 Repeatability for n=1 (%) -123.5 to 123.5
Variance ratio (F) 7.4 Variance ratio (F) 2.5
P-value for F 0.009 P-value for F 0.124
ICC 0.73 ICC 0.37
wCV 14.9% wCV 44.6%
Central Zone -  Late ADC Baseline Central Zone -  Late ADC 3 Months
Number of patients 7 Number of patients 7
Mean ROI size (pixels) 190 Mean ROI size (pixels) 145
Mean number of pixels 190 Mean number of pixels 145
Mean value (x10'3mmV1) 134.4 Mean value (x10'3mmV1) 121.7
Repeatability for n=1 (%) -30.6 to 30.6 Repeatability for n=1 (%) -55.8 to 55.8
Variance ratio (F) 5.5 Variance ratio (F) 0.5
P-value for F 0.021 P-value for F 0.076
ICC 0.65 ICC -0.37
wCV 11.0% wCV 20.2%
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Figure 3.1 Example of contrast retention between two MRI scans on 
consecutive days
A) Day 1, T2 weighting B) Day 1, Ti weighting
D) Day 2, Tj weighting
The pre-contrast Ti image 
(B) demonstrates low signal 
intensity throughout the
prostate. The following day, 
a similar pre-contrast image 
(D) exhibits prominent high 
signal intensity in the
posterior peripheral gland. 
As no intervention has
occurred between the two 
scans, the only reasonable 
explanation for this effect is 
pooling of Gd-DTPA from 
day 1 to day 2. The effect 
on the dynamic images is 
shown (E -  J). As there is 
already saturation of the 
tissues with gadolinium 
there is little or no increase 
in gadolinium concentration 
after bolus injection, 
resulting in poor curve 
fitting and loss of data from 
the affected regions. In this 
study this effect was seen 
on three occasions, two at 
baseline and one after 3 
months of androgen 
deprivation. The most 
striking example is shown.
c Da T2 htinwe i
H) Day 2, AUC60
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Table 3.6 Correlation coefficients (p) for Ti and T2* weighted DCE-MRI, R2* and ADC parameters at baseline
Whole Prostate
P
ve
p-value P
kep
p-value P
AUCeo
p-value P
rBV
P-
value
P
rBF
p-value P
r2*
P-
value
ADC 
(b-val 0-1000)
p p-value
ADC 
(b-val 0-50)
p p-value
ADC 
(b-val 150- 
1000) 
p p-value
^trans 0.79 <0.0001 0.57 0.009 0.95 <0.0001 0.68 0.0012 0.66 0.002 0.17 ns -0.5 ns -0.54 ns -0.5 ns
Ve 0.05 ns 0.74 0.0003 0.38 ns 0.31 ns 0.10 ns -0.43 ns -0.79 0.034 -0.43 ns
kep 0.62 0.0046 0.68 0.0013 0.70 0.0009 0.26 ns 0.04 ns 0.14 ns 0.04 ns
AUCeo 0.70 0.0008 0.67 0.0016 0.22 ns -0.5 ns -0.54 ns -0.5 ns
rBV 0.98 <0.0001 0.06 ns -0.29 ns 0.04 ns -0.29 ns
rBF 0.10 ns -0.29 ns 0.04 ns -0.29 ns
FV 0.43 ns -0.21 ns 0.42 ns
ADC (b-val 0- 
1000)
0.43 ns 1.0 0.0004
ADC (b-val 0-50) 0.43 ns
ns = not significant
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Table 3.7 Correlation coefficients (p) for Ti and 12* weighted DCE-MRI, R2* and ADC parameters at baseline
Tumour
P
Ve
p-value P
kep
p-value
AUCeo 
p p-value
rBV
P P- 
value
P
rBF
p-value P
FV
P-
value
ADC 
(b-val 0-1000)
p p-value
ADC 
(b-val 0-50)
p p-value
ADC 
(b-val 150- 
1000) 
p p-value
t^rans 0.57 0.008 0.80 <0.0001 0.98 <0.0001 0.56 0.0138 0.59 0.0086 0.29 ns 0.36 ns -0.5 ns 0.36 ns
Ve 0.16 ns 0.49 0.033 0.33 ns 0.35 ns 0.19 ns 0.64 ns -0.32 ns 0.57 ns
kep 0.83 <0.0001 0.58 0.011 0.59 0.0082 0.18 ns 0.14 ns -0.29 ns 0.04 ns
AUCeo 0.59 0.0094 0.62 0.0055 0.36 ns 0.43 ns -0.54 ns 0.50 ns
rBV
rBF
r2*
0.98 <0.0001
0.12
0.09
ns
ns
0.25
0.04
0.00
ns
ns
ns
0.57
0.42
-0.14
ns
ns
ns
0.00
-0.18
0.57
ns
ns
ns
ADC (b-val 0- 
1000)
0.21 ns 0.75 ns
ADC (b-val 0-50) 0.11 ns
ns = not significant
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Table 3.8 Correlation coefficients (p) for Ti and T2* weighted DCE-MRI, R2* and ADC parameters at baseline
Peripheral Zone
P
Ve
p-value P
kep
p-value P
AUCeo
p-value
rBV
P P- 
value
P
rBF
p-value P
r2*
P-
value
ADC 
(b-val 0-1000)
p p-value
ADC 
(b-val 0-50)
p p-value
ADC 
(b-val 150- 
1000) 
p p-value
l t^rans 0.59 0.011 0.67 0.0029 0.99 <0.0001 0.38 ns 0.38 ns 0.50 0.035 0.00 ns 0.36 ns -0.18 ns
Ve _ ns 0.61 0.0079 0.19 ns 0.16 ns 0.22 ns -0.18 ns 0.07 ns -0.29 ns
0.12
kep 0.65 0.0046 0.26 ns 0.29 ns 0.47 0.05 0.21 ns 0.46 ns 0.07 ns
AUCeo 0.41 ns 0.41 ns 0.50 0.0354 0.00 ns 0.36 ns -0.18 ns
rBV 0.98 <0.0001 ns -0.04 ns -0.11 ns 0.00 ns
0.17
rBF - ns -0.04 ns -0.11 ns 0.00 ns
0.10
R2* 0.11 ns 0.76 0.048 -0.11 ns
ADC (b-val 0- 0.00 ns 0.96 0.0028
1000)
ADC (b-val 0-50) -0.18 ns
ns = not significant
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Table 3.9 Correlation coefficients (p) for Ti and T2* weighted DCE-MRI, R2* and ADC parameters at baseline
Central Zone
P
ve
p-value P
kep
p-value
i
P
AUCeo
p-value P
rBV
P-
value
P
rBF
p-value P
r2*
P-
value
ADC 
(b-val 0-1000)
p p-value
ADC 
(b-val 0-50)
p p-value
ADC 
(b-val 150- 
1000) 
p p-value
j t^rans 0.77 0.0003 0.59 0.0105 0.96 <0.0001 0.47 ns 0.57 0.0137 0.29 ns -0.07 ns 0.43 ns -0.29 ns
Ve 0.02 ns 0.82 <0.0001 0.14 ns 0.27 ns 0.11 ns -0.71 ns 0.25 ns -0.89 0.0067
kep 0.53 0.0244 0.52 0.0277 0.52 0.027 0.25 ns 0.64 ns 0.50 ns 0.54 ns
AUCeo 0.42 ns 0.55 0.0198 0.22 ns -0.21 ns 0.50 ns -0.43 ns
rBV
rBF
R2*
0.95 <0.0001
0.09
0.08
ns
ns
0.39
0.39
0.68
ns
ns
ns
0.43
0.43
0.00
ns
ns
ns
0.39
0.39
0.43
ns
ns
ns
ADC (b-val 0- 
1000)
0.07 ns 0.89 0.0123
ADC (b-val 0-50) -0.07 ns
ns = not significant
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3.6 Discussion
This analysis has shown considerable difference in the variability of the four prostate 
regions of interest, namely whole prostate, tumour, normal peripheral zone and benign 
central gland. The fact that peripheral zone is the least reproducible is not surprising. 
This cohort of patients was made up of men about to undergo neo-adjuvant androgen 
deprivation prior to external beam radiotherapy. Given the fact that radical 
prostatectomy and the increasingly popular low dose-rate brachytherapy treatments 
are reserved for men with more limited, low-stage disease, the external-beam 
radiotherapy patient population in prostate cancer tends to have more extensive 
localised disease. 75% of men in this study had stage 2c disease or greater. As a 
result, the region of peripheral gland that met the criteria for ROI placement (i.e. 
homogeneous high signal intensity on non-contrast enhanced T2-weighted sequences) 
was usually small. This is reflected in the number of pixels used for parameter 
calculation, which for peripheral gland was only 2.2 -  6.4% of the number of pixels 
used for whole prostate calculations, depending on the parameter in question. With 
such low numbers of pixels to average, small differences in ROI placement between 
scans, spurious pixel values and gland movement during the scan will all have a 
proportionally greater influence on the final parameter value and thereby increase 
variability.
For whole prostate ROIs the reverse is true, making it the most reproducible region for 
analysis. For biological observations, whole prostate values may seem the least 
informative, being comprised of various different tissues, each of which may respond 
differently to any given intervention, thereby only giving a ‘global’ assessment of effect 
on the gland. However, with increasing evidence that a proportion of tumour cell kill 
results from vascular effects rather than direct cytotoxicity, a global assessment of 
prostate vascular status is becoming ever more relevant [12-15],
Tumour regions of interest are generally the most relevant, given that the tumour is the 
intended target for prostate cancer therapy. Differentiation of tumour from benign 
peripheral zone is often difficult and as a result is the most frequent subject of 
radiological publications concerning the prostate gland [16-30]. In this study great care 
was taken to utilise all the available information for tumour ROI delineation, including 
combinations of T2-weighted, contrast enhanced Tr weighted and diffusion ADC maps. 
In general, an irregular mass of low signal intensity in the peripheral zone seen on the 
T2-weighted images was considered to represent tumour. All regions were checked by 
a highly experienced radiologist with a specialist interest in prostate cancer (ARP).
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fGiven the challenges in defining tumour regions, it is encouraging that the 
reproducibility of tumour ROIs was generally not substantially inferior to whole prostate 
regions for T■, parameters (variance ratios of 4.9 to 23 for tumour compared with 5.7 to 
13.4 for whole prostate), T2* parameters (variance ratios of 2.2 to 2.5 for tumour versus 
3.5 -  3.7 for whole prostate) and for R2* (variance ratios of 2.3 for tumour versus 2.5 for 
whole prostate). This is despite a considerably smaller ROI size. The coefficients of 
variance are comparable to values published in the literature. For example, in this 
study the wCV for tumour Ktrans was 20.1% compared with 20.3% reported by 
Lankester [5] and 24% reported by Galbraith [4]. This is despite the fact that both of 
these studies investigated much more readily definable tumours such as ovarian, 
uterine and renal carcinomas as well as pelvic or thoracic sarcomas. Similar 
comparisons can be made for the other Ti parameters.
The reproducibility of the prostate T2* parameters rBV and rBF was poor, with variance 
ratios of 2.5 -  5.5 for baseline rBV and 2.2 -  3.9 for baseline rBF. wCV values were 
also disappointing, ranging from 42.5% to 116.3%. This is much worse than the only 
other reported reproducibility measures for T2* parameters, in gynaecological 
malignancy, of 12.1% for rBV and 16.8% for rBF [5]. Given the fact that the image 
matrix size for the T2* acquisition is half that of the Ti images (128 x 128 pixels as 
opposed to 256 x 256 pixels), resulting in each pixel being four times larger, one would 
expect a reduction in reproducibility. However, this factor alone cannot explain the poor 
results. Susceptibility-weighted MRI methods are more liable to be affected by 
susceptibility artefacts generated by changes in the volume of rectal gas. These 
artefacts tend to influence the posterior prostate due to its close proximity to the 
rectum. As a result tumour and peripheral zone ROIs are likely to be most affected by 
this phenomenon, given that these regions tended to lie posteriorly. Accordingly, wCV 
for tumour and peripheral zone (72.3% -116.3%) is worse than wCV for whole prostate 
(42.5% - 51.9%). Central zone T2* reproducibility is also likely to be affected by the fact 
that this region of the prostate is very heterogenous, with nodules of benign 
hyperplasia interspersed with normal glandular tissue and fibrosis. As a result blood 
flow is likely to vary considerably between these tissue types and small differences in 
ROI placement may result in large variations in blood volume and blood flow 
measurements.
The reproducibility of R2* in pelvic muscle is extremely good (wCV of 4%, F = 8.07 at 
baseline). This suggests that the measurement technique itself exhibits very low 
variability. However, when R2* is measured in tumours, reproducibility is significantly 
worse (wCV of 23.3%, F = 2.3). This may be explained by our understanding of tumour
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vasculature, which has chaotic structure, poorly formed, fragile vessels with high 
permeability to macromolecules. There is arteriovenous shunting, high vascular 
tortuosity and vasodilatation leading to intermittent or unstable flow due to transient 
rises in already raised interstitial pressure. This results in intermittent changes in blood 
flow causing periods of transient acute hypoxia. The variability of R2* may therefore 
reflect the intrinsic biology of prostate tumours rather than measurement error. This 
hypothesis is supported by the consistent improvement in the reproducibility of tumour 
R2* following androgen deprivation. Androgen withdrawal causes tumour vascular 
regression and a reduction in the proportion of abnormal blood vessels. As a result 
there is stabilisation of blood flow and less fluctuation of p02 levels.
The decline in reproducibility of the T^and T2*-weighted parameters following 
androgen deprivation is difficult to explain. In general, the reductions are modest and 
mixed in comparison with the consistent improvements seen in R2*. Using the same 
argument as for R2*, one would expect an improvement in the reproducibility of the 
values of relative blood flow and volume. The worsening of reproducibility may in part 
be due to the fact that these measures are relative because the absolute arterial input 
function is not known, making comparisons between studies more difficult. The 
technical difficulties of T2* methods due to susceptibility artefacts may also mask any 
physiological stabilisation to the tumour blood flow. Changes in the Ti parameters 
before and after androgen deprivation are smaller, with declines only occurring for 
certain measures (whole prostate and central zone whole prostate, peripheral 
and central zone ve, whole prostate, tumour and central zone keP and whole prostate, 
tumour and central zone AUC^)-
The deterioration in reproducibility for whole prostate, tumour and central gland regions 
of interest following androgen withdrawal may have a simpler explanation. Androgen 
deprivation causes a reduction in prostate volume (by an average of 34% in this study), 
thereby reducing the number of pixels for whole prostate analysis. The distinction 
between tumour and normal peripheral zone becomes even harder to discern following 
the reduction in peripheral zone signal intensity on T2-weighted sequences, making the 
definition of these regions less reliable. Similarly, the altered prostate morphology 
makes accurate recreation of central zone ROIs from examination to examination more 
difficult, thereby increasing variability.
The strong correlation observed between AUC6o and the quantitative Ti parameters 
confirms the observations reported by Lankester, validating the use of this semi- 
quantitative parameter, which is not dependent on mathematical modelling of
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gadolinium concentration -  time curves, as a ‘global’ measure of vascularity. The 
interdependence between and ve, Ktrans and kep and both Ktrans and kep with rBv 
and rBV reflect the intrinsic relationship between blood flow, vascular permeability, 
distribution within the extravascular compartment and re-entry of contrast into the 
vasculature. The fact that nothing correlates with R2* suggests that, for this series at 
least, the vascular deoxyhaemoglobin concentration is independent of flow or volume 
effects.
3.7 Conclusion
This study documents the variability and repeatability of T^and T2*-weighted DCE-MRI, 
R2* and apparent diffusion coefficients for the various regions of the human prostate 
gland. Together with published data for prostate gland and other tumour sites, data are 
emerging regarding the suitability of the various MRI parameters as measures of 
response to treatment in a variety of malignant tumours [4, 5, 11, 31]. Specifically, this 
study has served to provide estimates of variability, within the 20 patients imaged as 
part of this study, so as to determine the effect of androgen deprivation on the prostate 
gland accurately and to calculate, on an individual patient-by-patient basis, whether a 
parameter change following androgen withdrawal is statistically significant.
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Chapter 4
Experiments to evaluate the validity and 
reproducibility of Blood Oxygen Level 
Dependent MRI and its response to 
hvperoxia. in two human prostate cancer
xenografts.
4.1 Aims
1) To evaluate the correlation between the quantity and distribution of 
pimonidazole immunostaining and the BOLD-MRI derived R2* parameter in 
DU 145 and PC3 human prostate tumour xenografts.
2) To assess the reproducibility of R2* in these xenografts.
3) To determine the effect of carbogen gas breathing on the R2* parameter.
4.2 Introduction
This chapter contains details of the experiments performed to determine whether 
BOLD MRI is a valid technique to evaluate the oxygen status of prostate carcinoma 
and to determine the effect of an increased inspired oxygen concentration on tumour 
oxygenation.
Animal experiments were performed in order to evaluate the validity and reproducibility 
of this MR technique in a highly controlled environment without the confounding factors 
that are present in the clinical setting. Prostate cancer xenografts are suitable for 
imaging studies because they consist of solid tumour masses. Longer continuous 
acquisition times could be used with mice compared with human subjects because they 
could be rendered motionless using sedation. There is also more control in obtaining 
tumour sections in the same orientation as the MRI scan because there is no 
requirement for detailed pathological staging, which must always take priority to 
sectioning for research purposes in patients that undergo radical prostatectomy.
115
The DU 145 cell line was originally isolated from a lesion in the brain of a patient with 
metastatic carcinoma of the prostate and a 3 year history of lymphocytic leukaemia [1,
2]. It forms adenocarcinoma (grade II) consistent with a prostatic primary. The cell line 
is not detectably hormone sensitive, is only weakly positive for acid phosphatase and 
isolated cells form colonies in soft agar. The cells do not express prostate specific 
antigen. Ultrastructural analyses of both the cell line and original tumour reveals 
microvilli, tonofilaments, desmosomes, mitochondria, well developed Golgi and 
heterogenous lysosomes.
The PC-3 cell line was initiated from a bone metastasis of a stage IV prostate 
adenocarcinoma in a 62-year-old male Caucasian [3]. The line is not detectably 
hormone sensitive. Cells exhibit low acid phosphatase and testosterone-5-alpha 
reductase activities.
4.3 Materials and Methods
All animal experiments were performed in full compliance with government regulations 
and UKCCCR guidelines on animal welfare and were approved by the local Ethical 
Review Committee (Home office licence number 70/5823).
4.3.1 Cell Culture
DU145 and PC3 cells were incubated under 19.6% 0 2, 5% C02 and 75.4% N2 at 37°C. 
The cells were maintained in Dulbecco's Modified Eagle Media (DMEM) media 
supplemented with 10% foetal calf serum (FCS), 2mM L-glutamine, 100 units/ml 
penicillin and 100pg/ml streptomycin.
4.3.2 Implant
Tumours were initiated by injecting 0.05ml containing 2x106 cells (subcutaneously) 
onto the rear dorsum of 8-10 week old SCID mice. Animals were selected for treatment 
when their tumours reached 8-10mm geometric mean diameter (GMD).
4.3.3 Imaging
Three experiments were performed on each mouse using two imaging sessions over 
two days:
Mice were sedated for each MRI scan using 200pl of 1 : 10 hypnorm in water, injected 
into the peritoneal cavity. The sedated mouse was then placed in a six centimetre 
diameter quadrature birdcage coil (Varian, Palo Alto, CA, USA) in a 4.7 Tesla Varian 
MR system. A hot air blower with continuous temperature monitoring was used to 
maintain body temperature.
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Day 1
Baseline BOLD measurement:
Initial IVweighted sagital and transverse scans were obtained for localisation.
Multiple spoiled gradient echo (GRE) images were acquired on a single central slice 
with increasing TE times (4ms - 48ms, in 4ms steps), with TR 117 ms, flip angle (a) 
45°, slice thickness 1 mm and field of view 40 x 45 mm.
Carbogen breathing experiment:
Scanning time was divided into three gas-breathing periods with the mouse breathing 
air, carbogen (95% 0 2 and 5% C02) and then air again. The first air breathing period 
lasted four minutes, followed by 10 minutes of carbogen breathing and then a further 
four minutes breathing air. All gases were administered at 1 l.min'1 (gases obtained 
from BOC, UK). A vacuum- based gas scavenger was used to minimise changes in 
oxygen content within the magnet bore. GRE images with the same imaging 
parameters that were used for the baseline scan were acquired every minute 
throughout the experiment.
The mouse was returned to the animal house overnight.
Day 2
Pimonidazole administration:
Each mouse was weighed. Pimonidazole hydrochloride, made up to a concentration of 
6mg/ml was administered at a dose of 60mg/kg by intra-peritoneal injection one hour 
before the scan.
Imaging:
Sedation and immobilisation was performed as for day one. The imaging protocol was 
identical to the baseline scan on day one with the mouse breathing air only. The 
tumour was imaged in the same plane and at the same level as on the previous day. 
The animal was returned to its cage after the scan.
Euthanasia:
The mouse was killed by cervical dislocation two hours after the pimonidazole injection 
(i.e. about 20 minutes after imaging was complete). The tumour was immediately 
dissected.
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4.3.4 Histology and Immunohistochemical Analysis
These are detailed in the histological methods section -  appendix A.
4.3.5 Animal MR Image Analysis (Figure 4.1)
Multi-echo single-slice sequence images were processed using Matlab version 5 (The 
Mathworks, Nantick, MA, USA). A region of interest (ROI) was drawn around the 
tumour using the initial Tr weighted image. R2* (s'1) pixel-maps were then calculated for 
the baseline scan, for each time-point of the carbogen series and for the scans on day 
2. A grid-based analysis was then performed for each of the scans. The in-house 
analysis program written for the Matlab software created a 1mm x 1mm grid across the 
tumour. R2* pixel maps were generated for each grid element.
Animated GIF images were generated by the Matlab program and used to check for 
movement with the GIMP animation playback feature (GNU Image Manipulation 
Program, www.gimp.org). If movement was seen to occur, the individual image was 
excluded and the ROI re-positioned for subsequent analysis. Animals were excluded if 
there was movement through the imaging plane during the experiment.
4.3.6 Experimental Design
Validation
The validation experiment compared the level and distribution of R2* with the 
distribution of pimonidazole staining in the corresponding histological section. The 
median R2* value for the whole tumour ROI from day 2 of the experiment was 
compared with the whole tumour pimonidazole staining percentage (with and without 
the exclusion of necrotic areas). R2* from each grid element was also compared with 
the pimonidazole staining percentage from the corresponding grid element in the 
matching histological section. The grid-based analysis was only performed for non- 
necrotic tumour grid elements. The day 2 MRI parameter values were chosen for the 
histological comparison because this imaging procedure was performed only 20-30 
minutes prior to the excision and formalin fixation of the tumour. As a result there was 
minimal time for the oxygenation status of the tumour xenograft to change between the 
time-points of the MRI and immunohistochemical measurements of hypoxia.
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Figure 4.1 Animal MR Image Analysis
A
050106 ImqioO grid 0 9375mm 1 0547mm
B
C I
(A) shows the initial Ti-weighted image the entire mouse in cross section. A region of interest was drawn around each tumour (B). R2* (s-1) pixel-maps were then 
calculated (C). A grid-based analysis (1 x 1mm) was then performed for each scan (D).
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The distribution of each set of results was tested for normality using the Shapiro-Wilk 
test. For normally distributed data, correlation was assessed using the Pearson 
correlation coefficient (r). For non-parametric data the Spearman-Rank correlation 
coefficient was used. The Mann-Whitney U test was used to test for a significant 
difference between two categorical data sets, for example when the percentage of 
necrosis between the two xenografts was being compared.
A receiver operating characteristic (ROC) curve was plotted for both the whole tumour 
and grid-based data for the DU 145 tumours. This calculation provided an estimation of 
the sensitivity and specificity of BOLD MR when used to depict tumour hypoxia. It also 
established the R2* value with the optimum power to predict hypoxia within a grid 
element.
Reproducibility
The reproducibility experiment compared the whole tumour baseline R2* values 
between day 1 and day 2 for each mouse. The standard consensus approach to 
assessing reproducibility was used (see page 89).
Repeatability was assessed by comparing two of the baseline BOLD sequences taken 
one minute apart during the air breathing period at the beginning of the carbogen 
experiment on day 1 (time-points two and three). Again the standard consensus 
approach was used.
Carbogen breathing
The effect of hyperoxia on R2* was evaluated using the time series of repeated BOLD 
MRI scans during carbogen breahing. Changes in R2* for the whole xenograft and for 
every grid element of each tumour were calculated.
4.4 Results
4.4.1 Tumour Inclusion Criteria
Twenty-four DU 145 and twenty PC3 prostate tumour xenografts were imaged.
For four DU 145 tumours and three PC3 tumours the tumour became fragmented on 
dissection. For these tumours only average whole tumour measurements were 
possible. Very poor anatomical correlation between the MRI and histological section
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made grid based analysis impossible. Pimonidazole staining failed in two DU 145 
tumours for unknown reasons; these tumours were excluded from the 
immunohistochemical analysis. In one of the DU145 experiments no data was obtained 
for the day 2 MRI scan because of a temporary fault with the MRI software. In this case 
reproducibility analysis was not possible. The day 1 MRI scan was used for 
pathological correlation. In one DU145 tumour and three PC3 tumours there were no 
results for the carbogen breathing experiment. In each case this was due to data 
corruption during the MR image acquisition.
The following numbers of tumour xenografts were used for each analysis:
Table 4.1 The number of tumour xenografts used for analysis
Whole Tumour Grid Based
Pathological Pathological Reproducibility Carbogen
Correlation Correlation
DU145 22 19 23 23
PC3 20 17 20 17
4.4.2 Tumour Characteristics
Notable differences were identified between the two tumour types:
1) PC3 tumours were significantly more necrotic than DU 145 tumours with a median 
of 18.1% of the total cross-sectional PC3 tumour area being necrotic compared 
with 9.4% for DU145 tumours (p = 0.034, Mann-Whitney U test). Figure 4.2.
2) PC3 tumours contain significantly more blood vessels than DU 145 tumours. The 
mean vascular endothelial cross sectional area as a proportion of the whole tumour 
cross-sectional area for PC3 tumours was 17.3% compared with 3.8% for DU145 
tumours (p < 0.0001, Mann-Whitney U test). Figure 4.3.
3) The DU145 tumours were significantly more hypoxic than the PC3 tumours, this is 
compatible with the difference in vascularity. The median proportion of cells 
staining with pimonidazole was 22.5% for DU145 tumours versus 10.6% for PC3 
xenografts, p = 0.018 (20.3% and 10.7% respectively if necrosis is excluded, p = 
0.015, Mann-Whitney U test). Figure 4.4.
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Figure 4.2
The difference in the percentage of necrosis between DU145 and PC3 xenografts
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Figure 4.4
The difference in proportion of pimonidazole staining between DU145 and PC3 tumours
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4.4.3 Exclusion of necrosis
Intact living cells take up pimonidazole in an active process. Areas of necrosis should 
not, in theory, stain for pimonidazole. Pimonidazole labelling can be considered 
‘positive’ if the brown staining is cytoplasmic or nuclear, in other words the 
pimonidazole is bound within the cell as a result of the cell’s low oxygen environment. 
Extracellular staining is artefactual and usually a result of binding of the secondary 
antibody to extracellular protein elements within the tissue. The automated analysis of 
pimonidazole staining allowed for thresholding to compensate for the small amount of 
diffuse background staining. Despite this there was still a possibility that the inclusion of 
necrotic or acellular tumour regions may affect the results. Tumours ROIs were 
therefore drawn twice, initially including the entire tumour and then repeated with areas 
of necrosis excluded.
No statistically significant differences between the analyses including and excluding 
necrosis were observed. The average difference in the proportion of pimonidazole 
staining was 2.2% for DU 145 tumours and 0.1% for PC3 tumours (p = 0.69 for DU 145 
tumours, p = 0.82 for PC3 tumours, Mann-Whitney U test). This confirms the specificity 
of pimonidazole binding and indicates that background, extracellular staining was 
minimal and statistically irrelevant.
4.4.4 Reproducibility Analysis
The distribution of each parameter was not significantly different form normal. The 
difference between values for both DU 145 and PC3 tumours showed no dependence 
on the mean and therefore no logarithmic transformation was required for these data. A 
detailed discussion of reproducibility can be found in chapter 3, p110.
Repeatability statistics using whole tumour R2* values are as follows:
(Time-point 2 versus time-point 3, during the air breathing period at the beginning of 
the carbogen experiment on day 1)
Table 4.2 Repeatability statistics using whole tumour R2* values
DU145 >C3
Number of animals 23 
Repeatability for n=1 (%) +/-9.3 
Variance ratio (F) 287.8 
P-value for F < 0.0001 
Interclass correlation coefficient (ICC) 0.99 
Coefficient of variation (wCV) 3.4%
Number of animals 17 
Repeatability for n=1 (%) +/- 6.3% 
Variance ratio (F) 1580.2 
P-value for F < 0.0001 
Interclass correlation coefficient (ICC) 0.99 
Coefficient of variation (wCV) 2.2%
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The test proved to be extremely repeatable in both DU 145 and PC3 tumours. For an 
individual mouse, a reduction in R2* of 9.3% for DU 145 tumours and 6.3% for PC3 
tumours could be considered significant at the 95% confidence level (i.e. not simply a 
result of test variability). A very high degree of repeatability was seen for both tumour 
types in terms of both ICC and wCV.
Reproducibility statistics using whole tumour R2* values are as follows:
(Day 1 versus Day 2)
Table 4.3 Reproducibility statistics using whole tumour R2* values
>U145 »C3
slumber of animals 23 
Variance ratio (F) 10.3 
P-value for F < 0.0001 
nterclass correlation coefficient (ICC) 0.81 
Coefficient of variation (wCV) 5.2%
Number of animals 20 
Variance ratio (F) 23.6 
P-value for F < 0.0001 
Interclass correlation coefficient (ICC) 0.91 
Coefficient of variation (wCV) 9.1 %
A high degree of reproducibility was seen for both tumour types in terms of both ICC 
and wCV.
4.4.5 Histological Correlation
Whole Tumour Measurements
There is a statistically significant positive correlation between the R2* rate and the 
proportion of pimonidazole labelling within DU 145 and PC3 human prostate cancer 
xenografts, (figures 4.5 & 4.6). Pearson's product moment correlation coefficient (r) 
was calculated for both tumour types with necrosis included and excluded:
Table 4.4 The correlation between R2* and pimonidazole labelling
Necrosis Included Necrosis Excluded
r p-value r p-value
DU145 0.75 < 0.0001 0.75
PC3 0.73 0.0006 0.73
< 0.0001 
0.0006
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Figure 4.5
Scatter plot showing the relationship between whole DU 145 tumour R2* 
and the proportion of pimonidazole staining in corresponding tumour sections
(regression line shown in black)
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Figure 4.6
Scatter plot showing the relationship between whole PC3 tumour R2* 
and the proportion of pimonidazole staining in corresponding tumour sections
(regression line shown in black)
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The ROC analysis is dependent upon the pimonidazole-staining threshold above which 
a tumour was considered hypoxic. As a result four calculations were performed with 
increasing cut-off values (figure 4.7):
Table 4.5 ROC analysis -  whole tumour
. Pir ,H ida2j !  Ia^ " in9 >10%  > 20% >30% > 4 0 %threshold used to determine
whether a tumour was hypoxic
Area Under ROC curve 0.93 0.88 0.88 0.86
95% C.l. for ROC 0.78-1 0 .7 3 -1  0.74-1 0.70-1
Sensitivity 1 0.85 1 1
Specificity 0.75 0.78 0.71 0.83
R2* cut-off 40.8 50.1 52.43 60.52
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Figure 4.7 ROC analysis -  whole DU145 tumour
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Grid Analysis
917 DU145 and 864 PC3 corresponding grid pairs were identified between the MR 
images and the histological sections. For each MRI grid the median R2* value was 
used. The calculation of the percentage of pimonidazole proportion for each grid 
element involved the division of the area of staining by the total grid area. As a result, 
only grid squares that contained 100% tumour could be used for analysis. This left 536 
DU145 grid pairs and 412 PC3 grid pairs. Grid elements that contained necrosis were 
also excluded leaving a final number of grid pairs for analysis of 431 for DU 145 and 
319 for PC3.
A weak, but highly statistically significant correlation was seen between R2* and 
pimonidazole labelling in the DU145 grid-based analysis (r = 0.28, p < 0.0001) (figure 
4.8). No correlation was seen in the poorly staining PC3 tumours (figure 4.9).
The ROC for the grid based analysis for DU 145 tumours gave the following results 
(figure 4.10):
Table 4.6 ROC analysis -  grids
Pimonidazole labelling threshold
used to determine whether a >1 0%  > 20% > 30% > 40 %
tumour was hypoxic
Area Under ROC curve 0.64 0.62 0.63 0.62
95% C.l. for ROC 0.56-0.71 0.55-0 .69 0.57-0.70 0.54-0.68
Sensitivity 0.31 0.26 0.51 0.38
Specificity 0.95 0.96 0.72 0.83
R2* cut-off 54.6 47.9 47.9 54.7
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Figure 4.8
Graph showing the correlation between R2*
and the proportion of pimonidazole labelling 
in 19 DU145 tumours analysed using a 1x1mm grid
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Figure 4.9
Graph showing the correlation between R2*
and the proportion of pimonidazole labelling 
in 17 PC3 tumours analysed using a 1x1 mm grid
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Figure 4.10
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4.4.6 Carbogen Breathing
BOLD MRI measurements were made every minute during the carbogen experiment. 
The first four baseline R2* measurements, before the carbogen gas exposure was 
initiated, were averaged to give a single baseline value. The remaining R2* values 
(measurements 5 - 1 8 )  were subtracted from the baseline measurement to give a AR2* 
value, i.e. the change in R2* from baseline.
Analysis on an individual tumour by tumour basis for DU 145 and PC3 tumours showed 
that four DU 145 bearing mice and five PC3 bearing mice had a reduction in R2* during 
carbogen exposure that could be considered statistically significant and distinguishable 
from test variability at the 95% confidence level (figure 4.11). Analysis of the two 
groups as a whole showed a mean reduction in R2* of 3.52s"1 (p = 0.0032) for the 
DU 145 tumours and 6.01s"1 (p = 0.092) for the PC3 tumours, using the paired student’s 
t-test.
The carbogen time series graphs demonstrate the temporal effect of carbogen 
breathing on the oxygenation of the prostate cancer xenografts (figure 4.12). R2* 
values fall rapidly after the commencement of carbogen breathing as tumour oxygen 
levels increase. By the end of the experiment the R2* values have essentially returned 
to baseline. Interestingly, in both DU145 and PC3 tumours, R2* values seem to begin a 
return towards their baseline reading before the carbogen exposure has been 
terminated. For DU 145 tumours this occurs after approximately nine minutes and with 
PC3 tumours the effect is seen earlier, at about four to five minutes. Also, in the DU 145 
experiments there is a suggestion of a ‘rebound’ phenomenon in which the final R2* 
values appear to be higher than they were to start with. This effect was not statistically 
significant and not seen in the PC3 xenografts.
Grid analysis for the carbogen experiments
1110 individual tumour grid elements were evaluated from the 23 DU 145 tumours. 979 
grids were evaluated from the 17 PC3 tumours. Grids exhibiting R2* values less than 
5s"1 and greater than 100s"1 at baseline were excluded from the analysis because 
these values were likely to be artefactual. This left 882 DU145 and 796 PC3 grid 
elements for analysis. Because of the large volume of data, only five time points were 
used for the grid analysis; baseline (average of the first four pre-carbogen 
measurements), early carbogen (average of measurements 6 to 9), mid-carbogen 
(average of measurements 9 to 12), late carbogen (average of measurements 12 to 
15) and post carbogen (average of measurements 15 to 18).
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Figure 4.11
The effect of carbogen gas on individual DU145 tumours
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Individual tumours that demonstrated a statistically significant reduction in R2* are 
shown in red.
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Figure 4.12
The effect of carbogen gas breathing over time - DU145 tumours
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Figure 4.13 demonstrates that if all grid elements are averaged together, carbogen 
seems to have little effect on the R2* parameter value.
However, when the grids were stratified according to their baseline R2* value it 
becomes apparent that grid elements with high R2* values at baseline (i.e. the hypoxic 
grids) show a greater response to hyperoxic gas breathing. Grids were arranged into 
four categories depending upon the baseline R2* value:
Table 4.7 Stratification of grids based on initial R2*
R2* range Number of grids DU145 Number of grids PC3
5.00 - 24.99s'1 129 155
25.00 -  49.99s'1 338 301
50.00 -  74.99s'1 277 237
75.00-99.99s'1 138 104
Each of these was plotted separately against time (figure 4.14). In contrast to the 
whole tumour analysis, the more hypoxic DU 145 grid elements (i.e. those with the 
highest baseline R2*) showed the greatest carbogen response (figure 4.14a). In fact 
only grid elements with baseline R2* of between 75 and 100 s'1 show a statistically 
significant reduction in R2* in response to carbogen exposure (a difference between 
baseline and mid-carbogen exposure of 3.0s'1, p = 0.038).
PC3 tumours are much less hypoxic in general. In the grid analysis, no statistically 
significant reduction in R2* was demonstrated for any of the four R2* categories as a 
result of carbogen exposure (figure 4.14b).
There was no significant decrease in R2* during carbogen exposure for the least 
hypoxic grid regions (baseline values of 5 -  25s'1) for either DU 145 or PC3 tumours. 
However, there was a statistically significant increase in R2* after the carbogen 
exposure was terminated (an increase of 3.1s'1 for DU 145, p = 0.049 and 3.4s'1 for 
PC3, p = 0.047).
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Figure 4.14
The change in R2* with carbogen exposure stratified for baseline R:
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4.5 Discussion
Tumour Characteristics
DU 145 tumours contained fewer blood vessels and were consequently more hypoxic 
than the PC3 xenografts. In contrast, the PC3 tumours were significantly more necrotic. 
This indicated that the presence of necrosis in the PC3 tumours was not entirely 
attributable to a lack of blood supply. There are likely to be other genetic, biological and 
structural explanations to account for the cellular breakdown.
In light of these findings, it was predictable that the DU 145 prostate cancer xenografts 
were likely to be more informative than the PC3 tumours when used in experiments 
that were dependent on the identification of hypoxic areas in non-necrotic tumour 
regions.
Reproducibility:
The repeatability statistic indicates that for an individual tumour a change in R2* of 
greater or less than 9.3% for DU 145 tumours and 6.3% for PC3 tumours would be 
considered statistically significant at the 95% confidence level. In absolute terms, in 
these study groups, a change in an individual DU 145 tumour of 5.1s'1 and in an 
individual PC3 tumour of 3.5s'1 in either direction can be considered real and not simply 
a result of test variability. The repeatability statistic informs on the test itself rather than 
reflecting biological parameters that may change over time. Therefore, these results 
suggest that BOLD MRI is a highly repeatable test in this experimental setting.
The reproducibility analysis performed over two days not only reflects the repeatability 
of the test but also on the stability of the measured parameter (R2* in this case) over 
the study period (2 days). As a result measures of reproducibility will usually be worse 
than measures of repeatability for the same tumour type. For example, Taylor et al. 
performed a two-part study, in human pelvic tumours [4]. They calculated repeatability 
and reproducibility statistics in a group of 13 prostate cancer patients who were imaged 
with two sets of BOLD sequences 20 -  30 minutes apart. Reproducibility values were 
obtained from 13 women with gynaecological tumours imaged on consecutive days. 
The group of 13 same-day patients had a wCV of 2.78% with a 95% confidence 
interval of ± 2.13%. For a single subject a change of ± 1.8s'1 could be considered 
statistically significant. In the group of 13 consecutive day patients the wCV was higher 
(i.e. less reproducible), measuring 7.57% (95% Cl ± 5.82%) with a change of ± 4.4s'1 
required for significance.
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The reproducibility of the R2* parameter in DU 145 xenografts appears to be extremely 
good. A wCV value of 5.2% and a variance ratio of 10.3 are comparable to the human 
data previously described and better than that reported by Lankester et al. (wCV of 
17.5% in human pelvic tumours [5]). The PC3 tumours exhibited slightly less 
reproducibility in terms of wCV (9.1%). This may in part be due to the fact that there 
were fewer numbers (20 versus 23). The intra-class correlation coefficient 
demonstrated excellent reproducibility for both xenografts (0.81 and 0.91 for DU145 
and PC3 respectively).
BOLD-MRI is a technique with sufficient reproducibility to be useful in the assessment 
of changes to the R2* parameter in DU 145 and PC3 prostrate cancer xenografts.
Histological Correlation
Studies that attempt to correlate histological sections with imaging slices will always be 
subject to inherent errors. To start with, the correlation can only ever be as good as the 
accuracy to which the excised tumour is cut. A slight discrepancy between the level or 
plane of the tumour section may result in a mismatch of part or all of the slice. In this 
study, a 4pm immunohistologial section has been compared to a 1000pm MRI slice, a 
250-fold variation in thickness. There is no way to compensate for this disparity. 
Increasing tissue thickness would result in inadequate staining and poor cellular 
definition. Reducing MRI slice thickness is not possible within the current constraints of 
machine spatial resolution. Furthermore, the MRI scan evaluates the tumour in its 
intact living state whereas the histological specimen has been subject to excision, 
fixation and staining. As a result the final immunohistological section is contracted and 
distorted, bearing only a general resemblance to the shape of the original tumour. 
Despite the fact that the analysis process compensates for the two-dimensional change 
in shape with respect to the overall x and y diameter of the tumour, asymmetrical 
distortions can not be taken into account.
With these difficulties in mind, one can appreciate that even a perfect imaging test that 
measures exactly the same parameter as its histological correlate, will demonstrate 
imperfect correlation between to two modalities.
The correlation between R2* and the proportion of pimonidazole staining has other 
limitations. Pimonidazole is a lipid soluble nitroimidazole with a high partition 
coefficient, which diffuses freely throughout the tissues. R2* can only reflect on the 
oxygenation status of blood and on tissues adjacent to perfused vessels. The 
resolution of immunohistochemical analysis is at a cellular level of only a few
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micrometres, the MRI pixel dimension is approximately 175pm2, thus pimonidazole 
immunostaining represents hypoxia with greater spatial resolution than the R2* image.
BOLD MRI captures its parametric map over a period of seconds whereas 
pimonidazole is distributed over the two-hour period between injection and euthanasia. 
As a result, the MR image represents a near-instantaneous snapshot of oxygenation at 
a given moment, while pimonidazole represents the overall level and distribution of 
oxygen over a much longer time frame. Given that acute vascular effects have been 
demonstrated over 20 minute periods [6], the relative contributions of acute and chronic 
hypoxia may be represented differently using the two modalities.
Despite the differences at a microscopic and cellular level, there is likely to be a large 
degree of overlap between the processes measured by BOLD MRI and pimonidazole 
labelling at a macroscopic level. When assessing an entire tumour, or a substantial 
region within it, the degree of pimonidazole staining, whether caused by acute or 
chronic hypoxia effects, is likely to reflect an ‘average’ tissue p02 level for that 
particular area at the time of the investigation. Similarly, given the association between 
tissue p02 and intravascular deoxyhaemoglobin saturation, R2* is likely to reflect and 
average tissue p02 over the time period of the examination. Therefore, as long as the 
two examinations are carried out within a reasonable time of each other and 
acceptable anatomical correlation is achieved between the image slice and the 
histological section, reasonable correlation should be possible.
The results in this study confirm this. Whole tumour measurements exhibited 
reasonable correlation between pimonidazole labelling and R2* (r = 0.75, p < 0.0001 
and r = 0.73, p = 0.0006 for DU 145 and PC3 respectively). The ROC analysis 
emphasises this point. If pimonidazole staining is considered the ‘gold-standard’, R2* is 
able to detect hypoxia with an area under the ROC curve of between 0.86 and 0.93 
depending on the pimonidazole threshold used. The sensitivity of the test ranged 
between 85 and 100% and specificity varied between 71 and 83%. This indicates that 
despite the differences in the physiological processes being measured by the two 
techniques, they give similar results at the macroscopic level.
It would appear that it makes no difference whether necrosis is included or excluded 
from the analysis (figures 4.5 & 4.6). This finding is consistent with the original 
descriptions of pimonidazole immunohistochemistry [7]. Necrotic tissues do not take up 
pimonidazole, which involves an active process, and generate a low R2* signal 
because of its dependency upon intact red blood cells. Therefore, there should be
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minimal discrepancy between evaluations made between the two modalities, in regard 
to necrosis. However, there is a degree of background brown staining within necrotic 
areas of sections stained for pimonidazole caused by secondary antibody effects. It is 
clear from the results that the automated thresholding capability of the analysis 
software effectively excludes the extracellular staining, thereby negating any artefact it 
may cause.
The whole tumour results indicate that R2* correlates with pimonidazole labelling 
between tumours. From the ROC analysis in these tumour types, an R2* value above 
about 50s'1 predicts for pimonidazole staining most accurately (with an area under the 
ROC curve of 0.86 -  0.93). Pimonidazole is known to stain cells in regions with a tissue 
p02 of less than 10mmHg [8, 9]. It can therefore be inferred that for the DU 145 prostate 
cancer xenografts in a mouse model, an R2* value of 50s'1 or more is predictive of 
relevant tumour hypoxia.
The discrepancy between the whole tumour assessment and the grid-based analysis is 
difficult to explain in terms of biology. The whole tumour analysis assessed the 
correlation between pimonidazole staining and R2* between tumours, whereas the grid 
based analysis assessed the correlation between pimonidazole staining and R2* within 
tumours. Despite this difference, the analysis was performed on the same 
immunohistochemical sections and same MR images. It is fair to assume that because 
whole tumours that generally stain heavily with pimonidazole have high R2* values, it 
would follow that there would be a similar correlation for regions within the tumours. 
However the results for the grid-based analysis showed only a weak correlation for the 
DU145 tumours (r = 0.28, p < 0.0001) and no correlation at all for the PC3 xenografts.
One explanation lies with the analysis itself. Reducing the ‘functional unit* of evaluation 
from a whole tumour region of interest down to a 1 x 1 mm square inevitably 
exacerbates all of the problems related to anatomical registration and distortion 
between the MR and histology slices. A small mismatch between the MRI and histology 
grids of only a fraction of a millimetre could result in grids from one region of the 
histology slice being compared to a different part of the tumour on the MR image. 
Furthermore, for the PC3 tumours there was a reduced number of grid squares suitable 
for analysis and a lower level of pimonidazole labelling.
This may be sufficient to explain the inconsistency in correlation as one moves from a 
whole tumour level down to a regional level. However, a biological explanation may lie 
with the fact that regional variations in blood volume become more apparent at this
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resolution. To explain this hypothesis one could imagine a hypothetical situation in 
which an MR scanner was available with a spatial resolution of only a few micrometres 
and perfect anatomical registration with an immunohistochemical image was possible. 
In this situation, if one were to image a tumour voxel that contained red blood cells, 
such as in or around a blood vessel, then a meaningful BOLD signal would be 
produced and correlation with immunohistochemistry would be feasible. However, if 
one were to image an adjacent voxel without red blood cells, minimal BOLD signal 
would be produced and R2* would not correlate with any immunohistochemical 
measure of oxygenation. At a macroscopic level, the blood volume component is 
averaged out across all voxels in the section. As voxel size decreases, the analysis 
becomes more dependent upon blood volume. In this experiment the voxel diameter of 
175pm is of similar order to the oxygen diffusion distance in tumours of approximately 
100pm, with necrosis appearing at a distance of 160 - 180pm from the nearest vessel. 
It is therefore possible that micro-regional variations in blood volume are influencing the 
correlation seen.
Carbogen
Carbogen has been demonstrated to improve the oxygenation of both experimental 
and human tumours (see introduction, page 41). In human prostate cancer, BOLD-MRI 
during carbogen gas breathing has been used to improve diagnostic localisation of 
tumour within the heterogeneously enhancing malignant gland [10]. A significant signal 
intensity increase was found in normal central gland and peripheral zone (p = 0.004). 
Signal enhancement was significantly lower in carcinoma when compared to the 
contralateral normal side (p = 0.004). A series of experiments using the Dunning 
prostate R3327 rat tumour model has investigated this effect using needle electrode 
measurements and 19F NMR echo planar imaging after direct intratumoural injection of 
hexafluorobenzene [11-13]. Administration of carbogen gas reduced the hypoxic 
fraction (defined as measurements <10mmHg) from 59% to 22% (p < 0.0001). A 
further study using an anaplastic variant of the Dunning R3327 model attempted to 
determine whether microelectrode measurements predicted the avidity of two hypoxic 
markers in prostate tumour tissue [14]. In the course of the experiments carbogen gas 
was used. Median p02 values were found to increase significantly in response to 
carbogen breathing (p = 0.001). A study using the Eppendorf p02 histograph has 
specifically investigated the effects of carbogen breathing on DU 145 and PC3 
xenografts [15]. An average increase of 8.3 mmHg was seen in the DU145 tumours 
and of 9.8 mmHg was seen in the PC3 tumours.
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Prostate cancers exhibit regions of clinically relevant hypoxia [16, 17]. These reports 
suggest that the oxygenation of prostate tumours can be affected by carbogen 
breathing. However, no previous study has specifically examined the use of BOLD-MRI 
to quantify the changes induced by carbogen breathing in a prostate cancer model.
Only the DU 145 tumours showed a statistically significant change from baseline 
following carbogen exposure, with a mean reduction in R2* of 3.52s'1 (p = 0.0032). The 
PC3 tumours exhibited a greater mean reduction of 6.01s'1 but this was not significant, 
possibly due to the fewer numbers (17 versus 23). The AR2* versus time plots (figure 
4.12) suggest a trend of decreasing R2* as a result of carbogen breathing followed by a 
return to baseline following the resumption of air breathing. The pimonidazole staining 
demonstrated that the average proportion of each tumour that was considered to be 
hypoxic was only 22.5% for DU145 tumours and 12.5% for PC3 tumours. As a result, 
the whole tumour R2* measurements included all of the well-oxygenated tumour 
regions that were unlikely to respond to carbogen exposure. This may, at least in part, 
explain why the PC3 tumours did not exhibit a change that was statistically significant.
The grid analysis compensated for this effect by stratifying for baseline R2*. Using this 
method the most hypoxic regions of the tumour could be examined separately. For the 
DU 145 tumours a statistically significant reduction was then seen for tumour areas that 
started with a baseline R2* of above 75s'1 (p = 0.038), figure 4.14.
In both tumour types there is a suggestion that R2* begins to return to its baseline value 
before the cessation of carbogen breathing (figure 4.12). This phenomenon has been 
previously described. The early studies that investigated the use of carbogen gas as a 
radiosensitising agent identified optimum pre-irradiation breathing times. Chaplin 
reported that in KHT murine sarcomas, the minimum survival level for tumour cells was 
reached after approximately ten minutes of carbogen gas inspiration [18]. Longer 
breathing times gave a considerable range of surviving fraction values which 
suggested a slow reduction in tumour sensitisation relative to air. Further work from the 
same group confirmed these results in murine SCCVII tumours [19]. In this tumour the 
optimum breathing time appeared to be between 10 and 30 minutes with no sensitising 
effect observed after 90 minutes. The addition of nicotinamide reversed the time 
related reduction in radiosensitisation, resulting in the observation of a fully aerobic 
radiation response during 90 minutes of carbogen exposure.
It is possible that the physiological explanation lies in the development of perfusion- 
limited hypoxia as a result of tumour blood flow variations induced by prolonged
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carbogen exposure. These effects may, in turn, account for the apparent overshoot in 
R2* seen in the whole DU 145 tumour measurements and the rise in R2* measured in 
the non-hypoxic grids (baseline R2* of 5 - 25s'1) in both xenografts following the 
cessation of carbogen breathing. Nicotinamide is thought to act by reducing 
microregional alterations in tumour perfusion, thereby reducing this effect. It may 
therefore play a role in future studies that attempt to use carbogen gas to increase 
oxygenation in prostate tumours.
The carbogen experiments demonstrated a difference between DU 145 and PC3 
tumours. Only the DU 145 tumours exhibited a significant R2* reduction in response to 
carbogen. The PC3 tumours showed a more rapid return to baseline R2* levels during 
carbogen breathing and only the DU 145 tumours displayed a ‘rebound’ phenomenon 
(although this was not statistically significant). This cannot simply be a result of 
differences in vascular density because the CD31 staining has shown that the poorly 
responding PC3 tumours contained many more blood vessels (figure 4.3) and would 
therefore be assumed to have received greater oxygen delivery. Part of the altered 
carbogen response may be attributable to differences within the blood vessels, such as 
the proportion of mature and immature vessels (which affects their C 02 reactivity) and 
whether those vessels present may not be perfused. It would be interesting to test 
whether the incorporation of blood volume information would predict for response to 
carbogen gas breathing.
4.6 Conclusion
BOLD MRI is a repeatable and reproducible biological imaging technique. The above 
experiment has confirmed that R2* can predict for pimonidazole staining in DU 145 and 
PC3 prostate cancer xenografts with moderate accuracy, although it is arguable 
whether the R2* parameter alone would provide sufficient precision in mapping tumour 
hypoxia for specific targeting, as would be required for radiotherapy dose-painting. 
Despite this, there is sufficient credibility in these data to support the hypothesis that 
BOLD MRI is a valid non-invasive hypoxia imaging modality in prostate cancer, 
accordingly, human testing is justifiable and warranted.
This experiment has made no attempt to include blood volume or blood flow 
information. As described in chapter 2, these physiological parameters are important in 
the interpretation of the BOLD image. Further testing of the BOLD-MRI technique for 
the assessment of tumour hypoxia in human prostate cancer requires concomitant 
acquisition of R2* and quantitative blood flow data in order to assess whether this 
improves the diagnostic accuracy for hypoxia detection (see chapter 5).
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Furthermore, the experiment has confirmed that prostate cancer xenografts respond to 
carbogen exposure. As hypoxia is a firmly established cause of radioresistance, 
demonstration of this effect in human prostate cancer may provide a strategy to 
address this hurdle in the clinical setting.
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Chapter 5.
Intrinsic susceptibility weighted MRI as a
method for quantifying and mapping 
hypoxia in human prostate cancer
5.1 Aims
1) To determine whether the numerical value and distribution of the MRI derived 
R2* parameter correlates with the degree of pimonidazole labelling in the human 
prostate.
2) To assess whether the inclusion of blood volume information from dynamic 
susceptibility contrast MRI improves the sensitivity and specificity for hypoxia 
detection.
3) To determine whether carbogen breathing influences the ability to detect 
hypoxia in the human prostate and the extent to which it alters the oxygenation 
of prostate cancer.
4) To evaluate the repeatability of BOLD-MRI in the human prostate.
5.2 Introduction
This chapter contains details of experiments performed to determine whether BOLD 
and DSC-MRI are useful and valid techniques to evaluate the oxygen status of prostate 
carcinoma in patients about to undergo radical prostatectomy surgery. Information 
regarding the effect of carbogen breathing gas on prostate carcinoma was also 
obtained, which may have relevance in terms of radiosensitisation.
5.3 Patients and Methods
5.3.1 Patients, Treatment and Examination Schedule
Between November 2003 and July 2007, 17 patients with prostate cancer (age 56-76 
years, Gleason grade 6-8, PSA 1.9-32.0 ng/ml) that were due to be treated with a 
radical prostatectomy procedure were recruited. The histological diagnosis of prostate 
cancer was made by core biopsy in all patients. Details of tumour pathology, staging
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Table 5.1 MRI Study population
Patient
Number
Age
(years)
PSA
(ng/ml)
Clinical 
T  Stage
Pathological 
T  Stage
Gleason Grade 
(Biopsy)
Gleason
Grade
(Prostatectomy)
Resection Margins
1 62 9.0 2c 2c 3+3=6 3+3=6 Negative
2 66 17.3 2c 3a 4+3=7 3+4=7 Positive
3 71 11.0 1c 2b 3+3=6 3+3=6 Negative
4 76 6.7 1b 2c 3+3=6 3+3=7 Negative
5 64 23.4 2a 2b 4+3=7 4+3=7 Negative
6 61 12.7 1c 3a 3+4=7 3+4=7 Positive
7 63 6.8 1c 2c 4+3=7 4+3=7 Negative
8 75 7.65 2a 2c 4+4=8 4+3=7 Negative
9 62 17.98 1c 3b 3+3=6 3+4=7 Positive
10 61 9.8 2a 2b 3+4=7 3+4=7 Negative
11 67 32 2c 3a 3+4=7 4+3=7 Positive
12 56 4.0 2c 3a 3+3=6 3+4=7 Positive
13 63 11.7 1c 3a 3+4=7 4+3=7 Positive
14 56 4.2 1c 3a 3+4=7 3+3=6 Positive
15 67 1.9 2c 2c 3+3=6 3+3=6 Positive
16 63 4.8 1c 3a 3+3=6 3+4=7 Positive
17 69 8.3 2c 3a 3+4=7 3+4=7 Positive
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and treatment are shown in table 5.1. Inclusion criteria were: (1) Histologically-proven 
primary prostate carcinoma, (2) Intention to have the whole prostate gland removed 
surgically (3) Ability to give written informed consent and (4) Age over 18 years. 
Exclusion criteria were: (1) Contra-indication to MRI, (2) Known allergy to 
gadopentetate dimeglumine (Gd-DTPA) and (3) Known allergy to pimonidazole 
hydrochloride.
Each patient was examined with a multi-parameter MRI scan before surgery. The 
intention was to scan the patient on the day before surgery in order to minimise the 
time interval between the two measurements of oxygenation (namely the BOLD MRI 
and the pimonidazole immunohistochemistry). An intravenous pimonidazole infusion 
was administered 1 6 -2 4  hours before surgery.
5.3.2 Imaging
All MRI investigations were performed at the Paul Strickland Scanner Centre at Mount 
Vernon Hospital, Northwood, UK. Patients were imaged in a Symphony 1.5T MRI 
scanner (Siemens Medical Systems, Erlangen, Germany) using a phased array pelvic 
coil. The MRI protocols are detailed in appendix B. Patients were imaged using the 
following schedule:
1. Small field-of-view T, and T^weighted anatomical scans perpendicular to the 
urethra were used to stage tumours and to identify tumour slice locations. 
Images were inspected for the presence of a peripheral zone abnormality 
consistent with cancer. The central slice for functional imaging was chosen to 
contain a satisfactory tumour region for data analysis.
2. Initial BOLD MRI (breathing room air): To determine baseline R2* values for 
comparison with immunohistochemistry.
3. Second BOLD MRI (breathing room air): Performed immediately after the first 
BOLD scan to establish the repeatability of the BOLD technique.
4. Carbogen breathing commences.
5. Third BOLD scan initiated after 10 minutes of carbogen breathing. Carbogen is 
continued for the duration of the BOLD acquisition.
6. A ten minute period of breathing room air.
7. Ti-weighted Dynamic Contrast Enhanced MRI (DCE-MRI).
8. T2*-weighted Dynamic Susceptibility Contrast MRI (DSC-MRI).
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5.3.3 Carbogen Breathing:
A 98% 0 2 and 2% C02 mixture was used. A previous study has shown equivalent 
efficacy and increased tolerability with 2% C02 over 5% C02 [1]. Before entering the 
MRI scanner, each patient was allowed to breathe carbogen for several minutes to 
experience and adjust to the altered sensations that are caused by breathing the 
hypercapnic gas mixture (figure 5.1a). The patients were then asked to lie in the 
scanner and the equipment was positioned (figure 5.1b). The mask was positioned 
over the patient’s face. The initial air breathing period was performed with the mask in 
place but without the carbogen tubing connected. This was to reduce patient 
movement during the scan at the point when the carbogen gas was connected. A pulse 
oximeter recorded the subject’s heart rate and peripheral blood oxygen saturation. The 
tubing was disconnected as soon as the third BOLD scan was complete. The 
remaining imaging protocol was performed breathing room air without a mask.
Figure 5.1 Carbogen gas breathing during MR imaging
5.3.4 Pimonidazole Infusion
Pimonidazole infusion occurred between 16 and 24 hours before surgery. Patients 
were weighed and their height was measured. Body surface area (BSA) was calculated 
using the DuBois method (BSA = (Weight0425 x Height0 725) x 0.007184). The dose of 
Pimonidazole was 0.5g/m2 with a maximum dose of 1g. This was administered in 
100mls of normal saline over 20 minutes via a 20 gauge venous cannula using a 
screened photosensitive drug giving set.
5.3.5 Histology and Immunohistochemical Analysis
Prostate gland removal, sectioning, slide preparation, staining and
immunohistochemical analysis methods are detailed in appendix A
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5.3.6 Human MR Image Analysis
The procedures for the generation of functional parametric data are detailed in 
appendix B and Chapter 2.
5.4 Experimental Design and Statistical Methods
MRI characteristics
Differences between each prostate region for each of the parametric MRI values was 
assessed using the Kruskal-Wallis test
Tumour Localisation
Using the grid based analysis system described in appendix B, it was possible to 
determine how good each MRI parameter was at discriminating between benign 
prostate tissue and tumour. For each of the 17 patients a 5x5mm grid was 
superimposed on the anatomical T2 image. The same grid could then be used to derive 
functional parametric data for each grid element using BOLD, DCE and DSC MRI. Only 
grid elements that were fully occupied by prostate tissue were included:
ROC analysis was then used to determine the sensitivity, specificity and overall 
accuracy of each MRI parameter for tumour detection.
Validation
The validation experiment compared the numerical value and distribution of R2* with 
the distribution of pimonidazole staining in the corresponding whole-mount histological 
section. The mean of the two baseline (air breathing) median R2* values for the whole 
prostate, tumour, benign prostate peripheral zone and benign prostate central zone 
ROIs was compared with the pimonidazole staining percentage from the corresponding 
immunohistochemical sections (calculated as described in appendix A). R2* from each 
grid element was also compared with the pimonidazole staining percentage from the 
corresponding grid element in the matching histological section.
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The distribution of each set of results was tested for normality using the Shapiro-Wilk 
test. For normally distributed data, correlations were assessed using the Pearson 
correlation coefficient (r).
Receiver operating characteristic (ROC) curves were plotted for the grid-based data. 
These calculations provided an estimation of the sensitivity and specificity of BOLD MR 
and T2*-weighted DSC-MRI data when used to depict tumour hypoxia. They also 
established the R2* and rBV values with the optimum power to predict hypoxia within a 
grid element.
Repeatability
The repeatability experiment for the BOLD sequences compared the R2* values 
between air breathing scans 1 and 2 for each patient. The analysis was performed for 
whole prostate, tumour, benign prostate peripheral zone and benign prostate central 
zone ROIs separately. The standard consensus approach to assessing reproducibility 
was used (see Chapter 3, page 89). The procedure was repeated using each 
individual grid element from the grid-based analysis. The results of these experiments 
determined the intrinsic variability of the BOLD acquisition sequences in this particular 
group of patients. This, in turn, allowed calculation of whether a change in R2* as a 
result of carbogen exposure, for each individual patient, was statistically significant.
Carbogen breathing
The effect of increased inspired oxygen concentration on the BOLD image was 
evaluated by comparing the baseline R2* measurements (an average of the first two 
air-breathing BOLD sequences) and R2* measurements made after 10 minutes of 
carbogen breathing. Changes in R2* for the whole prostate, tumour, benign prostate 
peripheral zone and benign prostate central zone were calculated separately. A 5x5mm 
grid-based analysis was performed to determine the changes within each region of 
interest (appendix B).
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5.5 Results
5.5.1 General (table 5.2)
All 17 patients completed two baseline BOLD scans. One patient was unable to 
tolerate carbogen breathing, due to a feeling of claustrophobia whilst in the MRI 
scanner wearing a facemask, although he was able to complete the remainder of the 
imaging protocol without the mask. All 17 patients were imaged using both T  ^ and T2* 
weighted dynamic sequences. In one patient, rectal filling between the first and second 
BOLD scan caused such severe prostate movement that repeatability analysis was 
impossible. In another patient, transient gas filling caused a susceptibility artefact 
obscuring the tumour ROI. Every patient then went on to receive a pimonidazole 
infusion (without complication) and subsequent prostatectomy. Pathological staging 
details are given in table 5.1. In two cases, the 5mm histological section corresponding 
to the imaging slice did not contain any tumour, although tumour was found elsewhere 
in the prostatectomy specimen. As a result these patients were analysed in terms of 
whole prostate, benign peripheral zone and benign central zone only. Analysis of the 
correlation between tumour R2* and pimonidazole staining therefore only includes 15 
patients. The following numbers of patients were used for each analysis:
Table 5.2 The numbers of patients used for analysis
Pathological
Correlation
Repeatability Carbogen Dynamic
Analysis
Benign Tumour Benign Tumour Benign Tumour Benign Tumour
Patient
numbers 17 15 16 13 16 14 17 15
5.5.2 Overall Characteristics
On average there were 2.25 tumour foci in the imaging slice (range 0 -1 1 ). The mean 
proportion by surface area of the prostate that was malignant was 8.2% (range 0.2- 
29.1%) (Figure 5.2). The proportion of each prostate region that stained for 
pimonidazole is given in table 5.3 and shown graphically in figure 5.3.
Table 5.3 Pimonidazole Staining Proportion
Tumour 40.6% (range 0.6 -  90.0%)
Peripheral Zone 34.6% (range 0.2 -  71.4%)
Central Zone 38.5% (range 0.7 -  91.0%)
Whole Prostate 36.7% (range 0.6 -  76.9%)
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Figure 5.2 H&E stained whole-mounts (tumour outlined in black)
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Figure 5.3
The difference in the proportion of pimonidazole staining
between prostate regions
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There were no statistical differences between the four regions in terms of the 
proportion of pimonidazole staining (Kruskal-Wallis test). As described in previous 
reports [2, 3], there was a wide variation in hypoxia between patients. Pimonidazole 
scores varied between 0.2 and 91%, mirroring the p02 readings reported by Parker et 
at. of 0.2 to 57.3 mm Hg. This seems to be true for all of the prostate regions.
5.5.3 MRI Characteristics
The functional MRI values for each prostate region are given in table 5.4 and shown 
graphically in figure 5.4.
Table 5.4 Mean functional MRI values for each prostate region
R2*
(s'1)
j^ trans
(min'1)
ve
(x100%)
kep
(min'1)
AUCeo
(mmols'1)
rBV
(au)
rBF
(au)
Tumour 16.55 0.207 0.367 0.602 11.98 219.7 4.16
Peripheral
Zone
15.79 0.125 0.320 0.391 7.87 108.3 2.08
Central
Zone
13.20 0.277 0.401 0.713 15.47 131.8 2.61
Whole
Prostate
15.13 0.183 0.374 0.492 11.37 110.7 2.22
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Figure 5.4 The difference in MR parameters between prostate regions 
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The difference in rBF between prostate regions
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Using the Kruskal-Wallis test it is possible to determine whether there is a significant 
difference between the prostate regions for each imaging parameter. Results are 
presented in table 5.5.
Identifying the anatomical location of tumour within the prostate gland is important for 
prostate cancer management. The most important distinctions to identify are between 
tumour and normal peripheral zone and between tumour and benign central zone. 
There is a significant difference in parameter values between tumour and peripheral 
zone for Ktrans, keP, AUC6o, rBV and rBF. However, only the T2*-weighted DSC-MRI 
parameters (rBV and rBF) showed a significant difference between central gland and 
tumour, suggesting that ^-weighted DCE-MRI is not useful in this regard. These 
results confirm the findings of previous authors [4-6].
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Table 5.5 P-values for the Kruskal-Wallis significance tests between 
ROIs for each functional MRI parameter
t^rans
Ve
turn PZ CZ WP turn PZ cz WP
turn 0 . 0 0 2 2 0.0897 0.5524 turn 0.2963 0.3324 0.6319
PZ <0 . 0 0 0 1 0.0094 PZ 0.0401 0.1181
cz 0.0195 CZ 0.6107
WP WP
kep AUC60
turn PZ CZ WP turn PZ CZ WP
turn 0.0009 0.3752 0.1005 turn 0 . 0 1 1 1 0.0806 0.8677
PZ <0 . 0 0 0 1 0.0654 PZ <0 . 0 0 0 1 0.0139
CZ 0.0104 CZ 0.0491
WP WP
rBV rBF
turn PZ CZ WP turn PZ CZ WP
turn <0 . 0 0 0 1 0.0027 <0 . 0 0 0 1 turn <0 . 0 0 0 1 0.0013 <0 . 0 0 0 1
PZ 0.1634 0.4488 PZ 0.403 0.7513
CZ 0.0336 CZ 0.2503
WP WP
r2*
Green values show a statistically significant 
difference at the 95% confidence level 
Red values do not show a statistically 
significant difference at the 95% confidence 
level
turn PZ CZ WP
turn 0.8502 0.2814 0.6389
PZ 0.3578 0.7719
CZ 0.5276
WP
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5.5.4 Tumour Localisation
Total number of grid elements 827
Number of fully occupied grid elements 637
Number of tumour containing grids 121
Number of benign central zone grids 262
Number of benign peripheral zone grids 254
Table 5.6 ROC analysis for each MRI parameter
Parameter Area Under 
ROC curve
95% C.l. for 
ROC
Sensitivity Specificity Optimum
threshold
l^ trans 0.71 0.66 -  0.77 0.68 0.67 0.13 min1
Ve 0.56 0 .50-0 .63 0.60 0.57 35%
kep 0.71 0 .6 5 -0 .76 0.40 0.80 0.48 min'1
AUCeo 0.67 0.61 -  0.73 0.64 0.62 8.01 mmols
rBV 0.52 0.46 -  0.58 0.90 0.18 219 a.u.
rBF 0.51 0.44 -  0.57 0.58 0.47 1.00 a.u.
r2* 0.53 0.47 -  0.60 0.35 0.75 21.2s'1
For an area under the ROC curve to be considered statistically significant its 
confidence interval must not cross 0.5. Therefore it can be seen that only the DCE-MRI 
parameters (K"**, ve, kep and AUCeo) were reliable in this regard. The most reliable 
parameter for locating tumour proved to be K^08, with a sensitivity of 68%, a specificity 
of 67% and an overall accuracy of 68% using a threshold of 0.13 min'1 (figure 5.5)
5.5.5 Hypoxia detection - Regional Prostate Measurements
There is a statistically significant correlation between the level of R2* seen on the MRI 
image and the proportion of pimonidazole labelling within prostate tumour and for the 
benign prostate peripheral zone. There was no correlation for benign central gland or 
for the whole prostate ROI (figure 5.6). Pearson's product moment correlation 
coefficient (r) was calculated for the four prostate regions:
Table 5.7 Correlation coefficients (r) for the four prostate regions
r p-value
Prostate Tumour 0.64 0.0103
Peripheral Zone 0.49 0.0461
Central Zone 0.20 0.4486
Whole Prostate 0.41 0.0984
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Figure 5.5
The use of the Ktrans DCE-MRI parameter for tumour localisation
(Tumour shown with arrows)
A 62 year old gentleman who presented with a PSA of 17.98 had a clinically-staged T1c 
adenocarcinoma of the prostate (Gleason 3+3=6 on biopsy). The radical prostatectomy 
specimen revealed a margin-positive T3b, Gleason 3+4 tumour (image A). The preoperative T2- 
weighted MR image showed a low signal intensity region in the left posterior peripheral zone 
(arrow, image B). In the DCE-MRI image (image C) the median Kt ans value for the tumour 
region (arrowed) measured 0.23 min'1 compared to the median value for the remainder of the 
benign peripheral zone of 0.13 min'1.
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Figure 5.6
Scatter plot showing the relationship between tumour R2* 
and the proportion of pimonidazole staining in the corresponding
whole-mount section
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Scatter plot showing the relationship between peripheral zone 
R2* and the proportion of pimonidazole staining in the corresponding
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Scatter plot showing the relationship between central zone 
R2* and the proportion of pimonidazole staining in the corresponding
whole-mount section
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5.5.6 Hypoxia Detection  -  Grid Analysis
R2*, rBV and the proportion of pimonidazole labelling were calculated for each tumour 
containing grid element. Grids were excluded from the analysis if they were considered 
artefactual (R2* = 0, pimonidazole proportion = 100%, rBV >500)
Initial number of tumour containing grids 121
Grids with R2* = 0 3
Grids with pimonidazole proportion = 100% 8
Grids with rBV >500 14
Remaining grids for Analysis 96
Initially R2* was plotted against the proportion of pimonidazole labelling:
Figure 5.7
Graph showing the correlation between R2*and the proportion 
of pimonidazole labelling in prostate tumour using a 5x5mm grid
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Despite the lack of any significant correlation, it is possible to identify two separate 
populations of grid element, indicated by the dotted lines in figure 5.7. From the basic 
principles of BOLD MRI theory (chapter 2), we would predict that grids with low blood 
volume are unlikely to show a correlation between R2* and the proportion of
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pimonidazole labelling, due to the general lack of haemoglobin molecules available to 
cause the BOLD effect. Conversely, grids with sufficient blood volume may possibly 
show a relationship.
Grid elements were then stratified for blood volume, using an rBV threhold of 40 au:
Figure 5.8
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This confirms that the two populations seen in figure 5.7 were indeed representing 
grids of high and low blood volume. Furthermore, the graph indicates that grids with 
low rBV (green circles) are generally hypoxic, mostly appearing on the right side of the 
graph where the pimonidazole proportion >40%.
To highlight this distinction and demonstrate the profound effect of blood volume on the 
interpretation of the R2* parameter, the distributions of R2* and the proportion of 
pimonidazole staining were stratified for rBV (figure 5.9). These graphs show that grids 
with low rBV are more hypoxic than grids with high rBV in view of the higher proportion 
of pimonidazole labelling (89.1% versus 49.1%, p < 0.0001). Despite this, grids with 
low rBV exhibit significantly lower R2* values (11.2s'1 versus 20.7s'1, p < 0.0001) 
because of their inability to impart a BOLD effect due to the lack of haemoglobin 
delivery.
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Figure 5.9 Graph showing the difference in R2*for grids with high or low rBV
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Using rBV alone it is possible to discriminate hypoxic and non-hypoxic grids with 
excellent sensitivity but with low specificity. ROC analysis shows that the optimum cut­
off for rBV in this data set is 42.08:
ROC Ptot of using rBV to prefect tar pmonidazote star ng 
using a pimonidaaoie threshold of 40%
Figure 5.10
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Using the 42.08 cut-off, rBV alone gives:
Area under the ROC curve 0.71 (0.61 to 0.81)
Sensitivity 96.77% (83.3% to 99.92%)
Specificity 47.69% (35.15% to 60.46%)
Positive predictive value 46.88% (34.28% to 59.77%)
Negative predictive value 96.88% (83.78% to 99.92%)
It is therefore clear that rBV and R2* both need to be considered if hypoxia maps are to 
be generated using MRI. Excluding the low rBV grid elements significantly increases 
the correlation between R2* and the proportion of pimonidazole staining:
Figure 5.11
Correlation between R2* and pimonidazole labelling. Low rBV grids excluded. 
Simple linear regression line shown in black
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For grids with rBV > 42 a.u. there is a significant correlation between R2* and the 
proportion of pimonidazole staining of 0.478 (95% Cl 0.268 to 0.644, p < 0.0001). ROC 
analysis of the high rBV grids shows that R2* can predict for pimonidazole labeling with 
high sensitivity and specificity, depending on the pimonidazole threshold used:
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Table 5.8 ROC analysis of the high rBV grids (>42 a.u.)
Pimonidazole labelling 
threshold used to determine 
whether a tumour was hypoxic
> 10% > 20% > 30% > 40 %
Area Under ROC curve 0.87 0.77 0.77 0.72
95% C.l. for ROC 0.76 -  0.98 0.65 -  0.89 0 .65-0 .88 0.59-0 .84
Sensitivity 0.74 0.54 0.58 0.63
Specificity 1.00 1.00 0.90 0.80
R2* cut-off 16.8 21.3 21.3 21.3
RKiWfraiiVhpMirpMtalEMv ■MW pi— ifcn* hi hnMaf<O»fp0iigVypfcMp>)
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In light of these findings a test for hypoxia in regions of prostate cancer can be 
proposed:
Test Hypothesis:
Hypoxia in prostate cancer should be diagnosed if:
1) rBV is less than 42 a.u. OR,
2) rBV is greater than 42 a.u. AND R2* is greater than 21.3s'1
In other words: Hypoxia should NOT be diagnosed if:
rBV is greater than 42 a.u. AND R2* is less than 21.3s*1
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Using this test on the data from the above experiment, sensitivity and specificity vales 
can be produced:
Pimonidazole
Positive
Pimonidazole
Negative Total
MRI Test Positive 52 7 59
MRI Test Negative 13 24 37
Total 65 31 96
Using pimonidazole threshold of 40%
Sensitivity 80.00% (95% Ci 68.23% to 88.9%)
Specificity 77.42% (95% Cl 58.9% to 90.41%)
Positive Predictive Value 88.14% (95% Cl 77.07% to 95.09%)
Negative Predictive Value 64.86% (95% Cl 47.46% to 79.79%)
Overall Accuracy 79.17%
These test statistics vary when using alternate pimonidazole thresholds:
Table 5.9 How pimonidazole labelling threshold affects test statistics
Pimonidazole labelling threshold 
used to determine whether a 
tumour was hypoxic
> 10% >20% >30% >40% >5 0%
Sensitivity 80.0% 70.2% 74.7% 80.0% 81.7%
Specificity 100.0% 100.0% 85.7% 77.4% 72.2%
5.5.7 R e p e a t a b i l i t y  A n a ly s i s
Whole ROI measurements
The distribution of each parameter was not significantly different form normal. The 
difference between values for the four prostate regions of interest showed no 
dependence on the mean and therefore no logarithmic transformation was required for 
these data. A detailed discussion of repeatability can be found in chapter 3, p110. 
Repeatability statistics were as follows:
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Table 5.10 The repeatability of R2* - regional analysis
'
Whole Prostate Tumour
Number of patients 16 dumber of patients 13
Repeatability for n=1 (absolute) 2.39 Repeatability for n=1 (absolute) 1.95
Repeatability for n=1 (%) 16.53 % Repeatability for n=1 (%) 12.92 %
Variance ratio (F) 114.7 Variance ratio (F) 184.1
3-value for F <0.00001 3-value for F <0.00001
nterclass correlation coefficient (ICC) 0.98 Interclass correlation coefficient (ICC) 0.99
Coefficient of variation (wCV) 0.060 Coefficient of variation (wCV) 0.047
Benign Peripheral Zone Benign Central Zone
dumber of patients 16 dumber of patients 16
Repeatability for n=1 (absolute) 1.78 Repeatability for n=1 (absolute) 5.30
Repeatability for n=1 (%) 11.65 Repeatability for n=1 (%) 42.55
Variance ratio (F) 238.6 Variance ratio (F) 32.3
3-value for F <0.00001 P-value for F <0.00001
nterclass correlation coefficient (ICC) 0.99 nterclass correlation coefficient (ICC) 0.94
Coefficient of variation (wCV) 0.042 Coefficient of variation (wCV) 0.154
The susceptibility weighted BOLD technique proved to be extremely repeatable for all 
four ROIs. For an individual patient’s prostate tumour, a change in R2* of 1.95s'1 (or 
12.92%) could be considered significant at the 95% confidence level (i.e. not simply a 
result of test variability). A very high degree of repeatability was also seen for all 
regions in terms of both ICC (94-99%) and wCV (4.2-15.4%).
Grid based analysis
When the repeatability analysis was performed for each of the grid elements, the 
difference between values showed a dependence on the mean necessitating 
logarithmic transformation for these data.
Table 5.11 The repeatability of R2* - grid based analysis
All complete grid elements Tumour containing grid elements
Number of grids 121 
Repeatability for n=1 relative to mean 4.93-7.25 
Repeatability for n=1 (%) -31.9-46.9% 
Variance ratio (F) 20.96 
P-value for F <0.00001 
Interclass correlation coefficient (ICC) 0.149 
Coefficient of variation (wCV) 0.060
Number of grids 637 
Repeatability for n=1 relative to mean -4.49-6.21 
Repeatability for n=1 (%) -27.7-38.4% 
Variance ratio (F) 31.64 
P-value for F <0.00001 
Interclass correlation coefficient (ICC) 0.94 
Coefficient of variation (wCV) 0.124
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The tumour containing grid elements appeared to be slightly more reproducible than 
the benign grids, reflecting the results of the ROI based analysis presented above. For 
an individual tumour containing grid, a fall in R2* of 4.49s'1 (or 27.7%) could be 
considered significant at the 95% confidence level. The grid-based analysis is less 
repeatable than the regional analysis.
5.5.8 Carbogen Breathing
The two initial air-breathing R2* measurements for each patient were averaged and 
compared to the R2* value taken after 10 minutes of carbogen breathing.
Analysis of tumour regions on an individual patient-by-patient basis showed that nine of 
the 14 patients had a reduction in tumour R2* during carbogen exposure that could be 
considered statistically significant and distinguishable from test variability at the 95% 
confidence level (figure 5.13). Analysis of the group as a whole showed a mean 
reduction in R2* of 3.52s'1 or 21.6% (p = 0.0005) for the prostate tumour ROIs. Results 
for all four ROIs are given below:
Table 5.12 The response to carbogen breathing -  regional assessment
Tumour Benign
Peripheral
Zone
Benign
Central
Zone
Whole
Prostate
Number of patients 14 16 16 16
Mean AR2* (s'1) -3.52 -0.05 +0.22
(increase)
-0.36
AR2* (%) -21.6 -0.32 +1.70
(increase)
-2.40
Significance p = 0.0005 ns ns ns
No. of patients with 
individually significant change 
(95%CI)
9 of 14 4 of 16 1 of 16 1 of 16
ns Not Significant
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Figure 5.13
The change in R2* during carbogen gas breathing
(red lines indicate individual patients with 
changes significant at the 95% confidence level)
Tumour
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The change in R2* during carbogen gas breathing
(red lines indicate individual patients with 
changes significant at the 95% confidence level)
Peripheral Zone
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Baseline Carbogen
The change in R2* during carbogen gas breathing
(red lines indicate individual patients with 
changes significant at the 95% confidence level)
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35 n
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When the low rBV tumours (<40 a.u.) were excluded, there was a statistically 
significant correlation between the baseline R2* value and the change in R2* following 
carbogen exposure (figure 5.14). The tumour regions that were most hypoxic at 
baseline responded the most to carbogen breathing.
Figure 5.14
Graph showing the correlation between the initial R2* value
and AR2* during carbogen exposure
R = 0.67, p = 0.017
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Baseline R2* (s'1)
Grid based analysis
When the analysis was repeated for each tumour-containing grid the following results 
were obtained:
Number of un-evaluable grids 
Mean reduction in R2* (absolute)
Mean reduction in R2* (relative)
Proportion of grids that have significant reduction in R2* 
Proportion of grids that have significant increase in R2*
10
1.42 s'1 
8 .0%
14.4% (16 of 111) 
1.8% (2 of 111)
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Figure 5.15 The change in R2* during carbogen gas breathing
40 n
0   i-----------------------------------------------------------1------------------
Baseline Carbogen
Red lines represent individual grid elements that have a statistically significant decrease in R2* 
following carbogen gas exposure (at the 95% confidence level). Blue lines represent individual 
grid elements that have a statistically significant increase in R2* at the 95% confidence level. 
Black lines denote grids that do not exhibit a significant change in R2* during carbogen 
breathing.
It is worth noting that both of the grid elements that exhibited an increase in R2* 
following carbogen breathing demonstrated very low rBV on DSC-MRI (0.01 a.u. and 
8.4 a.u.).
5.6 Discussion
Tumour localisation
It was not the intended purpose of this study to assess the ability of dynamic or 
susceptibility weighted MR for the purpose of tumour detection. However, given the 
methodology used, tumour regions had to be defined as part of the hypoxia 
assessment. Therefore the investigation of how effective each MRI parameter was at 
locating tumour amongst benign prostatic tissue became an intrinsic part of the 
analysis process and as a result has been presented here. Numerous studies have 
reported the diagnostic accuracy of T,-weighted DCE MRI for this purpose (Chapter 2, 
page 65 and table 2.2), predominately using K*3"8 or AUC as the parameters of 
choice. The current study confirms as the optimum parameter for tumour
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localisation (Table 5.6) with an area under the ROC curve of 0.71, a sensitivity of 68% 
and a specificity of 67%.
No previous publication has reported the use of T2*-weighted DSC MRI for a similar 
objective. It appears that rBV has good sensitivity (90%) at the expense of poor 
specificity (18%). This results in a predictive value of a positive test of 34.7% and the 
predictive value of a negative test of 78.9%. In other words, a low rBV value (below 
about 220 a.u.) is reasonably good at excluding tumour but a high rBV does not 
necessarily indicate the presence of cancer.
A previous report has suggested the use of carbogen stimulated BOLD-MRI for tumour 
detection [7]. A significant T2*-weighted signal intensity increase (P = 0.004) was found 
in normal central gland and peripheral zone during carbogen breathing. Signal 
enhancement in carcinoma was significantly lower compared with the contralateral 
normal side. The study did not attempt to perform a grid or pixel based analysis in 
order to determine any test statistics such as positive predictive value or negative 
predictive value for tumour detection, instead choosing to simply highlight the 
difference in BOLD signal enhancement between benign and malignant tissue. The 
current study confirms these results with only tumour ROIs showing a significant 
change in R2* during carbogen exposure (a change of 21.6%, p = 0.0005; table 5.12). 
However, a static R2* measurement alone is not particularly useful for tumour 
localisation with a sensitivity of 35% and specificity of 75% and unlikely to improve on 
the accuracy of the other functional MRI modalities such as DCE, MRS or DWI for this 
purpose.
Hypoxia Detection
The investigation of tumour hypoxia in human prostate cancer is a greater challenge 
than the analysis of hypoxia in animals bearing prostate tumour xenografts. This is 
mainly for two reasons. Firstly, the human prostate is made up of several different 
tissue types, each with different physiological and vascular characteristics. Secondly, in 
the modem era where there are a number of forms of treatment for the prostate cancer 
and more accurate pre-operative staging, radical prostatectomy is generally reserved 
for patients with low-volume, low-risk disease. As a result only a small proportion of 
excised tissue is in fact malignant (8.2% in this series). Despite this, if an imaging 
modality is to be validated as a tool for the detection of tumour hypoxia it must be 
compared with the current ‘gold-standard’. Since the demise of the needle electrode 
(see chapter 1) immunohistochemical analysis of the excised gland is the only proven 
method for this purpose. Therefore, notwithstanding the inherent difficulties in the
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quantitative comparison between a ‘thick’ radiological image and a ‘thin’ histological 
section, this is the only available strategy. The results of such an analysis needs to be 
interpreted with the understanding that even a ‘perfect’ imaging technique, that 
measures exactly the same biological process as the immunohistochemistry, would fail 
to show ‘perfect’ correlation because of the issues of anatomical registration and 
distortion of corresponding imaging and pathological slices.
In spite of these facts, the results of this study corroborate the animal data presented in 
chapter 4 and show that it is possible to identify hypoxic regions within human prostate 
cancer using MRI. For the correlation between pimonidazole staining and R2* alone, 
using the tumour ROI analysis, the Pearson correlation coefficient was 0.64 (p = 
0.0103) which is of a similar order to the correlation seen for the animal tumours (r = 
0.73-0.75, p < 0.0006). As predicted from the mechanism of the BOLD effect, the 
inclusion of blood volume information is critical to the interpretation of the parametric 
R2* map (figure 5.16).
Based on the data presented above and by using the optimum thresholds suggested 
by ROC analysis of the same data, it is possible to achieve a sensitivity of 80% and a 
specificity of 77% for the detection of hypoxia by combining the R2* and rBV 
measurements. Furthermore, of more relevance to clinical practice, the predictive value 
of a positive test, i.e. the post-test likelihood of hypoxia, was 88% and the predictive 
value of a negative test, i.e. the post-test likelihood of no hypoxia, was 65%.
Earlier work using the combination of BOLD and T2*-weighted dynamic MRI, reported 
by Hoskin et. al, demonstrated excellent sensitivity (95%) but low specificity (29%) for 
hypoxia detection [8]. In that study, regions of prostate cancer were designated as 
hypoxic depending on whether the R2* value was greater or less than that of the 
obturator intemus muscle and whether rBV was greater or less than ischiorectal fat. 
This binary method does not permit ROC analysis and therefore the optimum 
thresholds for R2* and rBV could not be calculated. The study presented in this chapter 
has demonstrated an overall accuracy of 79%, using the combined test, by determining 
these thresholds.
Changing the pimonidazole thresholds used in this analysis can alter the results. In this 
study pimonidazole is being used as the ‘gold-standard’ to establish if the MRI 
determination of whether a grid is hypoxic is in fact ‘true’ or ‘false’. Therefore 
ascertaining the proportion of brown staining in a grid for it to be considered hypoxic 
would seem critical.
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Figure 5.16 The theoretical change in BOLD MRI signal
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(A) Oxygenation status determination with BOLD-MRI images requires blood volume 
information. This graph depicts the theoretical change in BOLDMRI signal (R2*) that would be 
expected as tissue oxygenation reduces. To correctly interpret R2* images to infer oxygenation 
status, it is necessary to know whether blood is being delivered to the tissues. With the absence 
of red blood cell delivery, R2* levels fall despite the presence of hypoxia. (B) Data from the 
current study confirms that in the presence of high blood volume (red circles), R2* correlates 
with oxygenation. For data points that represent tumour grids with low blood volume (green 
circles) R2* becomes slower and the correlation is lost.
However, as shown in table 5.8, although varying the pimonidazole threshold between 
20, 30 and 40% causes some change to the sensitivity and specificity of R2* (when 
used without rBV), it does not change the R2* threshold, which remains at 21.3s'1. 
Reducing the pimonidazole threshold to 10% does alter the R2* cut-off to 16.8s'1.
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Calculation of the final test statistics for the combination of R2* and rBV shows that 
altering the pimonidazole threshold between 10 and 50% makes only small differences 
to the final result, with sensitivities ranging between 70.2 and 81.7% and specificities 
ranging between 72.2 and 100% (see table 5.9). In other words, the very presence of 
pimonidazole in a grid has more relevance than the amount of pimonidazole in a grid. 
This is consistent with previous reports using pimonidazole immunohistochemistry in 
which computerised analysis has been used to quantify the proportion of pimonidazole 
uptake in a region of tissue [9, 10]. So despite the fact that the test statistics can be 
manipulated to a degree, depending on how the ‘gold-standard1 is defined, the 
sensitivity and specificity of the combined BOLD and T2*-weighted DSC-MRI test for 
determining hypoxia never fall below 70%. Given the aforementioned difficulties of 
registration and distortion between the imaging and pathological slices, the difference 
in section thickness and the fact that the two modalities are not measuring precisely the 
same process, these findings are very encouraging.
Clearly, testing a hypothesis on the same data that was used for its own generation will 
produce optimum results. The only way to confirm the validity of the test suggested by 
these data (i.e. ‘hypoxia should be diagnosed if rBV is less than 42 a.u. OR rBV is 
greater than 42 a.u. AND R2* is greater than 21.3s'1’) is by repeating the study using a 
new group of patients, preferably at another imaging centre. It is quite possible that in 
order to further increase diagnostic accuracy the threshold values may need to be 
refined as the number of patients included in the analysis grows.
It must also be noted that this test is only valid for regions of prostate cancer and not 
for the benign gland. Given the large differences in vascularity between the tissue 
types of the benign gland (see figure 5.4 for an illustration of the difference in dynamic 
MR properties between benign central and peripheral zone), it is highly likely that 
threshold values for R2* and rBV would be different for each tissue type. As a result, 
this method of hypoxia detection can only ever be as good as the ability of MRI to 
locate tumour. As described in chapter 2, with the inclusion of Ti-weighted dynamic 
MRI, MRS and diffusion weighted imaging, sensitivities and specificities for tumour 
localisation in excess of 90% have been demonstrated. Future strategies for 
anatomical and biological staging of prostate cancer are therefore likely to include a 
multi-parameter functional MRI protocol combining several or all of the functional 
imaging technologies.
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Repeatability
The repeatability statistic indicates that for the prostate cancer in an individual patient a 
change in R2* of greater or less than 12.9% would be considered statistically significant 
at the 95% confidence level. In absolute terms a change in R2* for an individual 
prostate tumour of 1.95s'1 in either direction can be considered real and not simply a 
result of test variability. Considered in conjunction with an ICC of 99% and wCV of
0.047, these results suggest that BOLD MRI is a highly repeatable test for human 
prostate cancer, reflecting the results of the animal data presented in the previous 
chapter. It is true to say that the repeatability statistic is only valid in experiments where 
patient set-up and machine factors are stable. In situations where the patient needs to 
be moved between measurements or when imaging occurs on different days 
reproducibility is likely to reduce. Despite this, BOLD-MRI is a technique with sufficient 
repeatability to be useful in the assessment of changes to the R2* parameter human 
prostate cancer over short periods of time.
Carbogen
Chapter 4 described how BOLD-MRI could be used to detect changes in the 
oxygenation of prostate tumour xenografts as a result of carbogen breathing. In the 
DU 145 animal tumour model an average reduction in R2* of 3.52s'1 was demonstrated, 
representing a 9.8% change from baseline. The human study demonstrated a greater 
effect, coincidentally also with an average reduction of 3.52s'1, representing a 21.6% 
change from baseline in the malignant prostate regions. Nine out of the 14 patients 
who received carbogen and had detectable tumour at prostatectomy showed a 
significant decrease in R2* during carbogen exposure.
There was minimal change in R2* in the benign central or peripheral prostate zones. 
For the peripheral zone, four of the 16 patients had a significant reduction in R2* 
following carbogen exposure and in the benign central gland only one patient showed a 
significant response. As shown in the previous chapter, it would appear that the most 
hypoxic regions respond most to an increase in the inspired oxygen concentration. As 
depicted in figures 5.3 the benign prostate tissue is generally less hypoxic than tumour 
and should therefore demonstrate less of a reduction in R2*. The failure to demonstrate 
any response in the benign peripheral gland is most likely to represent a failure of the 
test itself. Figure 5.4 shows that the peripheral zone has generally low blood volume 
compared to benign central zone or prostate tumour. This study has already 
demonstrated the critical dependence of R2* on blood volume. Therefore, it may follow 
that the benign peripheral gland simply has insufficient vascular supply for the BOLD 
effect to arise.
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It should be noted that a previous study by Taylor et a/. reports more consistent BOLD 
changes in the benign gland [11]. 13 men with normal prostate glands (four normal 
volunteers and nine patients with tumours elsewhere in the body) were imaged before 
and during carbogen gas exposure. Whole prostate measurements were made with no 
attempt to distinguish between central and peripheral zones. Analysable data were 
obtained from nine of the patients. There was no significant MR signal intensity change 
in four patients, and a significant change in five (mean 11.4%, range 8.4-14.0%). 
Because of the small numbers involved it is not possible to determine whether these 
results conflict with the current study. Furthermore, since only whole prostate 
measurements were made, the variation in response between patients may simply 
reflect the different proportions of benign central gland and benign peripheral gland in 
each prostate.
Carbogen gas, usually administered with nicotinamide, has radiosensitising properties 
(see chapter 1). It has been used with success in improving the local control rates of 
radical radiotherapy for squamous cell carcinoma of the head and neck (ARCON) [12]. 
This study provides in-vivo human evidence for an oxygen enhancing effect of 
carbogen breathing in prostate cancer. The tolerability of carbogen and nicotinamide 
when given in conjunction with pelvic radiotherapy has already been demonstrated in 
schedules such as BCON for bladder cancer and in radical radiotherapy for cervix 
cancer [13]. As a result a pilot study using an ARCON-like radiotherapy schedule is 
justifiable and supported by the data presented in this thesis.
5.7 Conclusion
The data presented in this chapter demonstrates that real-time non-invasive hypoxia 
detection in human prostate cancer, using magnetic resonance imaging, is a realistic 
prospect. The BOLD technique is fast and reproducible adding only a few minutes to a 
standard diagnostic prostate staging protocol. The experiment has confirmed the 
importance of combining blood volume information with an R2* study. The test 
proposed by this study requires further validation with at least one new data set using 
different patients and refinements of R2* and rBV thresholds are likely. Once this 
process is complete, modem MR analysis software could be adapted to combine the 
BOLD and DSC parametric maps with the relevant thresholds for hypoxia detection 
and fuse the resulting ‘hypoxia map’ with sequences devised for tumour localisation.
However, the major limitation that would prevent the immediate clinical implementation 
of this technique is the limited volume of the prostate that can be imaged with DSC- 
MRI during each session. With the current limits of technology, T2*-weighted dynamic
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imaging using a gradient echo protocol can image two, eight millimetre thick, slices at 
the very most. This is not sufficient to visualise an entire prostate gland. Because of the 
amount of gadolinium contrast required for each examination and the increasing 
awareness of complications resulting from exposure to high volumes of contrast (such 
as nephrogenic systemic fibrosis), it is not possible to simply repeat the examination 
until the whole gland has been imaged. Using echo-planar imaging sequences multiple 
slices can be generated, although susceptibility artefact can be much worse. Therefore, 
given these technical constraints, blood volume maps can only be generated for limited 
portions of each patient’s prostate gland.
As previously described, these functional imaging methods are only valid for tumour 
regions, necessitating accurate tumour localisation in the first place. Therefore, one 
solution may simply be to image the regions of the prostate that contain tumour. This is 
not entirely satisfactory given the scattered nature of prostate cancer and the fact that 
patients may have large volume disease that encases much of their peripheral gland. 
An alternative approach may be to use other methods to obtain blood volume 
information. The DCE-MRI parameter K**" is well known to reflect blood flow (and 
therefore blood volume) information as well as representing vascular permeability and 
surface area. Further scrutiny of the data presented in this chapter and of other similar 
studies may confirm whether K**"5 is a valid substitute for rBV. Other than the fact that 
multi-slice acquisition is easily obtained with DCE-MRI, there are other advantages. 
The technique is more reproducible, uses less intravenous contrast and tumour 
localisation is good (figure 5.5). Also, there is a greater experience with DSC-MRI and 
some commercially available software applications can already generate Ktrans maps 
without the need for laborious post-processing.
This experiment has dealt solely with prostate cancer, however there is no reason 
suggest that the technique would not also apply to other tumour types. In fact many 
other solid malignancies form larger tumours that are not interspersed with benign 
tissues making them potentially more suitable for assessment in this way. A similar 
process of validation would be required, necessitating a comparison between imaging 
and pathology. This may be difficult for certain tumour types where it is uncommon to 
remove the tumour in its entirety, such as brain tumours, or in regions that may be 
difficult to orientate in three dimensions once the tumour has been removed from the 
body, such as lung or oesophago-gastric malignancies. Despite this, many tumours 
such as cervix, breast or head and neck, would appear to be ideal candidates for 
investigation.
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Chapter 6
The effect of androgen deprivation on the
volume, vascular kinetics and oxygenation 
of the prostate gland and prostate tumour, 
as measured bv functional Magnetic 
Resonance Imaging
6.1 Aims
To assess the changes in vascular permeability, blood flow, blood volume and 
oxygenation in benign and malignant prostate tissue during a three month period of 
androgen deprivation, using functional MRI methods.
6.2 Introduction
This chapter contains details of experiments performed to determine whether androgen 
deprivation causes changes in the vascular kinetics and oxygenation of prostate 
cancer. DCE-MRI, DSC-MRI, BOLD MRI and Diffusion weighted imaging parameters 
were used to evaluate patients during a three-month course of androgen deprivation.
6.3 Patients and Methods
6.3.1 Patients, Treatment and Examination Schedule
Between January and October 2005, 20 patients with prostate cancer (age 57-78, 
Gleason grade 6-9, PSA 3.7-34.0 ng/ml) that were due to be treated with neo-adjuvant 
androgen deprivation prior to radical radiotherapy were recruited prospectively. The 
histologic diagnosis of prostate cancer was made by core biopsy in all 20 patients. 
Patient demographics, tumour pathology, staging and treatment details are shown in 
table 6.1. Inclusion criteria were: (1) Histologically-proven primary prostate carcinoma, 
(2) Intention to commence at least three months of androgen deprivation therapy (3) 
Ability to give written informed consent and (4) Age over 18 years. Exclusion criteria 
were: (1) Contra-indication to MRI, (2) Known allergy to gadopentetate dimeglumine 
(Gd-DTPA) and (3) Prior exposure to androgen deprivation.
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Table 6.1 Androgen Deprivation -  MRI Study population
Patient
No.
Age Clinical
Stage
(TNM)
MRI Stage 
(TNM)
PSA
(ng/ml)
Total
Gleason
Score
Gleason
Grade
Treatment Received
1 78 T1c NO MO 2c NO MO 10.9 6 3 + 3 Iodine Seed Brachytherapy
2 73 T1c NO MO 2c NO MO 29.8 7 4 + 3 External Beam Radiotherapy
3 67 T2b NO MO T3a NO MO 22.5 7 3 + 4 External Beam Radiotherapy
4 66 T3 NO MO 3b NO MO 8.7 6 3 + 3 High Dose Rate Brachytherapy
5 62 T1c NO MO 3a NO MO 12.1 7 3 + 4 External Beam Radiotherapy
6 73 T1b NO MO 1b NO MO 34 7 4 + 3 External Beam Radiotherapy
7 66 T2c NO MO T2c NO MO 30 8 4 + 4 Androgen Deprivation Alone
8 66 T2c NO MO T2c NO MO 8.4 8 4 + 4 External Beam Radiotherapy
9 72 T2a NO MO T2b NO MO 26 7 3 + 4 External Beam Radiotherapy
10 62 T1c NO MO T2c NO MO 15 7 3 + 4 External Beam Radiotherapy
11 59 T1c NO MO T2a NO MO 13.8 7 3 + 4 External Beam Radiotherapy
12 67 T1c NO MO T1c NO MO 7.7 6 3 + 3 External Beam Radiotherapy
13 68 T1c NO MO T3a NO MO 7.9 6 3 + 3 External Beam Radiotherapy
14 57 T2a NO MO T2a NO MO 5.7 7 3 + 4 External Beam Radiotherapy
15 75 T1c NO MO T3a NO MO 15.2 7 4 + 3 External Beam Radiotherapy
16 61 T2a NO MO T3a NO MO 3.7 7 Not specified High Dose Rate Brachytherapy
17 78 T2 NO MO T3b NO MO 17.7 6 3 + 3 External Beam Radiotherapy plus HDR Brachytherapy boost
18 70 T2b NO MO T3a NO MO 9.9 9 5 + 4 External Beam Radiotherapy
19 67 T1c NO MO T3b N2 M1 6.26 9 5 + 4 Androgen Deprivation Alone
20 65 T1c NO MO T3a NO MO 11.3 7 3 + 4 External Beam Radiotherapy plus HDR Brachytherapy boost
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Each patient was examined with five multi-parameter MRI scans. Two prior to the 
commencement of androgen suppression to define the baseline values and assess 
reproducibility, one after a month of hormone treatment and two further scans after 
three months of therapy, to measure the lasting effect of androgen deprivation and to 
reassess reproducibility whilst on hormones. The examination schedule is depicted in 
figure 6.1.
After completing the two baseline scans, patients were commenced on androgen 
deprivation therapy. This consisted of two drugs:
1. Bicalutamide (Casodex®, AstraZeneca) 50mg daily for 28 days
2. Goserelin (Zoladex® LA, AstraZeneca) 10.8mg subcutaneous injection 
given after 14 days of bicalutamide therapy, repeated every 12 weeks until 
completion of the androgen deprivation treatment period.
Gonadorelin analogues reduce serum testosterone to castrate levels by the depression 
of lutenising hormone (LH) release from the pituitary gland. However after 
administration, initial stimulation of LH release occurs, which may produce a theoretical 
risk of lumour flare’ caused by the transient rise in testosterone production. In 
susceptible patients this may cause urinary retention. Bicalutamide, a pure non­
steroidal anti-androgen, was administered during the initial stages of gonadorelin 
analogue therapy to reduce this risk.
Each patient was to receive at least three months of androgen deprivation therapy 
alone, before proceeding to any further local or systemic treatment for prostate cancer. 
Androgen deprivation was continued according to the clinical oncologist’s discretion. 
The duration of treatment ranged from six months to lifelong depending on the patient’s 
individual circumstances. In each case, whatever the treatment duration, the study 
period was the first three months of androgen deprivation. 18 patients subsequently 
received radical radiotherapy, either in the form of external beam treatment or 
brachytherapy. Two patients continued on long-term androgen deprivation therapy 
without radical treatment (one because of personal preference and the other due to the 
subsequent discovery of iliac and para-aortic lymph node involvement).
This cohort of 20 patients comprised the same group as that studied for the 
reproducibility analysis. The paired reproducibility scans (1 and 2 for baseline and 4 
and 5 for three months) were combined for the purpose of assessment of change
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Figure 6.1 MRI schedule for the androgen deprivation study
Week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
MRI +4,
Patient goes on either 
to receive radical
Scans 1 & 2 are performed on consecutive days, prior to the commencement of androgen deprivation therapy 
Scan 3 is performed after 4 weeks of androgen deprivation therapy
Scans 4 & 5 are performed on consecutive days, after 12 weeks of androgen deprivation therapy
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between baseline, one month and three months following the start of androgen
withdrawal.
6.3.2 Multi-Parameter Functional MRI Methods
All MRI investigations were performed at the Paul Strickland Scanner Centre at Mount 
Vernon Hospital, Northwood, UK. Patients were imaged in a Symphony 1.5T MRI 
scanner (Siemens AG, Munich, Germany) using a phased array pelvic coil.
All patients were imaged using the following functional MRI techniques:
•  Blood Oxygen Level Dependent (BOLD) MRI
•  ^-weighted Dynamic Contrast Enhanced MRI (DCE-MRI)
•  T2*-weighted Dynamic Susceptibility Contrast MRI (DSC-MRI)
Seven patients were also imaged with Diffusion Weighted Imaging (DWI). This facility 
only became available at the Paul Strickland Scanner Centre towards the latter stages 
of this study.
The MRI procedure and protocols and methods for the generation of functional 
parametric data are detailed in appendix B.
6.3.3 Volume measurements
Prostate volume was estimated by using the prolate spheroid formula [1]: volume = 
width x length x antero-posterior diameter x (tt/6). Width and AP diameter was 
measured on axial T2-weighted sequences and length was measured using coronal 
and sagittal images. Tumour volumes were not calculated because of lack of 
confidence in the measurements obtained. Although it was possible to confidently 
define a region of interest that contained tumour, the extent of tumour was not 
evaluable because of the lack of sensitivity of the imaging methods in the androgen- 
deprived gland.
6.3.4 Statistical Methods
Methods for the reproducibility analysis are described in detail in chapter 3. The 
repeatability statistic r was calculated for n=1 and expressed as a percentage. This 
gave a range, based upon the repeatability of the entire group, of change required for 
any given individual at 1 or 3 months, to be considered statistically significant at the
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95% confidence level and not simply be due to the natural variability of that parameter. 
For the logarithmically transformed data, this range is asymmetrical about the mean by 
virtue of the fact that logarithmic data are symmetrical around 1 rather than 0 as is the 
case with standard decimal values. For example, the repeatability statistic for tumour 
K^ ns was o.508 (n=19). Recalculated for n=1 and expressed as a percentage a 
range of -39.8% to +66.2% was obtained. This means that for an individual patient, a 
reduction of 39.8% or an increase of 66.2% in tumour K*'308 following androgen 
deprivation can be considered to be due to the therapeutic intervention rather than the 
test variability, at the 95% confidence level.
Significance testing of parameter changes between baseline and 1 month, baseline 
and 3 months and between 1 and 3 months were performed using a paired student’s t- 
test:
Baseline values were calculated as the mean of the median parameter values for 
scans 1 and 2 and three month values were calculated as the mean of the median 
parameter values for scans 4 and 5. This was performed for each parameter for each 
patient. In the event of missing data for one scan of the reproducibility pair, the median 
parameter value of the other scan was used.
The difference d between each pair of median parameter values was calculated for 
each patient. The distribution of d was tested for normality using the Shapiro-Wilk test. 
This was repeated for each time period (i.e. baseline to 1 month, baseline to 3 months 
and 1 to 3 months). The paired students t-test was then performed on the data sets for 
each parameter, each ROI and each time period. The significance of volume changes 
following androgen deprivation was calculated in the same way as the MRI parameter 
changes (see above).
In order to determine whether there was any significant correlation between volume 
change and change to any of the kinetic parameter values, Spearman’s p (rho) was 
calculated. Spearman’s p (rho) was also used to determine whether there was a 
correlation between initial parameter value and the magnitude of change of the same 
parameter.
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6.4 Results
6.4.1 General
All 20 patients underwent the five MRI studies according to schedule. All 20 patients 
were imaged with BOLD and TVweighted DCE MRI scans at each of the five study 
periods (resulting in 100 BOLD and 100 Tr weighted DCE MRI scans available for 
analysis). Due to operator error, one patient did not receive a T2*-weighted imaging 
sequence during his second scan (leaving 99 T2*-weighted DSC-MRI images available 
for analysis). Seven patients were imaged with DWI at each study visit (35 diffusion 
images available for analysis). No adverse events occurred during the running of the 
study. The median time between the first two scans and the last two scans was 2 days 
and 1.5 days respectively. The median time between starting androgen deprivation and 
the third scan was 29.5 days and was 91.5 days for the fourth scan (scheduling details 
are given in table 6.2).
One patient moved excessively (several centimetres) during the T, dynamic experiment 
of his first scan resulting in no data being available from this study. For this patient the 
baseline T-i values are therefore derived from one scan rather than two. Similarly, for 
the T2* analysis, no data was acquired during the second scan of one patient because 
of operator error, therefore the baseline rBV and rBF parameter values are also only 
derived from one scan for this subject. Due to the variation in the pattern of malignant 
infiltration between patients, tumour was not visible on every slice for each scan, 
therefore for some scans ‘tumour5 values may represent only one or two slices through 
the prostate. One patient had no tumour visible on any scan, despite positive histology 
on prostate biopsy, reducing the number of patients evaluable for tumour ROI changes 
to 19. As expected, with the decrease in peripheral zone signal intensity and the 
resulting reduction in contrast between benign peripheral zone and tumour on T2- 
weighted sequences following androgen deprivation, areas of malignancy became 
harder to define. In these instances, ROIs were manually copied from the 
corresponding slice of the pre-treatment scan. Occasionally this was not possible due 
to poor morphological definition and in these cases only definite areas of tumour were 
outlined. Out of the 120 scan slices at baseline, 60 slices at one month and 120 slices 
at three months 112, 55 and 106 tumour ROIs were delineated respectively. For the T2* 
parameters, it was not possible to obtain tumour ROI values from scan two of one 
patient and scan five of another, therefore the baseline data of the first patient and the 
three month data of the second is calculated from one scan only. As for the T, data, 
one patient had no discemable tumour leaving a total of 19 patients for tumour ROI 
analysis.
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Table 6.2 Schedule information
Median (Mean) / days Range / days
Number of days between scan 
1 and scan 2
2 (2.75) 1 -8
Number of days between start 
of AD and scan 3
29.5 (30.65) 26-41
Number of days between start 
of AD and scan 4
91.5(92) 82-105
Number of days between scan 
4 and scan 5
1.5 (2.55) 1 -14
AD Androgen deprivation
In one instance no normal peripheral zone could be identified because of widespread 
malignant involvement and one patient had a large homogenous nodular structure 
occupying much of the central and peripheral gland making delineation of normal 
peripheral zone and benign central gland impossible. One patient had no normal 
central zone because of prior trans-urethral resection. This reduced the number of 
evaluable patients for peripheral and central gland analysis to 18.
6.4.2 Volume Changes (Table 6.3, Figure 6.2)
As expected, androgen deprivation caused shrinkage of the prostate gland. At one 
month the whole prostate had reduced in volume by an average of 4 mis (9.3%) and by 
an average of 14.4 mis (34.5%) at 3 months. Volume reduction was statistically 
significant at each time point. Volume change did not correlate with MRI parameter 
changes (table 6.4) indicating that the functional imaging measurements are likely to 
be evaluating physiological processes that are independent of volume.
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Table 6.3 Summary of changes in prostate volume caused by androgen deprivation at 1 and 3 months
Mean Mean Mean Mean Two- Mean Two- Mean Two-
Value Value Value Difference sided p- Difference sided p- Difference sided p-
(ml) (ml) (ml) (% change) 
(ml)
value (% change) 
(ml)
value (% change) 
(ml)
value
baseline 1 month 3 months baseline -1  
month
baseline
-1
month
baseline -  3 
months
baseline
- 3
months
1 month -  3 
months
1 month -  
3 months
42.4 38.3 28.0 4.0 (9.3%) < 0.0001 14.4 (34.5%) < 0.0001 10.3(28.2%) < 0.0001
p-values in green signify statistically significant results at the 95% confidence level
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Figure 6.2 Prostate Volume Changes
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60 -
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Start of Androgen Deprivation
2 30 1
Time (months)
The mean values are shown in red
6.4.3 Ti-weighted DCE MRI analysis
There is a statistically significant reduction in K1"5118, kep and AUC60 from baseline at both 
one and three months for the whole prostate, tumour and peripheral zone ROIs. The 
overall reductions for whole prostate, tumour, peripheral zone and central zones are: 
l^ tranS' 28 go/o (p = 0.0005), 52.4% (p < 0.0001), 45.3% (p = 0.0023) and 18.3% (p = 
0.19) respectively; k^, 36.2% (p < 0.0001), 54.2% (p < 0.0001), 52.9% (p = 0.0002) 
and 38.2% (p = 0.0002) respectively; AUCeo, 31.2% (p = 0.0003), 48.8% (p < 0.0001), 
34.0% (p = 0.0102) and 7.7% (p = 0.55) respectively. For Ve the overall increases were 
13.7% (p = 0.0752), 10.0% (p = 0.26), 20.6% (p = 0.106) and 30.0% (p = 0.0233) 
respectively. The rate of change is greatest during the first month, as illustrated in 
figure 6.4, although for whole prostate and tumour K**ns and AUC, the change that 
occurs between one and three months continues to be significant.
Based on the reproducibility statistics described in the chapter 3 (table 3.1), the 
proportion of individual patients that achieved a significant change in parameter values 
after three months of androgen deprivation for whole prostate and tumour 
measurements respectively was: 50% and 68% for K^08, 50% and 53% for Ve, 75% 
and 84% for kep, and 35% and 56% for AUC.
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Table 6.4 Correlation between volume changes and MRI parameter changes
All values quoted are the Spearman's Rank Correlation Coefficient p (rho)
Time-point ROI l^ trans v. kep AUCeo rBV rBF FV ADC 
(b-value 0- 
1000)
ADC 
(b-value 0- 
50)
ADC
(b-value
150-1000)
Baseline -  
1 month
Whole Prostate 0.17 -0.26 0.36 0.25 -0.13 -0.16 -0.15 -0.21 0.21 -0.25
Baseline -  
3 months
Whole Prostate 0.06 -0.16 0.39 0.11 -0.22 -0.25 -0.12 0.07 -0.54 -0.14
All values for p (rho) were not statistically significant results at the 95% confidence level
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6.4.4 T2*-weighted DSC-MRI analysis 
fTable 6.6, Figures 6.11-6.14)
Blood volume and flow parameter changes proved to be even more striking, with 
tumour values decreasing by 83% and 79% respectively in the first month (figures 
6.11 and 6.13). Reductions in both rBV and rBF for whole prostate, tumour and 
peripheral gland were complete by one month, with no significant reduction occurring 
between one and three months. Only central gland volume and flow parameter 
changes occurred more slowly, with no significant change in either parameter by one 
month but a reduction of 56% and 57% respectively by three months (p = 0.007 and p 
= 0.0024 respectively). 14 out of the 19 evaluable patients demonstrated an individually 
significant change in tumour rBV at one month.
6.4.5 BOLD MRI analysis 
(Table 6.7, Figures 6.15-6.17)
By three months significant increases in R2* had occurred for all ROIs, most notably for 
tumour, with a rise of 41.1% (p < 0.0001). The tumour ROI was the only region to 
demonstrate a significant change by one month (15.8%, p = 0.0064), with the other 
areas changing more slowly. Due to the relatively high variability in the R2* 
measurement compared to the degree of change in R2* caused by androgen 
deprivation, the highly significant changes seen for the group did not translate into high 
proportions of individual patients with confirmed significant R2* increase, at the 95% 
confidence level (1 out of 20 for whole prostate and 4 out of 19 for tumour).
6.4.6 DWI analysis 
(Table 6.8, Figures 6.18-6.23)
Due to small patient numbers, changes in diffusion ADC values were generally non­
significant. The only exceptions to this were a 14% reduction in whole prostate overall 
ADC at three months (p = 0.0288) and a 29% reduction in peripheral zone ADC 
between one and three months (p = 0.0358). The trend for overall ADC (b-values of 0 - 
1000 s/mm2) was for an increase between baseline and one month and then a 
decrease between one and three months, with the final ADC measurement being lower 
than the starting value. The trend pattern for ‘late’ ADC values (b-values of 150 - 1000 
s/mm2) was similar. The ‘early’, flow-dependent, ADC measurment (b-values of 0 - 50 
s/mm2), showed a mixed trend with initial decreases for whole prostate and tumour and 
initial increases for peripheral and central gland ROIs. By three months only the tumour 
values remained higher than their value at baseline.
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Table 6.5 Summary of changes in MRI parameters caused by androgen deprivation at 1 and 3 months -
T1-weighted DCE MRI Parameters
Para­ ROI Mean Mean Mean Mean Two- Mean Two- Mean Two- Proportion of Proportion of
meter Value Value Value Difference sided p- Difference sided p- Difference sided p- patients with patients with
(% change) value (% change) value (% change) value individually individually
significant significant
change change
baseline 1 month 3 months baseline -1 baseline- baseline -  3 baseline- 1 month -  3 1 month -
month 1 month months 3 months months 3 months at 1 month at 3 months
^ t r a n s Whole Prostate 0.206 0.170 0.146 -0.035 (-17.1) 0.0138 -0.059 (-28.9) 0.0005 -0.024 (-14.2) 0.0265 7 out of 20 1 0  out of 2 0
min'1 Tumour 0.273 0.164 0.130 -0.109 (-39.8) 0.0011 -0.143 (-52.4) <0.0001 -0.034 (-20.9) 0.0056 9 out of 19 13 out of 19
Peripheral Zone 0.126 0.082 0.069 -0.044 (-35.0) 0.0042 -0.057 (-45.3) 0.0023 -0.013 (-15.8) 0.1024 3 out of 18 4 out of 18
Central Zone 0.253 0 . 2 0 0 0.206 -0.052 (-20.7) 0.0655 -0.046 (-18.3) 0.1938 0.006 (3.0) 0.7956 3 out of 18 8 out of 18
Ve Whole Prostate 0.416 0.494 0.473 0.078(18.8) 0.0014 0.057(13.7) 0.0752 -0.021 (-4.3) 0.3815 7 out of 20 1 0  out of 2 0
x100% Tumour 0.412 0.461 0.453 0.050(12.1) 0.1185 0.041 (10.0) 0.2554 -0.009 (-1.9) 0.7215 6 out of 19 10 out of 19
Peripheral Zone 0.292 0.349 0.352 0.056(19.3) 0.0396 0.060 (20.6) 0.1055 0.004(1.1) 0.9184 5 out of 18 10 out of 18
Central Zone 0.326 0.388 0.422 0.063(19.4) 0.0039 0.097 (30.0) 0.0233 0.034 (8.9) 0.3069 6 out of 18 10 out of 18
Kep Whole Prostate 0.513 0.360 0.327 -0.153 (-29.8) < 0.0001 -0.186 (-36.2) < 0.0001 -0.033 (-9.1) 0.0786 10 out of 20 15 out of 20
min Tumour 0.680 0.368 0.311 -0.312 (-45.9) < 0.0001 -0.369 (-54.2) < 0.0001 -0.057 (-15.4) 0.0719 9 out of 19 16 out of 19
Peripheral Zone 0.461 0.252 0.217 -0.209 (-45.3) 0.0001 -0.244 (-52.9) 0.0002 -0.035 (-13.9) 0.0726 2 out of 18 5 out of 18
Central Zone 0.808 0.548 0.500 -0.260 (-32.2) 0.0015 -0.309 (-38.2) 0.0002 -0.049 (-8.8) 0.3819 8 out of 18 10 out of 18
AUC Whole Prostate 10.84 8.88 7.46 -1.96 (-18.1) 0.0141 -3.38 (-31.2) 0.0003 -1.43 (-16.1) 0.0173 8 out of 20 7 out of 20
mmol.8 Tumour 14.23 9.09 7.28 -5.14 (-36.1) 0.0019 -6.95 (-48.8) < 0.0001 -1.81 (-19.9) 0.007 9 out of 19 12 out of 19
Peripheral Zone 7.32 5.50 4.84 -1.82 (-24.8) 0.0177 -2.49 (-34.0) 0.0102 -0.67 (-12.1) 0.144 3 out of 18 4 out of 18
Central Zone 13.02 11.17 12.01 -1.84 (-14.1) 0.1528 -1.00 (-7.7) 0.5575 0.84 (7.5) 0.4938 5 out of 18 10 out of 18
p-values in green signify statistically significant results at the 95% confidence level 
p-values in red signify statistically non-significant results at the 95% confidence level
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Figure 6.3 Changes in Ktrans during androgen deprivation
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Figure 6.4 illustration of the change in K4™8 during 3 months of
Androgen deprivation.
Baseline T? image
trans1 month K1 3 month K
A 67 year old patient with T3b, Gleason 5+4 Carcinoma of the prostate which can 
be seen on the T2-weighted MRI image as a region of low signal intensity within the 
otherwise bright peripheral gland (arrow, top left). The baseline K^ans map (top right) 
shows high permeability in the tumour. A reduction in is demonstrated at both 
one and three month following androgen deprivation (bottom images).
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Figure 6.5 Changes in Ve during androgen deprivation
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Figure 6.6 Illustration of the change in Ve during 3 months of
Androgen deprivation.
Baseline Ve map
1 month Ve map
A 67 year old patient with T3b, Gleason 5+4 Carcinoma of the prostate which can 
be seen on the T2-weighted MRI image as a region of low signal intensity within the 
otherwise bright peripheral gland (arrow, top left). This patient’s scan is consistent 
with the overall group data, with little overall change in Ve for whole prostate, 
tumour or peripheral zone but a noticeable change in central gland values after 3 
months of androgen deprivation (bottom left).
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Figure 6.7 Changes in KeP during androgen deprivation
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Figure 6.8 Illustration of the change in keP during 3 months of
Androgen deprivation.
Baseline T2 image
1 month keP map 3 month kep ma
A 67 year old patient with T3b, Gleason 5+4 Carcinoma of the prostate which can 
be seen on the T2-weighted MRI image as a region of low signal intensity within the 
otherwise bright peripheral gland (arrow, top left). The baseline kep map (top right) 
shows high membrane permeability in the tumour. A reduction in keP is 
demonstrated at both one and three month following androgen deprivation (bottom 
images).
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Figure 6.9 Changes in AUC during androgen deprivation
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Figure 6.10 Illustration of the change in AUC6o during 3
months of Androgen deprivation.
Baseline T2 image Baseline AUC6q map
1 month AUC6omap 3 month AUC6o map
A 67 year old patient with T3b, Gleason 5+4 Carcinoma of the prostate which can 
be seen on the T2-weighted MRI image as a region of low signal intensity within the 
otherwise bright peripheral gland (arrow, top left). The baseline AUC60 map (top 
right) shows high parameter values in the tumour (arrow). A reduction in AUC60 is 
demonstrated at both one and three month following androgen deprivation (arrow, 
bottom images).
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Table 6.6 Summary of changes in MRI parameters caused by androgen deprivation at 1 and 3 months -  
T2*-weighted DSC MRI Parameters
Para­ ROI Mean Mean Mean Mean Two- Mean Two- Mean Two- Proportion of Proportion of
meter Value Value Value Difference sided p- Difference sided p- Difference sided p- patients with patients with
(% change) value (% change) value (% change) value individually individually
significant significant
change change
baseline 1 month 3 months baseline -1 baseline- baseline -  3 baseline- 1 month -  3 1 month -
month 1 month months 3 months months 3 months at 1 month at 3 months
rBV Whole Prostate 141.42 55.71 47.94 -85.71 (-60.6) 0.0002 -93.48 (-66.1) 0.0002 -7.77 (-13.9) 0.4803 9 out of 20 11 out of 20
Tumour 251.77 42.17 34.18 -209.6 (-83.3) < 0.0001 -217.6 (-86.4) 0.0001 -7.99 (-18.9) 0.447 14 out of 19 12 out of 19
Peripheral Zone 86.97 35.39 23.69 -51.57 (-59.3) 0.050 -63.28 (-72.8) 0.015 -11.7 (-33.1) 0.1251 2 out of 18 2 out of 18
Central Zone 164.80 130.97 72.60 -33.82 (-20.5) 0.3588 -92.19 (-55.9) 0.007 -58.37 (-44.6) 0.0831 2 out of 18 6 out of 18
rBF Whole Prostate 2.368 1.033 0.979 -1.336 (-56.4) < 0.0001 -1.390 (-58.6) 0.0003 -0.054 (-5.2) 0.7585 9 out of 20 7 out of 20
Tumour 4.198 0.878 0.783 -3.319 (-79.1) < 0.0001 -3.415 (-81.3) <0.0001 -0.095 (-10.9) 0.6064 11 out of 19 12 out of 19
Peripheral Zone 1.536 0.689 0.515 -0.847 (-55.1) 0.0307 -1.021 (-66.5) 0.0055 -0.174 (-25.3) 0.1569 2 out of 18 1 out of 18
Central Zone 2.817 2.146 1.220 -0.671 (-23.8) 0.2578 -1.597 (-56.7) 0.0024 -0.926 (-43.2) 0.0641 4 out of 18 8 out of 18
p-values in green signify statistically significant results at the 95% confidence level 
p-values in red signify statistically non-significant results at the 95% confidence level
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Figure 6.11 Changes in relative Blood Volume during
androgen deprivation
0 1 2 
Time (months)
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Tumour
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Figure 6.12 Illustration of the change in rBV during 3
months of Androgen deprivation.
Baseline T2 image
1 month rBV ma 3 month rBV map
A 70 year old patient with T3a, Gleason 5+4 Carcinoma of the prostate, outlined on 
the T2-weighted MRI image (top left). The baseline relative blood volume map (top 
right) shows high blood volume in the left posterior gland, within a tumour region. A 
reduction in blood volume is demonstrated at both one and three months following 
androgen deprivation (bottom images). A reduction in blood volume within the non- 
malignant regions of the prostate can also be seen. High blood volume is seen 
within the well vascularised normal rectum throughout the experiment.
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Figure 6.13 Changes in relative Blood Flow during
androgen deprivation
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Figure 6.14 Illustration of the change in rBF during
3 months of Androgen deprivation.
Baseline T2 image Baseline rBF map
1 month rBF map 3 month rBF map
A 70 year old patient with T3a, Gleason 5+4 Carcinoma of the prostate, outlined on 
the T2-weighted MRI image (top left). The baseline relative blood flow map (top 
right) shows high blood volume in the left posterior gland, within a tumour region. A 
reduction in blood flow is demonstrated at both one and three months following 
androgen deprivation (bottom images). A reduction in blood flow within the non- 
malignant regions of the prostate can also be seen. High blood volume is seen 
within the well vascularised normal rectum throughout the experiment.
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Table 6.7 Summary of changes in MRI parameters caused by androgen deprivation at 1 and 3 months -
R2* (BOLD MRI)
Para­ ROI Mean Mean Mean Mean Two- Mean Two- Mean Two- Proportion of Proportion of
meter Value Value Value Difference sided p- Difference sided p- Difference sided p- patients with patients with
(% change) value (% change) value (% change) value individually
significant
change
individually
significant
change
baseline 1 month 3 months baseline -1 baseline- baseline -  3 baseline- 1 month -  3 1 month-
month 1 month months 3 months months 3 months at 1 month at 3 months
r2; Whole Prostate 17.24 17.45 20.73 0.21 (1.2) 0.7716 3.50 (20.3) < 0.0001 3.28(18.8) 0.0002 0 out of 20 1 out of 20
(s'1) Tumour 16.59 19.21 23.41 2.62(15.8) 0.0064 6.82 (41.1) < 0.0001 4.20 (21.9) 0.0006 2 out of 19 4 out of 19
Peripheral Zone 14.09 14.47 19.66 0.38 (2.7) 0.7562 5.57 (39.5) <0.0001 5.19(35.9) 0.0014 2 out of 18 2 out of 18
Central Zone 10.35 9.72 13.73 -0.63 (-6.1) 0.6016 3.38 (32.7) 0.0197 4.01 (41.3) 0.0207 1 out of 18 1 out of 18
p-values in green signify statistically significant results at the 95% confidence level 
p-values in red signify statistically non-significant results at the 95% confidence level
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Figure 6.15 Changes in R2* during androgen deprivation
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Figure 6.16 Illustration of the change in R2* during
3 months of Androgen deprivation.
Baseline R2* mapBaseline T2 image
3 month R2* map1 month R2* ma
A 68 year old patient with T2c, Gleason 4+3 Carcinoma of the prostate, outlined on 
the T2-weighted MRI image (top left). The baseline R2* map (top right) is dark 
throughout the prostate indicating no evidence of hypoxia. After three months of 
androgen deprivation there appears to be an increase in deoxyhaemoglobin level 
across the posterior gland.
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Figure 6.17 Illustration of the change in R2* during
3 months of Androgen deprivation.
Baseline R2* maBaseline T2 image
1 month R2* map 3 month R2* ma
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Table 6.8 Summary of changes in MRI parameters caused by androgen deprivation at 1 and 3 months -  Diffusion Weighted
ADC values
Para­ ROI Mean Mean Mean Mean Two- Mean Two- Mean Two- Proportion of Proportion of
meter Value Value Value Difference sided p- Difference sided p- Difference sided p- patients with patients with
(% change) value (% change) value (% change) value individually individually
significant significant
change change
Base­ 1 3 baseline - baseline- baseline - baseline- 1 month - 1 month -
line month months 1 month 1 month 3 months 3 months 3 months 3 months at 1 month at 3 months
ADC Whole Prostate 130.4 131.0 112.1 0.6 (0.4) 0.924 -18.3 (-14.0) 0.0288 -18.9 (-14.4) 0.0837 0 out of 7 1 out of 7
(b-value Tumour 62.7 62.9 53.8 0.1 (0.2) 0.9933 -9.0 (-14.3) 0.4435 -9.1 (-14.5) 0.4239 0 out of 7 0 out of 7
0-1000) Peripheral Zone 149.4 168.5 119.2 19.1 (12.8) 0.3403 -30.3 (-20.3) 0.0881 -49.4 (-29.3) 0.0358 3 out of 7 2 out of 7
Central Zone 152.0 184.9 142.1 32.9 (21.6) 0.1358 -9.9 (-6.5) 0.399 -42.8 (-23.2) 0.0847 4 out of 7 3 out of 7
ADC Whole Prostate 414.9 380.1 381.4 -34.8 (-8.4) 0.1637 -33.5 (-8.1) 0.1039 1.3(0.3) 0.9578 0 out of 7 0 out of 7
(b-value Tumour 385.5 351.2 434.8 -34.3 (-8.9) 0.8004 49.3(12.8) 0.6656 83.6 (23.8) 0.1679 3 out of 7 2 out of 7
0-50) Peripheral Zone 405.8 467.4 357.2 61.6(15.2) 0.3863 -48.6 (-12.0) 0.288 -110.2 (-23.6) 0.1431 0 out of 7 0 out of 7
Central Zone 366.1 380.2 361.1 14.1 (3.8) 0.8036 -5.0 (-1.4) 0.9309 -19.1 (-5.0) 0.6997 0 out of 7 0 out of 7
ADC Whole Prostate 104.0 107.9 87.3 3.9 (3.7) 0.5988 -16.7 (-16.1) 0.0533 -20.6 (-19.1) 0.0953 0 out of 7 1 out of 7
(b-value Tumour 42.3 47.2 38.6 4.9(11.6) 0.7763 -3.7 (-8.8) 0.5109 -8.6 (-18.3) 0.5974 1 out of 7 0 out of 7
150- Peripheral Zone 126.8 140.2 91.7 13.4(10.6) 0.6379 -35.1 (-27.7) 0.0685 -48.5 (-34.6) 0.0943 3 out of 7 2 out of 7
1000) Central Zone 134.4 170.3 121.7 35.9 (26.7) 0.1037 -12.7 (-9.4) 0.2024 -48.6 (-28.5) 0.0671 3 out of 7 1 out of 7
p-values in green signify statistically significant results at the 95% confidence level 
p-values in red signify statistically non-significant results at the 95% confidence level
216
Ap
pa
re
nt
 D
iff
us
io
n 
Co
ef
fic
ie
nt
 (
x1
03 
ra
m
'.i
 
') 
Ap
pa
re
nt
 D
iff
us
io
n 
Co
ef
fic
ie
nt
 (
x1
0‘
3 m
m
'
Figure 6.18 Changes in Apparent Diffusion Coefficient during androgen
deprivation
(b-values 0 -  1000 s/mm2)
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Figure 6.19 Illustration of the change in ADC during
3 months of Androgen deprivation
(b-values 0 -  1000 s/mm2).
Baseline ADC mapBaseline T2 image
3 month ADC map1 month ADC ma
A 65 year old patient with T3a, Gleason 3+4 Carcinoma of the prostate, shown on 
the T2-weighted MRI image (arrow, top left). The baseline ADC map (top right) 
shows a discrete area of restriction in the tumour region. One month following the 
start of androgen deprivation there is evidence of an increase in ADC value (less 
restriction) in the tumour. After three months there appears to be some further 
restriction in the tumour region but not significantly different to that seen at 1 month.
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Figure 6.20 Changes in Apparent Diffusion Coefficient
during androgen deprivation
(b-values 0 - 5 0  s/mm2)
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Figure 6.21 Illustration of the change in ADC during
3 months of Androgen deprivation
(b-values 0 -  1000 s/mm2).
Baseline ADC ma
3 month ADC map1 month ADC ma
’ A
\ T
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A 65 year old patient with T3a, Gleason 3+4 Carcinoma of the prostate, shown on 
the T2-weighted MRI image (arrow, top left). The baseline ADC map (top right) 
shows a discrete area of restriction in the tumour region. One month following the 
start of androgen deprivation there is evidence of an increase in ADC value (less 
restriction) in the tumour. After three months there appears to be some further 
restriction in the tumour region but not significantly different to that seen at 1 month.
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Figure 6.22 Changes in Apparent Diffusion Coefficient
during androgen deprivation
(b-values 150 -  1000 s/mm2)
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Figure 6.23 Illustration of the change in ADC during
3 months of Androgen deprivation 
(b-values 150 -  1000 s/mm2).
Baseline ADC map
3 month ADC map1 month ADC ma
’ . ' I *
f  • » •  A *  l v V
A 70 year old patient with T3a, Gleason 5+4 Carcinoma of the prostate, outlined on 
the T2-weighted MRI image (top left). The baseline ADC map (top right) shows a 
discrete area of restriction in the tumour region indicating relatively high cellularity. 
Restriction decreases during the course of androgen deprivation as the number of 
cells per unit volume decreases (bottom images).
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6.5 Discussion
One of the initial reasons that investigation into androgen deprivation therapy prior to 
radiotherapy began was the assumption that a reduction in whole prostate volume 
would lead to a smaller target and therefore smaller radiation field sizes. Radiotherapy 
planning studies have demonstrated a theoretical reduction in rectal and bladder dose 
if radiation were to be deferred until after hormonal gland reduction, with the promise of 
an improvement in acute and late radiation toxicity to these organs [2, 3]. Many studies 
have confirmed that androgen withdrawal reduces prostate gland volume [4-7], with 
reductions of 10 -  52% reported in the literature. This study offers no surprises, with 
whole prostate volumes reducing by an average of 9.3% at one month and by 34.5% at 
three months. However, the hope that volume reduction induced by androgen 
withdrawal would lead to an increased therapeutic ratio has not been realised, with 
most studies demonstrating no toxicity improvement or even worsening of side effects 
following radiotherapy, particularly in regard to sexual function [8-11].
The dynamic T, experiments reflect changes in capillary permeability and the volume of 
extracellular ‘leakage’ space. This study confirms the findings reported by Padhani et 
al. [12] with a demonstration of reduced permeability and no change in leakage space 
at three months. Padhani reported a 56% (42% - 64%, p = 0.1) reduction in tumour 
K*308 at 3 months. This study shows remarkably similar results with a corresponding 
reduction in tumour Ktransof 52.4% (31.3% - 73.5%, p < 0.0001). A comparison between 
this study and the study of Padhani et al, which are the only two studies to have 
investigated the change in dynamic T, parameters following androgen deprivation in 
human prostate cancer, is shown in table 6.9. The only real differences between the 
results of the two studies is a significant reduction in central gland demonstrated 
by Padhani, with only a trend for this ROI in the current study. Similarly, Padhani et al 
showed a significant rise in peripheral gland ve, with this study again showing only a 
trend. These differences are likely to be due to greater patient numbers (38 evaluable) 
in their study.
The current study reveals a number of outcomes that have not been reported 
previously. Most notably, that the change in vascular permeability predominately 
occurs during the first month after the start of androgen deprivation. For every 
parameter measured in all four ROIs, the percentage change between baseline and 
one month exceeded the change between one and three months. In fact for kep, 
changes in parameter values appear to be complete by one month, with no further 
significant changes occurring during the remainder of the study period. These findings 
do not lend weight to previous supposition that the reduction in capillary permeability
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Table 6.9 Comparison of changes in Ktrans and Ve, induced by three months of androgen deprivation 
between Padhani e t  a l. and the current study.
Peripheral
Zone
Padhani et al.
Central
Gland
Tumour Peripheral
Zone
Current Studv
Central
Gland
Tumour
Percentage reduction in Ktrans 
(95% Confidence Interval)
31
(10-50)
41
(4-59
56
(42-64)
45.3
(18.8-71.8)
18 3 
(-10.3-46.9)
52.4
(31.3-73.5)
P-value < 0.001 < 0.009 0.01 0.0023 0.19 < 0.0001
Percentage increase in Ve 
(95% Confidence Interval)
46
(10-100)
20
(10-44)
0
(-9-22)
20.6
(-4.8-46.0)
30.0
(4.7-55.3)
10.0
(-7.8-27.8)
P-value 0.02 < 0.001 >0.05 0.11 0.0233 0.26
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may be, at least in part, due to the development of interstitial fibrosis, which is known to 
occur as a result of androgen withdrawal [13, 14]. Mature collagen deposition is a 
recognised cause of a decrease in permeability to low molecular weight contrast media 
but is unlikely to develop within four weeks of starting treatment.
The reduction in vascular endothelial growth factor, VEGF (also know as vascular 
permeability factor) is likely to be the predominant initiator for permeability change 
following androgen deprivation. Studies in normal male rats and in mice bearing human 
prostate carcinomas have shown that castration results in a rapid decrease in VEGF 
expression within 24 hours and a marked reduction in neovascularization by three days 
[15, 16]. Similarly, biopsy of the human prostate, before and after ablative endocrine 
therapy, demonstrates a significant reduction in VEGF levels post-treatment [17, 18]. 
These changes in VEGF result in physiological and architectural changes to the 
vasculature within days and are therefore likely to be apparent when imaged at one 
month.
Relative blood volume and blood flow changes during androgen deprivation in the 
human prostate have never been reported before. The results are unequivocal, with 
five-fold reductions of both parameters compared to the pre-treatment values in the 
regions of prostate carcinoma (p < 0.0001). These vascular changes appear to have 
concluded by the end of the first treatment month, with no further significant alterations 
occurring during the remainder of the study period. Once again, the reduction in VEGF 
is the most likely factor causing the induction and maintenance of these changes. In 
both tumour xenografts and primary human tumours, the neo-vasculature contains a 
substantial proportion of immature blood vessels, characterized by a lack of 
periendothelial cells. These cells undergo selective apoptosis in the absence of VEGF 
[19]. In the Shionogi tumour model, endothelial cells begin to undergo apoptosis before 
neoplastic cells, and degeneration of tumour vessels precedes the decrease in tumour 
size. The regressing vessels begin to exhibit normal phenotype, i.e., lower diameter, 
tortuosity, vascular permeability, and leukocyte adhesion [20]. Two weeks after 
castration, a second wave of angiogenesis and tumour growth begins with a 
concomitant increase in VEGF expression as both vascular endothelium and tumour 
cells become hormone refractory. This pattern of capillary architecture change has also 
been demonstrated by the examination of whole-mount prostatectomy specimens from 
untreated and androgen-ablated patients [17].
These anti-vascular and anti-angiogenic effects, exhibited in both prostate cancer as 
well as benign prostatic tissue as a result of androgen withdrawal, are confirmed by the
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T2* experiments in this study. Figures 6.11 and 6.13 depict the extent of change in 
blood volume and flow within the first month of therapy in both the benign but 
especially the malignant gland. The maintenance of vascular function in the non- 
androgen dependent rectal mucosa is also demonstrated.
Hypoxic tumours are more radioresistant that well oxygenated ones [21]. Hypoxia can 
inhibit the action of some chemotherapeutic agents and there is evidence that hypoxic 
tumours are more likely to invade and metastasise. There is increasing published data 
that hypoxia is a poor prognostic indicator in prostate cancer [22-26]. Mathematical 
modelling studies strongly suggest that severe hypoxia in the prostates of certain 
patients may limit the overall cancer cure rate by conventional radiation therapy [27]. 
The finding that androgen deprivation may induce or worsen existing hypoxia therefore 
has serious implications regarding the timing of androgen withdrawal with radiotherapy.
The reproducibility of the R2* parameter itself has been confirmed by repeatability 
measurements in normal tissue (obturator intemus muscle) (table 3.4, chapter 3). The 
variability in prostate cancer is greater, reflecting the heterogeneity and instability of the 
tumour blood supply, resulting in changes to individual patients being harder to confirm 
with statistical significance. Nevertheless, for the group of twenty patients as a whole, 
there is a significant increase in R2* for every prostate region, with a 41% rise in tumour 
R2* (p < 0.0001) at three months. Increases in R2* are consistent with increased 
presence of paramagnetic species. As previously mentioned, interstitial fibrosis is 
known to gradually develop following months of androgen withdrawal. Collagen 
contains paramagnetic species and as a result causes inhomogeneity in the 
microscopic magnetic field gradients in fibrotic regions, which is reflected by high R2*. 
However, in this experiment the change in R2* was too rapid to be explicable by the 
development of fibrosis (an increase at one month of 15.8%, p=0.0064), making the 
development of tumour hypoxia a more likely explanation.
R2* measurements taken in isolation neither reflect tissue p02 nor do they reflect 0 2 
consumption by tumour cells. R2* reflects the number of deoxyhaemoglobin molecules 
per unit volume imaged, thereby being dependent of blood flow and volume. For 
example, a hypoxic tumour region with low blood volume may contain fewer 
deoxyhaemoglobin molecules than a similar region that is well oxygenated with a 
greater blood volume, despite the ratio of deoxygenated haemoglobin to oxygenated 
haemoglobin being greater, simply because there is more blood, and therefore more 
haem, in the latter.
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In this study blood volume and blood flow was measured in conjunction with R2*. The 
increases seen in R2* occurred despite a reduction of flow and volume. Tumour R2* 
values increased in 84% of the patients. It follows that three months of androgen 
deprivation therapy may well be causing, or at least exacerbating existing hypoxia 
within the prostate and in regions of prostate cancer.
In previous studies, the R2* value of obturator intemus has been used as a benchmark 
to determine whether clinically relevant hypoxia is present [28]. Using this method of 
analysis for the current study, 5% of prostate tumours would be considered hypoxic at 
baseline compared with 32% following three months of hormonal treatment. It is likely 
that the use of obturator intemus as an internal standard results in a conservative 
assessment of the prevalence of hypoxia. The BOLD effect in skeletal muscle is at 
least as complex as the effect seen in tumours, complicated by the presence of 
myoglobin, which has an identical haem structure as haemoglobin but a dramatically 
different volume of distribution [29, 30]. Muscle contraction also has a significant effect, 
with higher R2* values obtained when the muscle is at rest, as would be the case when 
lying supine during an MRI examination [31]. In this experiment obturator intemus gave 
an R2* value of 25.0s'1 (24.04s'1 -  25.95s'1).
A method more appropriate for the assessment of tumour hypoxia that may be of 
clinical significance, as suggested by the validation experiments in chapter 5 would be 
to use a combined test, diagnosing hypoxia if rBV is less than 42 a.u. or if rBV is 
greater than 42 a.u. and R2* is greater than 21.3s'1. Using this as the hypoxia cut-off 
value for the current study, 25% of the regions of prostate tumour would be considered 
hypoxic at baseline (five of the 20 patients) compared with 90% following three months 
of hormonal therapy (18 of the 20 patients). This was calculated as follows:
Baseline 3 months
Number of patients with rBV < 42 au 4 17
Number of patients with rBV > 42 au AND R2* >21.3s'1 1 1
Number of patients with hypoxic tumours 5 18
The under-powered diffusion data is difficult to interpret with any degree of confidence. 
However, some of the trends observed warrant further study. The overall apparent 
diffusion coefficient (ADC) encompasses both the diffusion of water molecules within 
tissue as well as contributions from the flow of water molecules within vessels. It is 
possible to distinguish between these two components of measured water diffusion by 
altering the degree of diffusion weighting. Lower b-values (0 -  50 s/mm2) reflecting 
perfusion and higher b-values (150 -  1000 s/mm2) giving an indication of tumour 
cellularity. As previously demonstrated, androgen deprivation causes a considerable
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and persistent reduction in blood flow. It also reduces prostate cellularity, most notably 
in the regions of tumour. As a result, one would expect a decrease in the restriction to 
the movement of water molecules and therefore an increase in ADC measurements.
Indeed the early, perfusion weighted, ADC values for tumour rise over the three-month 
study period (not significant) but the dramatic changes in blood flow seen after only one 
month with the T2*-weighted dynamic imaging, are not apparent. The trend for changes 
induced by androgen deprivation as measured by the late, cellularity weighted ADC 
values, follows a similar pattern for each of the prostate regions. An initial rise during 
the first month is followed by a fall between one and three months, to a value similar to 
or slightly lower than baseline. The explanation for this may be due to the balance of 
two competing factors. The decrease in cellularity, caused by androgen withdrawal 
causes an initial rise in ADC. The subsequent development of interstitial fibrosis, which 
may be established by three months [13, 14], causes further restriction to the diffusion 
of water molecules and results in a fall of ADC, countering the effect of reduced 
cellularity. This initial rise followed by a fall in ADC may limit the potential of cellularity- 
weighted diffusion MRI to evaluate early response to endocrine therapy, however these 
results need to be viewed with caution given the patient numbers involved.
6.6 Conclusion
Considering the results of the T1f T2* and BOLD experiments together, androgen 
deprivation not only causes substantial morphological changes to the prostate gland 
but also induces profound vascular collapse and a reduction in capillary membrane 
permeability. Increased R2* in regions of prostate cancer and a reduction in blood 
volume, suggest the induction of tumour hypoxia.
These findings have considerable implications regarding the timing of androgen 
deprivation and radiotherapy. In pre-clinical models, the fact that an increase in 
radiation-induced post-mitotic apoptosis as a result of androgen withdrawal is not 
associated with an overall increase in tumour cell death [32], suggests that the supra- 
additivity in one tumour cell population is offset by sub-additivity in another. The 
induction of tumour hypoxia as a result of substantial vascular shutdown may be the 
mechanism for this apparent induction of radio-resistance in a susceptible group of 
tumour cells.
Clinical data is largely supportive of the use of androgen deprivation with radiotherapy, 
although as previously described; none of the clinical studies can differentiate between 
additive and synergistic effects for the combination. Neo-adjuvant studies have
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generally assessed androgen deprivation prior to and during radiotherapy versus no 
hormonal therapy at all. The resulting relapse-free survival benefits suggest that the 
tumour cell-killing effects of androgen withdrawal outweigh any inhibition to cell death 
caused by radio-resistance. However, if the benefits of combined therapy are indeed 
additive rather than synergistic, then deferring hormonal therapy until after radiotherapy 
is complete may offer an even greater advantage, with similar cytotoxicity without the 
negative effects of radio-resistance. This may be why in contrast to the neo-adjuvant 
trials, the adjuvant studies have been able to show a true survival advantage.
This study has demonstrated that non-invasive MR imaging at multiple-time points 
during androgen deprivation therapy, is a valuable clinical technique. It has 
demonstrated the potent effects of hormonal treatment on the prostate and tumour 
vasculature and provided evidence that the resulting environment may support tumour 
hypoxia. Given the lack of convincing clinical evidence for the superiority of 
neoadjuvant androgen withdrawal over the use of androgen deprivation in the adjuvant 
setting, these findings raise questions regarding the indiscriminate use of hormonal 
therapy prior to radical radiotherapy.
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Chapter 7 
Concluding Discussion
The experiments described in this thesis have demonstrated that functional magnetic 
resonance imaging techniques are capable of mapping hypoxia within prostate cancer 
with a sensitivity of 70 - 82% and a specificity of 72 - 100%, depending on the 
thresholds used for the test. Accounting for the intrinsic difficulties with the 
methodology required to prove the accuracy of such a test, requiring the correlation 
between a pathological section and an MRI image, these results are very promising. 
The functional MR examination process itself is fast and minimally invasive, making it 
readily incorporate within existing diagnostic MR schedules.
The parametric maps produced using BOLD and Ti-weighted dynamic sequences are 
highly repeatable and reproducible, suggesting that they are potentially robust clinical 
tools. The T2*-weighted dynamic scans proved to be much less reproducible, largely 
resulting from the susceptibility artefacts generated by rectal gas. Strategies to combat 
rectal gas formation and faster imaging at increased magnetic field strength may 
improve this matter. This study is the first to document the variability and repeatability 
of Tp and T2*-weighted dynamic MRI and ISW-MRI for the various regions of the 
human prostate gland. Reproducibility statistics for each kinetic parameter in every 
prostate region have been documented and will provide a valuable source of reference 
for any group that plans to use these measures as a method for assessing treatment 
response in the benign or malignant prostate. Awareness of the intrinsic variability of 
any biomarker is vital for accurate study design. In particular, knowledge of the degree 
a particular parameter has to change, on an individual patient basis, for the change to 
be considered statistically significant, will facilitate accurate power calculations. 
derived kinetic parameters exhibit a high degree of reproducibility compared to the T2* 
weighted measures. Both sets of parameters become more variable following 
androgen deprivation. In contrast, the reproducibility of R2* improves with androgen 
ablation therapy reflecting the antiangiogenic effects of this treatment.
Another important conclusion of the studies reported in this work is that the 
oxygenation of prostate cancer improves during carbogen gas breathing. There is an 
average R2* decrease of 9.8 -10% in prostate cancer xenografts and 21.6% in human 
tumours. Carbogen, in conjunction with nicotinamide (ARCON), has radiosensitizing
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properties. Over the past 15 years a number of early phase human studies have been 
conducted using ARCON in a variety of tumour sites. A study of 215 patients with 
locally advanced head and neck cancer indicated very favourable rates of locoregional 
tumour control and overall survival. The actuarial 3-year local control rates were 80% 
for larynx, 69% for hypopharynx, 88% for oropharynx, and 37% for oral cavity tumors. 
Regional control rates were 100% for NO, 93% for N1, and 74% for N2 disease. 
Following this promising early data, the ARCON schedule has also been tested in 
bladder cancer. A multi-centre phase III trial (BCON) comparing 55Gy in 20 fractions of 
external beam with or without carbogen and nicotinamide has recently completed 
accrual. No study has ever investigated carbogen in the clinical setting for prostate 
cancer. The results presented here suggest that a study of similar design to BCON is 
justified.
Despite recent advances, many patients treated for prostate cancer with curative intent 
do not remain disease free in the long term, with disease-free 5-year survival rates for 
T1-T2 disease of 63-96% for external beam radiotherapy and 83-92% in equivalent risk 
patients treated with extemal-beam plus a brachytherapy boost. For T3 disease the 
corresponding 5-year disease-free survival rates are 32-87% and 31-56% respectively. 
The two principle causes for this failure remain inadequate initial staging leading to the 
incorrect assumption that the disease is localized at presentation and biological 
resistance which may reflect varying degrees of hypoxia and intrinsic resistance.
Part of this problem may be due to the fact that many aspects of prostate cancer 
therapy have traditionally been anatomically based. Staging procedures assess the 
pattern and depth of invasion and the number and distribution of metastases. 
Therapeutic strategies are defined by the primary tumour stage and radiation 
treatments and dosing constraints are subject to anatomical boundaries. Functional 
magnetic resonance imaging techniques have the ability to look beyond anatomy to 
identify specific cellular characteristics. Maps of intrinsic radio-resistance within the 
prostate can potentially be produced for every patient.
In-vivo hypoxia and vascular imaging techniques may serve several roles in clinical 
oncology. At the time of initial diagnosis and staging, an estimation of the extent of 
tumour hypoxia and angiogenesis would provide additional information for risk- 
stratification and assessment of prognosis. The functional information gained in the 
treatment planning stages may lead to the optimal choice of treatment modality, or 
combination of treatment modalities. For example, if the tumour is found to be very 
hypoxic, radiotherapy could be combined with hypoxic sensitizers or the breathing of
232
high oxygen containing gas mixtures. Highly proliferating cancers may be more 
appropriately treated with combined chemo-radiotherapy or in conjunction with other 
biological agents. Tumours with extensive evidence of neo-vascularization or 
expression of vascular growth factors may benefit from treatment with anti-angiogenic 
or anti-vascular drugs.
Currently, radiotherapy is planned using physical tumour volumes. However, tumours 
are heterogeneous with areas of varying radiosensitivity based on biological 
characteristics. The ability to incorporate biological information into the radiotherapy 
planning process and to increase the dose administered to relatively resistant regions 
could achieve better local tumour control and overall survival.
In order to test the hypothesis that biologically targeted radiotherapy offers an 
advantage over anatomically based radiotherapy planning, three processes require 
integration: (1) Quantitative imaging of the biological characteristics of tumours. (2) The 
generation of radiotherapy dose-distributions that optimise dose to biological sub­
volumes within the target and (3) Precise radiation delivery. This thesis has begun to 
address the first of these issues with regard to prostate cancer. With the phenomenal 
technological advances in radiotherapy over the past few years there has been 
considerable progress in the remaining two areas.
Modelling studies have demonstrated theoretical advantages for biological 
conformality. However the translation of these ideas into clinical studies has been 
limited for two major reasons: Most groups have concentrated on extemal-beam 
Intensity-Modulated Radiotherapy (IMRT) for treatment delivery. There are a number of 
technical limitations of IMRT that need to be overcome before efficacy studies of 
biological conformality can be undertaken. IMRT requires a motionless target if precise 
doses are to be administered to small regions within tumours. Immobilisation devices, 
respiratory gating and image guidance technology are becoming highly advanced and 
have already reached the levels of accuracy required for biological ‘dose-painting’. 
However most centres are still gaining technical and clinical experience with IMRT, 
making the prospect of delivering biological conformal radiotherapy using this method 
some years away.
Brachytherapy is a technique in which radiation sources are placed within the tumour 
itself, bypassing the need for immobilisation and image guidance during treatment 
delivery. High dose gradients are achieved providing the most conformal dose 
distributions of all radiotherapy techniques. High dose-rate (HDR) brachytherapy is
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delivered over a period of minutes rather than weeks. This eliminates the effects of 
tumour cell repopulation and the difficulties that may be encountered when attempting 
to deliver radiation to a biologically relevant tumour sub-volume that may change over 
a prolonged treatment course. This technology is available for use today and fulfils 
every physical requirement for biological dose painting. It is for these reasons that HDR 
brachytherapy may be the ideal treatment strategy with which to explore the principle of 
biologically based treatment planning in the clinic.
In the future, as our familiarity with image guidance grows, external beam IMRT will 
become a realistic option for the delivery of biologically optimised dose distributions 
and may be used in combination with HDR brachytherapy for prostate cancer, or as 
sole modality therapy for tumour sites that are not suitable for implantation.
As exemplified by the experiments detailed in chapter 6, biological imaging also 
provides new endpoints for response assessment. This thesis has established the 
value of vascular imaging for the demonstration of blood flow changes induced by 
therapeutic strategies such as androgen deprivation. With the proliferation of second 
line treatment strategies such as cryotherapy or high frequency ultrasound and the 
development of new targeted agents including antibodies and vaccines, the importance 
of early response assessment after, or even during, the primary treatment has 
increased considerably. The conflicting results of clinical studies that have tried to 
assess the role of androgen deprivation in conjunction with radical radiotherapy (as 
outlined in the introduction to chapter 6) suggests that not all patients benefit from 
treatment with hormones prior to radiation. It would be interesting to correlate the 
degree and nature of the response to neo-adjuvant androgen deprivation, in terms of 
changes to blood flow, vascular permeability and oxygenation, with response to 
radiotherapy and final outcome. This approach could lead to individualised treatments 
based on the intrinsic biology of each tumour.
Further work has already begun using identical MR sequences to examine the vascular 
and oxygenation changes that occur during a course of radical external beam 
radiotherapy to the prostate. Similar to what is seen with androgen deprivation, 
changes in vascular and oxygenation parameters may inform on a tumour’s individual 
radiobiology. Furthermore, the parametric maps generated by this process will 
determine the feasibility of specific targeting of sub-volumes within the prostate and 
how these regions change throughout a course of treatment.
In coming years, as novel PET tracers become validated and the signal to noise ratio of 
PET imaging improves, it will be possible to integrate these techniques into the
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biological targeting process. As for MR, PET imaging of hypoxia is still in an 
experimental phase. The two most promising radiotracers for this purpose, 18F- 
misonidazole and Cu-ATSM, both have significant difficulties that are yet to be 
overcome. With 18F-misonidazole there is a low tumour to background ratio and a slow 
washout time for normoxic cells. Cu-ATSM appears to have a critical dependence on 
blood flow and would necessitate concomitant blood flow estimation. Furthermore the 
radiopharmaceuticals are difficult and expensive to make and require the presence of a 
nearby cyclotron facility that is willing to temporarily suspend FDG production for the 
time it takes to produce these investigational tracers.
Even with highly validated PET tracers, such as FDG, incorporating the biological 
information it produces into radiotherapy planning protocols is fraught with difficulty. On 
a PET image tumour boundaries are generally defined as a percentage of the 
maximum standardised uptake value (SUV). However many factors affect SUV 
measurements and therefore it is hard enough to delineate the tumour borders let 
alone devise a way to determine the margins of biological targets within tumours. There 
are also considerable issues regarding registration when dealing with images of low 
signal-to-noise ratio. Furthermore, PET is also at a disadvantage in terms of response 
assessment, with a limitation in the number of examinations that can be performed as a 
result of the radiation exposure to each patient.
In summary, this research has demonstrated the feasibility of hypoxia imaging in 
prostate cancer. Although there is, as yet, no imaging modality that can precisely map 
tissue p02, the combination of BOLD-MRI and dynamic susceptibility contrast MRI 
provides a valuable surrogate and predicts the pattern of hypoxia, as determined by 
pimonidazole immunohistochemistry, with reasonable accuracy. The research has also 
shown that prostate cancer responds to carbogen gas breathing and that androgen 
deprivation causes profound vascular collapse within one month of starting therapy. 
These findings should help in the rational design of future studies that aim to target 
tumour vasculature and combat tumour hypoxia in prostate cancer.
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Appendix A 
Methods for Histological Analysis
A1 Tumour removal and cutting
A1. Tumour xenografts in mice (figure A1)
1) The dead mouse is positioned in the same orientation as in the MRI scanner.
2) The right side of the tumour is painted with Indian ink to facilitate orientation 
during analysis.
3) The tumour is cut in the transverse plane at the same level as the MRI scan. The 
front portion is placed directly in formalin (40% w/v formaldehyde in water) and 
the rear portion is placed in zinc fixative.
4) Samples were protected from light.
5) The samples were then paraffin embedded, and cut into 4pm sections using a 
microtome and mounted on to glass slides for staining.
A1.2 Human prostate specimens (figure A2)
1) The prostate was removed from the patient during a radical prostatectomy 
procedure.
2) The prostate was immediately placed in formalin.
3) 24 - 48 hours later the specimen was ready to be cut.
4) The MRI image was used to orientate the specimen prior to cutting.
5) The prostate was sliced in one action through the same plane that was used to
obtain the MRI images. A 5 mm thick section was cut and replaced in formalin for 
transportation from the hospital to the laboratory.
6) The whole 5mm thick axial section of prostate was then paraffin embedded, and 
cut into 4pm sections using a microtome and mounted on to glass slides for 
staining.
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Figure A2 Cutting and preparation of human 
prostate specimens
The specimen is cut in the same plane and at the same level as the central MRI
slice using the MRI data and measurements as a guide
The whole 5mm thick axial section of prostate is then paraffin embedded, and 
cut into 4jam sections using a microtome and mounted on to glass slides for 
staining with H&E, Hypoxyprobe-1 antibody and Mouse anti-Human CD34 
antibody:
H&E Pimonidazole CD34
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A2 Slide preparation for pimonidazole staining
1) The 4pm thick formalin fixed paraffin embedded sections were dewaxed in xylene 
for five minutes.
2) Sections were rehydrated through graded alcohols (100, 90, 70%) to water.
3) Antigen retrieval was performed on the slides by placing them in a bath of 10mM 
citric acid (pH6) and boiling for 8 minutes using an 800W microwave oven (2450 
MHz Panasonic NN-6453BBPQ).
4) The volume of fluid was topped up to its original level and the slides were then left 
to stand for 20 minutes at room temperature before being washed well in running 
tap water.
A3 Pimonidazole Staining 
A3.1 For tumour xenografts in mice
1) Sections were rinsed in Tris Buffer Saline (TBS).
2) Dako Protein Block (DakoCytomation Ely Cambs X0909) was applied for 5
minutes.
3) Excess was tipped off.
4) Hypoxyprobe-1 antibody (Chemicon Europe Ltd Hamps HP2-100) diluted 1/100 in 
antibody diluent (DakoCytomation S2022) was applied for 60 minutes.
5) Sections were washed in TBS (3mins).
6) Anti-FITC monoclonal antibody (Chemicon Europe Ltd) diluted 1.100 in Dako 
antibody diluent was applied for 30 minutes.
7) Sections were washed three times in TBS (3mins).
8) DAB substrate (DakoCytomation K3467) was applied for 5 mins.
9) Sections were rinsed in TBS and then washed well in running tap water.
10) Sections were counterstained in Mayers haematoxylin (Surgipath Europe Ltd 
Peterborough UK Cat No 01582E) for 10-60 seconds.
11) Sections were washed well in running tap water.
12) Finally, sections were dehydrated through graded alcohols, cleared in xylene and 
mounted in DPX (Surgipath Europe Ltd 08600E).
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A3.2 For Human Prostates
1. Endogenous peroxidase was blocked using Dako peroxidase block 
(DakoCytomation S2023)) for 5 mins
2. Sections were washed in running tap water
3. Dako Protein Block (X0909) was applied for 5 minutes.
4. Excess was tipped off.
5. Anti-Pimonidazole IGg1 antibody (Chemicon Europe Cat no HP1) diluted 1/100 in 
TBS for 30mins was applied.
6. Specimens were washed three times in TBS (3mins).
7. Envision HRP polymer (DakoCytomation K5007) was applied for 30 minutes.
8. Wash three times in TBS (3mins)
9. DAB substrate (DakoCytomation,part of K5007 kit) was applied for 5 minutes.
10. Specimens were rinsed in TBS and then washed well in running tap water.
11. Specimens were counterstained with Mayers Haematoxylin (Surgipath Europe 
Ltd, 01522E) for 10-60 seconds.
12. Specimens were washed again in running tap water.
13. Specimens were then dehydrated through graded alcohols, cleared in xylene and 
mounted in DPX (Surgipath Europe Ltd 08600E).
A4 Slide preparation for vascular endothelial staining 
(CD31 / CD34)
1) 4um paraffin sections were dewaxed in xylene and rehydrated through grade 
alcohols (100,90 and 70%) to water.
2) Sections were transferred to a slide tray and rinsed with TBS (Tris Buffered 
Saline). Sections were dried and circled with a resin pen.
A4.1 CD31 staining for tumour xenografts in mice
1) Dako Peroxidase blocking reagent (S2023) was applied for five minutes.
2) Sections were rinsed in distilled water.
3) Sections were rinsed in TBS.
4) Dako serum free protein block (X0909) was applied for five minutes.
5) Excess solution was discarded and rat anti-mouse CD31 (pecam-1) antibody was
applied (Pharmingen Int., 01951 A) diluted 1/500 in TBS for one hour at room 
temperature.
6) Sections were washed three times in TBS, over three minutes.
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7) Biotinylated rabbit anti-rat IqG (DAKO, E0468) diluted 1/400 in TBS was applied 
for one hour at room temperature.
8) Sections were washed three times in TBS (three minutes).
9) Dako StreptABComplex DakoCytomation K0377 was applied for one hour room
temperature.
10) Sections were washed three times in TBS (three minutes).
11) Excess fluid was drained off and DAB solution was applied for five minutes
(Vector SK-4100).
12) Sections were rinsed in distilled water and then washed well in tap water.
13) Mayers Haematoxylin counter stain was applied for 5-60 seconds.
14) Sections were washed in running tap water.
15) Sections were dehydrated through graded alcohols, cleared in xylene and 
mounted in DPX. (surgipath 08600E).
A4.2 CD34 staining for human prostates
1) Slides were pre-treated for 5 minutes in an enzyme bath containing 0.1% trypsin 
and 1% calcium chloride at 37°C.
2) Slides were washed well in water.
3) Endogenous peroxidase was blocked with DakoCytomation peroxidase block 
(Dako Cytomation S2023) for 5 minutes.
4) Slides were washed well in water.
5) Slides were rinsed in TBS
6) Protein Block (Dako Cytomation X0909) was applied for 5 minutes.
7) Excess was tipped off.
8) Mouse anti-Human CD34 antibody (Novacastra Labs Ltd Peterborough UK, NCL- 
L-END) diluted 1/75 in antibody diluent (DakoCytomation UK, S2023).) was 
applied for 1 hour at room temperature.
9) Slides were washed three times in TBS (3minutes).
10) Dako Envision HRP Mouse polymer ((K5007) was applied for 30 minutes.
11) Slides were washed in TBS.
12) DAB substrate (20ul DAB/1 ml) was applied.
13) Slides were rinsed in TBS and then washed well in running tap water.
14) Slides were counterstained in Mayers haematoxylin for 10-60 seconds.
15) Slides were washed well in running tap water.
16) Slides were dehydrate through graded alcohols, cleared in xylene and mounted in 
DPX.
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A5 Digitisation of histology slides [1] (figure A3)
1) The prepared glass slide with a cover slip was cleaned to remove dust and debris 
and mounted on a Nikon eclipse TE2000-E microscope.
2) Microscopy was performed at x40 (x4 objective lens and x10 eyepiece).
3) Background corrections were performed to compensate for any artefact caused 
by particles on the lens or due to discolouration of the slide. The *white average’ 
was created using a clean area of the slide adjacent to the specimen. The ‘black 
average’ was determined by blocking the light source.
4) The region of interest was defined on the computer screen using x and y co­
ordinates.
5) The focal plane was defined by focusing on three co-ordinates in a triangular 
pattern within the region of interest (chosen by the computer). The computer then 
calculated and compensated for any variations in the thickness of the specimen, 
which may have caused parts of the image to be out of focus. This was 
particularly important for the large prostate whole-mount specimens.
6) Multiple images were acquired using the computer controlled motorised 
microscope stage. In order that no part of the specimen was omitted, a 10% 
overlap between each image was specified.
7) The separate images were then ‘stitched’ together using an in-house program 
(‘Image Stitching’ -  Gray Cancer Institute, Northwood, Middlesex, UK). The 
program used pixel data that allowed alignment at a cellular level. The 10% 
overlap was removed at this stage.
8) The resulting image was saved as a .tif file.
9) Every pixel of the image contained information in an 8-bit format with a value 
between 0 and 255 for each of the colours red, green and blue. 0 indicating a 
total absence of that colour and 255 indicating complete saturation. This provided 
quantification of colour and allowed subsequent analysis of each histology image 
on the basis of colour intensity.
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Figure A3 Digitisation of histology slides
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resolution images with 
a 10% overlap
The images 
are ‘stitched’ 
together using 
pixel data, so 
that the images 
now align at a 
cellular level
Each image is captured 
at very high resolution. 
As a result, even 
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staining can be
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A6 Histological Analysis (figure A4)
Analysis was performed using customised histological image analysis software 
developed at the Gray Cancer Institute (TRI2’ -  Gray Cancer Institute, Northwood, 
Middlesex, UK).
The following data were obtained:
■ Percentage area stained for whole ROI
■ Percentage area stained for each grid element
■ Staining Intensity for whole ROI
■ Staining Intensity for each grid element
■ Summary statistics for each of the above
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Figure A4 Histological Analysis
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The .tif image was loaded 
into the TRI2 software.
The image was re-scaled 
using a standard binning 
method
The image was then 
rotated to match the 
orientation of the MRI 
scan.
The region of 
interest (ROI) 
was drawn.
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Linear unmixing was performed on the image. 
This process picked out the brown pixels from 
the non-brown pixels. The range of saturation 
and hue for the brown colour was pre-chosen 
to match the colour range of the 
immunohistochemical staining.
Pre-determined intensity thresholds were set 
to exclude background staining. These 
thresholds varied between tumour type and 
between immunohistochemical stains.
The resulting image was converted to 8-bit 
format to facilitate data processing.
Grids were applied.
Computerised calculation provided data for the 
whole region of interest and for each grid 
element within it.
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A7 Validation
Computerised analysis methods for immunohistochemical analysis have been used 
countless times in the literature [2-6]. The ‘in-house’ software at the Gray Cancer 
Institute that was used in these experiments is the latest version of continually evolving 
software that has been in development since 2003.
Despite this, it was felt that a degree of internal validation was required to provide 
confidence in the results obtained. As a result, manual verification using light 
microscopy was performed for approximately 10% of the grid elements for each stain in 
each tumour:
A) Pimonidazole staining
Pimonidazole labelling can be considered ‘positive’ if the brown staining is cytoplasmic 
or nuclear, in other words the pimonidazole is bound within the cell as a result of the 
cell’s low oxygen environment. Extracellular staining is artefactual and usually a result 
of secondary antibody binding to extracellular protein elements within the tissue.
As can be seen in the high power light microscopy images in figure A5, taken from one 
of the specimens in this study, intracellular pimonidazole labelling predominates with 
virtually no background staining. There is sharp demarcation between labelled and 
unlabelled cells. It is therefore likely that brown pixels on the computerised analysis 
image correspond accurately to intracellular pimonidazole staining.
The manual verification has confirmed this:
10% of grid squares were manually scored using light microscopy at x400 power. 
Estimates of the percentage area of pimonidazole staining per grid were made to the 
nearest 10%. These were compared with the results obtained by computerised 
analysis. A high degree of correlation was seen (r2 = 0.95).
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Figure A5 A high power light microscopy image showing the 
cytoplasmic and nuclear pimonidazole staining in a 
section of human prostate carcinoma.
Note that there is virtually no background brown staining.
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B) CD31 / CD34 staining
This situation with CD31/CD34 is more complex than fo r pimonidazole labelling 
because of two factors:
1) There is a higher degree of background staining, especially fo r fibrotic tumours.
2) Computerised analysis calculates the proportion of brown stain within any given 
region and can therefore only reflect the total vascular endothelial cross 
sectional area, NOT the microvessel density.
Despite these factors, the critical point that requires clarification is whether the 
proportion of brown staining, as determined by computer analysis, correlates with the 
number of blood vessels within any given region of interest. Correlations between MVD 
counts and total vascular endothelial area counts have already been reported in the 
literature [7, 8]. A  manual verification analysis was performed for both the animal and 
human imm unohistochem istry used in the experiments presented in this thesis:
10% of grid squares were manually scored using light microscopy at x400 power. 
Estimates of the m icrovessel density per grid were made. These were compared with 
the results obtained by computerised analysis. Reasonable correlation was seen fo r 
the animal tum ours (r2 = 0.59), less correlation was observed in the human prostates 
reflecting the high degree of fibrosis in areas of benign hyperplasia (r2 = 0.28):
Comparison between automated mean vascular endothelial 
area calculation and manual microvessel density 
(xenograft)
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Comparison between automated mean vascular endothelial 
area calculation and manual microvessel density (human
prostate)
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Appendix B 
Functional MRI protocols and image 
analysis for the human experiments
This appendix details the methods used to generate parametric maps for biological 
imaging of the human prostate in the experiments described in chapters 4, 5 and 6.
B1 General
Prior to scanning each patient was asked to sign an MRI safety questionnaire and an 
informed consent document. A 20 gauge disposable plastic intravenous cannula was 
inserted into the dorsum of the hand. Immediately before the scan patients was asked 
to empty their bladder and rectum.
B2 Anatomical Scanning
Small field-of-view Ti and T2-weighted anatomical scans perpendicular to the urethra 
were used to stage tumours and to identify tumour slice locations. Images were 
inspected for the presence of a peripheral zone abnormality consistent with cancer. 
The central slice for functional imaging was chosen to contain a satisfactory tumour 
region for data analysis.
B3 Functional Imaging
1. BOLD-MRI: Five spoiled gradient-echo images were acquired for three slices 
through the prostate with varying TE (5-60ms), TR=100ms, flip angle=40°, 
FOV=200mm, 2562 matrix, from which R2* maps were calculated.
2. DCE-MRI: Proton density weighted (PDW) images were acquired for three 
slices to facilitate the calculation of kinetic parameters (TE 10ms, TR 350ms, 
flip angle=10°, three slices of eight millimetre thickness). Ti.weighted spoiled 
gradient recall echo [FLASH] sequences (TE 5ms, TR 74ms, flip angle = 70°, 3 
slices) were acquired with a time resolution of 12 seconds (40 time points over 
8 minutes) for three slices through the prostate. A bolus of 0.1 mmol/kg b.w. of 
gadopentetate dimeglumine contrast agent was administered at 4 millilitres per 
second during the fifth image acquisition (i.e. beginning after 48 seconds) using 
a power injector.
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3. DSC-MRI: A T2*-weighted sequence was used to acquire data every 2 seconds 
over 2 minutes (TE 20ms, TR 30ms, flip angle = 40 °, one slice of eight 
millimetre thickness). A bolus of 0.2 mmol/kg b.w. of Gd-DTPA was 
administered at 4ml/s after 20 seconds.
4. Diffusion Imaging: Five images were obtained for three slices through the 
prostate (TE 137ms, TR 3600ms, flip angle = 90 °) with b-values of 0, 50, 150, 
500 and 1000 from which ADC maps were calculated.
B4 MRI data Analysis
Voxel based calculations were performed using two customised analysis software 
packages developed at the Institute of Cancer Research, Royal Marsden Hospital, 
London, UK. For the T, and T2* weighted dynamic imaging, Magnetic Resonance 
Imaging Workbench© (MRIW) version 4.2.1 was used. For the BOLD-MRI and 
diffusion weighted imaging analysis, DiffusionView© version 2.1.3 was used.
R2* maps were calculated using in-house software written in IDL (Research Systems; 
Boulder, CO). A straight line was fitted to a plot of InSt against TE for each pixel using a 
least-squares approach, of which the gradient is -R2* (units s'1) (figure B1). Pixels with 
either negative or zero values were excluded from analysis. The dynamic MRI images 
were analyzed using custom analysis software (MRIW). R2* values were calculated for 
each time point of the T2*- weighted DCE-MRI data set and fitted using a y-variate 
function:
C(t)aAR2*(t) = ~ \ n  
TE
Where C(t) is contrast agent concentration in blood at time t, S0 and S(t) are the signal 
intensities at the baseline and at time t, respectively and TE is the echo time of the MR 
sequence used. The relative blood volume (rBV; arbitrary units) is then the integral of 
the AR2*-time curve (using the y-variate fit).
rBV  = |A «2 *(t)dt
The relative mean transit time (MTT) was approximated by measuring the width of the 
AR2*-time curve at half its maximum value. Relative blood flow (rBF) was then obtained 
by substituting in the transit time equation:
MTT = rBV/rBF
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Figure B1
Blood oxygenation level dependent (BOLD)-MRI data collection and analysis.
The top two rows show the native BOLD-MRI images acquired with lengthening echo 
time values raging from 5 to 75 ms. It can be seen that the back of the gland darkens 
faster than the front of the gland. Signal intensity and In signal intensity changes are 
shown in the graph, as well as the linear regression of the In signal intensity data. The 
gradient of the linear regression is the R2* value in s'1. This process is repeated for 
every pixel to yield the R2* map (bottom row, left). The positions of the two regions of 
interest (ROIs) shown in the graph are indicated on the R2* map.
B5 Region of interest (ROI) definition
Initially, four regions of interest were outlined for each prostate (whole prostate, tumour, 
peripheral zone and central zone), (figure B2)
ROIs were defined using information from several acquisition sequences. The whole 
prostate ROIs were defined on T2-weighted images. Tumour ROIs were defined using 
combinations of T2-weighted, contrast enhanced Ti-weighted and diffusion ADC maps. 
In general, an irregular mass of low signal intensity in the peripheral zone seen on the 
T2-weighted images was considered to represent tumour. When an obvious malignant 
peripheral zone tumour was contiguous with homogeneous low signal intensity in the 
central gland, the finding was interpreted as probable central glandular involvement. A 
consultant radiologist with a specialist interest in prostate cancer independently verified 
these regions (ARP). Normal peripheral zone was determined on the basis of 
homogeneous high signal intensity on non-contrast enhanced T2-weighted sequences. 
Benign prostatic hyperplasia, which arises from the transitional zone, was considered
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part of the central gland of the prostate (central and transitional zones). The MR 
imaging features of benign prostatic hyperplasia were uniform areas of low signal 
intensity (glandular benign prostatic hyperplasia) or areas of nodular whorls with low 
signal intensity. Central zone ROIs were also outlined on non-contrast enhanced T2- 
weighted sequences, based on anatomical detail.
For the androgen deprivation / reproducibility experiments this was performed for each 
of the five scans per patient and for all three slices per MRI examination (apart from the 
T2*-weighted DSC-MRI scan for which only one slice through the prostate was acquired 
-  see above). Giving a total of 60 ROIs per patient for BOLD, ^-weighted DCE-MRI 
and DWI analysis and 20 ROIs per patient for the T2*-weighted DSC-MRI analysis. For 
each scan, data from the three slices were combined to produce single values for each 
of the four prostate regions. ROI definition was performed on the same day for all five 
scans for each patient to minimise intra-observer variability.
For the immunohistochemical analysis in chapter 5, 5x5mm grid-based ROIs were 
defined using the DiffusionView© software package and then transposed to MRIW for 
the dynamic analysis (figure B3). The DiffusionView© software was able to analyse all 
grid elements simoultaneously, whereas in MRIW each grid element had to be 
analysed separately. The following parameters were measured / calculated:
BOLD MRI R2*
Ti.weighted DCE MRI (semi-quantitative) AUC
Ti.weighted DCE MRI (quantitative) Ktrans
B6 Arterial Input Function
The methods and models used to calculate each parameter are described in detail in 
chapter 2. For quantitative perfusion measurements it is necessary to measure the 
exact delivery of a tracer, the arterial input function, to the organ in question. In all of 
the perfusion experiments presented in this thesis, the modified Fritz-Hansen method 
was used [1-3]. This technique has been validated against arterial blood samples.
T2_weighted DSC MRI
Kep
Ve
rBV
rBF
Diffusion Weighted Imaging Overall ADC, b-values 0-1000 
Early ADC, b-values 0-150 
Late ADC, b-values 500-1000
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Figure B2 Illustration of the method for ROI definition
n — •:—  -r :-------- Whole Prostate ROI
Tumour ROI Peripheral and Central Zone ROIs
ROIs were defined on T2-weighted MRI sequences. For tumour regions, information from 
dynamic and diffusion images were also used to aid localisation and discriminate tumour 
from benign peripheral zone.
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Figure B3 Grid-based ROI definition
DiffusionView©
MRIW
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Appendix C
K
Difference between median parameter values plotted against mean of median 
parameter values. Mean difference is shown with 95% confidence interval.
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BOLD-MRI
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Diffusion weighted ADC parameters
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